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(Under the direction of Leaf Huang) 
 
          Melanoma, the most lethal skin cancer, has an incremental incidence, few durable 
therapies, and a low survival rate of less than 10 % for late-stage patients in clinics. In 
desmoplastic melanoma, a rare histological variant of melanoma, the highly fibrotic morphology 
as well as the immune-suppressive tumor microenvironment led to distinct clinical behavior 
when compared with other melanoma subtypes, thus hindering treatment efficacy. To overcome 
these therapeutic hurdles, herein in this dissertation work I developed multiple innovative 
strategies based on targeted nano-delivery systems. These strategies include the effective 
delivery of therapeutic vaccination, immune-modulating chemo-drugs and active compounds, 
gene therapy, and a combination of chemo-immune initiated/guided treatment.  
          A total of five aims were sequentially designed, including 1) nano-vaccination. The tumor-
specific antigen peptides were efficiently delivered to antigen-presenting cells along with 
immune-stimulating adjuvant. This therapeutic vaccine inhibited aggressive tumor growth. 2) 
nano-sunitinib. The FDA approved drug sunitinib was targeted delivered to the tumor with 
improved anti-tumor efficacy, furthermore, it largely remodeled immune suppressive 
microenvironment and facilitated vaccination efficacy. 3) nano-fraxinellone. The active 
compound fraxinellone was nano-delivered to the tumor microenvironment, inhibiting the 
transition of tumor associated fibroblasts and skewed TGF-β/IFN- γ balancing toward 
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pro-inflammatory settings. 4) nano-wnt5a trap. Key molecular wnt5a secreted by tumor cells in 
inducing dendritic cell tolerance and tumor fibrosis was locally trapped, thus significantly tuned 
immune recognition and surveillance of cancer progression. 5) nano-delivery of mitoxantrone 
and celastrol. Two drugs were screened out with highest anti-tumor and anti-fibrosis potentials 
and worked synergistically in inducing immunogenic tumor cell death and long-term memory 
immune responses.  
          Using animal models of desmoplastic melanoma, our nanomedicine designs significantly 
elicited an overall anti-tumor immunity with increased efficacy, safety profiles, and prolonged 
host survival, suggesting their high translatability to the clinic. This dissertation research work 
further sheds light on a deeper understanding of cancer type-specific microenvironment and 
immune modulators, as well as future mechanism studies in designing immunotherapy for 
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1.1 Introduction and significance 
          Melanoma derived from melanocytes is the most aggressive type of skin cancer, it 
accounts for nearly 80 % of skin cancer deaths.1 Despite recent improvements in prevention and 
early detection, approximately 20 % of melanoma patients still die from the disease. Melanoma 
incidence is not only correlated with age, but it is one of the most general causes of cancer and 
cancer deaths in people aged 20–35. Overall, melanoma is a strong example of how genetics and 
the environment cooperate to stimulate carcinogenesis.2, 3 Conventional melanoma treatment, 
whether radiotherapy or chemotherapy, present a short therapeutic window and a high incidence 
of recurrence/metastasis.4 Major drawbacks of such therapies are that the tumor-specific immune 
response is insufficiently evoked and that the lack of specificity results in side effects to the 
whole-body immunity.5 Besides, the immune response of the tumor microenvironment (TME) 
has been poorly studied. The TME comprises not only tumor cells but also immune and 
interstitial cells. Thus, an effective therapy should be based upon the specific cancer type and a 
thorough understanding of its TME.6  
          Currently, there are five types of standard treatment for melanoma patients, including 
surgery, radiation therapy, chemotherapy, immunotherapy, and targeted therapy.7 In the study of  
                                                          
1 This chapter previously appeared as an article in Advanced Drug Delivery Reviews. The original is as follows: Q 
Liu, M Das, Y Liu, L Huang. “Targeted drug delivery to melanoma.” Advanced drug delivery reviews. 2017 Sep 19. 
 2  
 
new targeted therapies, B‑Raf proto-oncogene (BRAF) and mitogen-activated protein kinase 
(MEK) specific inhibitors have emerged with distinct survival benefits. Despite ongoing 
advancement in the study of metastatic melanoma, emerging drug resistance and systemic 
toxicity limit efficacy. Overall, the success rate for the treatment of melanoma is relatively low.  
          Facing the challenges of off-target effects, serious toxic adverse effects, and short 
circulation time in conventional systemic drug administration, researchers have developed 
nanoparticle (NP) technologies as a means of overcoming these disadvantages. Over the past few 
years, significant advances in NP-based drug delivery has made it easier for researchers to 
develop effective treatments. Because NPs offer excellent barrier protection to avoid host 
immune system attack and enzymatic degradation, immune-modifiers can be administrated to 
downregulate oncogenes or restore tumor suppressor microenvironment for more effective 
cancer chemotherapy, thus combating drug resistance. NP-based strategies have presented 
effective delivery of therapeutically payload in treating melanoma (Figure 1). 
 
Figure 1. NP-based strategies for targeted drug delivery to melanoma 
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1.2 Biology of melanoma 
          Melanocytes are located at the bottom of the skin epidermal layer and are responsible for 
generating melanin, which is the pigment responsible for a suntan and protects the skin against 
damage from ultraviolet exposure. In general, people with pale skin color (e.g., Caucasians) have 
an increased risk of melanoma-genesis comparing to darker skin populations (e.g., Africans, East 
Asians, Hispanics). Similarly, people who have excessive sun exposure are at higher risk for 
tumorigenesis.  
          The development of melanoma is a multistep process with clinical and histological 
characteristics.8 Melanoma-genesis can be histologically divided into five stages. In stage one, 
acquired nevi form because of increased melanocyte proliferation. Nevi are benign skin lesions; 
however, most malignant melanomas are derived from nevi.9 In stage two, melanocytes grow 
into dysplastic nevi showing abnormal differentiation. In stage three, dysplastic nevi continue 
developing into the radial growth phase (RGP) primary tumor. RGP melanomas develop within 
the epidermis but do not have the ability to invade into the dermis. In stage four, RGP 
melanomas acquire invasive potential through genetic alterations and invade into the dermis. 
This is the so called vertical growth phase (VGP). At this phase, melanomas possess the potential 
of self-sufficient growth signals and the ability to invade, thus making treatment options more 
limited. In the fifth and last stage of melanoma development, the metastatic lesion is formed. In 
this stage, VGP melanomas continue to grow larger and invade surrounding tissues. Metastatic 
lesions form in distant organs the melanoma becomes metastatic. 
          During the past few decades, epidemiological studies have identified several melanoma 
risk factors. These factors include excessive ultraviolet (UV) light exposure, moles (nevi), family 
history of melanoma, and a weakened immune system.10   
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1.3 Oncogenic pathways 
          Melanoma cells develop multiple unique signaling pathways in regulating tumor 
proliferation, migration, cell differentiation, as well as apoptosis. Downregulated signaling 
pathways often lead to tumorigenesis for melanoma development. Signal pathways can be 
activated by external stimuli and function to convey a signaling cascade from the cell surface to 
intracellular downstream effectors or to be activated by constitutively activated internal 
oncogenes without external stimuli. Deregulated cell proliferation and apoptosis are two major 
common factors required for most of the human malignant tumor development that is mediated 
by oncogenic signaling pathways. 
          The neuroblastoma RAS viral oncogene homolog (N-RAS) oncogene is mutated at codon 
61 in 20% of melanomas.9 Most mutations result in the constitutive activation of the N-RAS 
oncogene that then impairs guanosine triphosphate (GTP) hydrolysis.11 Constitutively active N-
RAS activates the BRAF/MEK/Extracellular Signal-regulated Kinase (ERK) (MAPK) and 
Phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)/ serine/threonine-protein kinases (AKT) 
cascades that further facilitate the proliferation, evasion, and metastases of tumor cells.  
A. MAPK and ERK1/2 pathways  
          The mitogen-activated protein kinase (MAPK) pathway is often referred to as the ERK1/2 
signaling pathway for its growth factor receptor-mediated (e.g., epidermal growth factor receptor 
(EGFR)-mediated) activation initiated from the plasma membrane. Once activated, the MAPK 
pathway would facilitate a series of signaling cascades, including RAS/RAF/MEK/ERK. It 
begins with a growth receptor receiving stimuli and then activating RAS by converting inactive 
RAS-GDP to active RAS-GTP.12 The active RAF-GTP recruits RAF and activates RAF by 
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phosphorylation specific to the cell membrane. Phosphorylated RAF then phosphorylates 
MEK1/2, which then activates ERK1/2 by phosphorylation. Activated ERK1/2 signaling 
pathway boosts cell proliferation by conveying signaling through protein phosphorylation to 
cytoplasmic and nuclear effectors. The phosphorylation results in fast cell proliferation by 
regulating Cyclin D1, p21, p27, and c-myc.13 The classic MAPK/ERK1/2 pathway needs 
extracellular stimuli to initiate activation of the signaling cascade. However, in melanoma and 
other human cancers, including thyroid and colorectal cancers, constitutively activated ERK1/2 
signaling resulting from a BRAF (V600E) mutation could promote tumorigenesis.14, 15 
          BRAF, also referred to as the proto-oncogene B-RAF or V-RAF murine sarcoma viral 
oncogene homolog B1, is a serine/threonine-protein kinase. B-RAF, A-RAF, and C-RAF (also 
known as RAF-1) constitute the RAF kinase family.16 Through a BRAF mutation, the MAP 
kinase pathway is activated in ~7 % of human carcinomas, with ~60 % of cutaneous melanomas 
having activating mutations.17 A BRAF mutation is very common in cutaneous melanoma; its 
incidence is very rare in acral, mucosal, conjunctival, and uveal melanomas.18 In 90 % of BRAF-
mutant melanoma tumors, the BRAF mutation is a single-base missense from T to A; this would 
change valine to glutamic acid at codon 600 (V600E) in exon 15.19 Mutated BRAF (V600E) 
protein is highly activated comparing to wild-type, owing to a conformational transform in 
protein structure, where glutamate phosphorylation occurs at the thr598 and ser601 
phosphorylation sites.20 
          Although the BRAF (V600E)-initiated, constitutively-activated ERK1/2 pathway 
contributes to increased cell proliferation for tumor development, recent reports indicate hyper-
activated ERK1/2 activity at a level that could lead to cell senescence for nevi formation without 
melanoma formation in transgenic mice. Previously, other groups have indicated that BRAF 
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(V600E) is critical to promoting melanocyte proliferation for the formation of benign nevi, but it 
is not the only key factor for melanoma development.21 Collectively, it is accepted that more 
than just a BRAF (V600E) mutation is required for melanoma development. 
B. PI3K/AKT pathways 
          The PI3K/AKT pathway participates in fast cell proliferation, and drug resistance.22 The 
PI3K/AKT pathway is activated by extra-cellular stimulation of receptor tyrosine kinases. The 
activated AKT then trans-locates to the cytoplasm or nucleus to activate downstream effectors 
for different signaling cascades. During the process of activation, PI3K/AKT signaling can be 
inhibited by phosphatase and tensin homologue deleted on chromosome 10 (PTEN).23 
          There are three AKT family members, AKT1, AKT2, and AKT3, known as important 
downstream effectors that relay the signal transduction cascade coming from PI3K. AKT3 plays 
major role in melanoma-genesis. Earlier immunohistochemical studies found that ~70 % of 
cutaneous melanomas have elevated AKT expression compared to normal melanocytes. 
Furthermore, previous studies have shown that, of the three AKT family members, major AKT3 
activation facilitates tumor progression. Inhibition of AKT3 using siRNA leads to decreased 
melanoma development.24, 25 
 
1.4 Animal models in melanoma research 
          More advanced pre-clinical melanoma models have been developed that assemble the 
relevant clinical conditions. To gain a broader understanding of tumor biology, these in vivo 
models mirror true melanoma settings. The most widely used pre-clinical model are murine 
models, including but not limited to xenograft, syngeneic, and genetically engineered models.26 
 7  
 
A. Xenograft models  
          Xenograft models are built upon the inoculation of human melanoma cells into an 
immune-deficient mouse. Once subcutaneously implanted, melanoma cells proliferate and 
metastasize along lymphatic tissue and blood vessels, which strongly resemble the human 
condition.27 Studies based on xenograft models mainly focus on tumor growth mechanisms, 
major tumorigenesis pathways, pharmaceutical therapy, bio-availability and toxicities.  
          Unfortunately, cultured melanoma cell lines are purified clones that differ from the 
original parent patient-derived cells. They may lose certain metastasis promoting markers while 
proliferating under the subcutaneous microenvironment. This results in irrelevant predictions of 
clinical outcome and explains many clinical trial failures.28 Patient derived tumors can be 
xenografted directly into animal models, but the expenses of model establishment and 
maintenance are rather high, comparing to purified cell lines.  
B. Syngeneic allograft 
          Syngeneic models are developed by inoculation of melanoma cells into the same species 
and genetic background.29 These mice are immune-competent with a fully functional immune 
system. In the study of melanoma microenvironment, dendritic cells (DCs) presenting tumor 
released antigens, thus allow the natural interaction between melanocytes and immune cells, such 
as T cells and B cells.30 
          Several types of cells have been applied to syngeneic transplantations. The most 
commonly utilized cell types are building upon C57BL/6J mice, which all induced by specific 
chemical reagents. This cell line, so called the B16 cell line, is characterized by a variety of 
behaviors including tumor growth, invasion, and metastasis. The two well-established sub-
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clones, established by in vivo passaging are the B16F1 and B16F10 cell lines. B16F1 has the 
notable distinguishing feature of low metastatic potential and can therefore be used to study the 
growth of primary tumors. In contrast, B16F10 usually shows a higher metastatic ability to 
distant organs, with the highest probability of metastasis in the lungs.31 Due to its rapid growth 
and high turnaround rate, B16 models are perfect for animal in vivo studies. For instance, 
subcutaneous tumors usually reach therapeutic window within two to four weeks.32 
          The B16 model has brought valuable insight into melanoma immunology studies, as well 
as immunotherapy strategies; however, when compared with human melanoma, the adhesion 
proteins and growth factors of mouse cell lines are quite different. Despite the B16 cells being 
able to produce a variety of sub-clones, they come from a unitary inbred mouse, thus 
unrepresentative of human conditions. Scientific interpretations based on such model can 
therefore be misleading.33 
C. Genetically engineered models (GEMs) 
          Genetic engineering models build upon transgenic mice with engineered gene expression 
specific to melanoma-genesis. We have gained a tremendous understanding of gene functions 
through studies of GEMs for effective targeting therapy.  By combining with other neoplasm-
inducing strategies such as UV-induction, melanoma development is more accurately assessed in 
a GEM. Compared with other pre-clinical models, GEMs are more precise in predicting drug 
efficiency.34 
          RAS model. It has been found that RAS family proteins contain a high number of 
mutations in cutaneous melanoma.35 Their specific mutations have been investigated in depth in 
murine models, in order to explain underlying mechanisms of melanoma-genesis.  
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          PTEN/BRAF models. Researchers have found that 65 % of malignant melanoma cells 
carry somatic missense BRAF mutations. In most malignant melanoma cases, BRAF mutations 
and RAS mutations are mutually exclusive, whereas MAPK signal transduction is excessively 
activated.36 The silencing of PTEN further induces excessive activation of AKT signal pathway, 
thus up-regulating BRAF gene expression to be activated.  
          RET model. This model is established upon the RET proto-oncogene, which encodes for 
glial cell-derived neurotrophic factor-specific receptor tyrosine kinase.37 RET gene expression 
can cause the progressive growth of melanoma. As a result, benign melanoma tumors occur 
months later, followed by eventual malignant tumor growth and organ metastasis. During 
tumorigenesis, the MAPK signaling cascades are highly activated, where the expression of RET 
transgene is found to increase in a gradual manner. 
          Although GEMs models are highly applicable, we are still challenged with multiple 
limitations. Genetic modified murine strains accompanied with significant labor costs, and the 
expenditure is rather high. In addition, some genetic alterations have adverse effects on 
reproductive ability, thus dampen the effective genotyping for targeted therapy. 
D. Physical or chemically induced models 
          Models induced by UV radiation could form highly assembled natural human melanoma-
genesis. But the drawbacks of murine models are evitable when comparing to human conditions. 
For one, human skin and mouse skin melanoma cells reside in different locations. Human 
melanocytes are mainly located in the basal layer of the cuticle and the epidermal dermis 
junction; therefore, they are vulnerable to be invaded by UV radiation. However, in murine 
models melanocytes are in the deep dermis and are well protected, therefore there is less chance 
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of a natural occurrence of melanoma.38 7,12-Dimethylbenz[a]anthracene (DMBA) and 12-O-
Tetradecanoylphorbol-13-acetate (TPA) can be utilized in situ to stimulate melanoma-genesis, 
but the tumor cells induced contain no melanin pigments, thus they are less representative of 
natural settings.39  
          Research based on different murine models provide significant insights and valuable 
interpretations of melanoma development. By comparing respective advantages and 
disadvantages of each model, great progression has been achieved. The studies of various pre-
clinical models are of great translational value in the diagnosis, treatment, and prevention of 
melanoma. Although currently incurable, an increasing understating of disease biology will offer 
more effective treatment options for patients with advanced melanoma. 
 
1.5 Current treatment of melanoma 
          The first-line treatment options for melanoma patients are surgical removal and radiation 
therapy. Surgery can involve a wide local excision, lymphadenectomy, and sentinel lymph node 
(LN) removal. In many cases, surgical removal of melanoma can be combined with 
chemotherapy, radiation therapy, biologic therapy, and targeted therapy. Radiation therapy uses 
high-energy radiation to induce melanoma cell death. Depending on the site, radiation can be 
classified into two categories, external and internal.40 An external source of radiation can be used 
to direct high-energy beams to the tumor with external therapy versus an internal therapeutic 
approach where radiation is targeted to internal metastatic melanoma using wire needles or 
catheters.41 
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          Unfortunately, metastasis results in poor melanoma prognosis. Metastatic melanoma is 
aggressively resistant to chemotherapeutic regimes. Many studies on the molecular basis of 
melanoma survival and proliferation have identified apoptotic resistance of melanoma cells as 
the underlying cause of chemo-resistance.42 This presents a formidable challenge in devising 
treatment strategies for advanced melanoma, and until recently there was little advancement in 
standards of care. Dacarbazine has been the sole first-line treatment for melanoma since its FDA 
approval in 1976. It has demonstrated a response rate of 10–20 % in Phase I and Phase II clinical 
trials, but the benefit in overall survival (OS) has never been clearly established.43 Interferon 
alpha (IFN-α), a type I interferon, is used for adjuvant immunotherapy in advanced melanoma; 
however, improvements in OS are debatable, and the clinical markers for the subset of patients 
sensitive to the adjuvant therapy have not been identified. High-dose Interleukin-2 (IL-2) was 
approved in 1998, but, again, the response rate is only about 10 %, and therapy involves grade 3 
toxicities.44 
          Advancement in understanding of cancer progression and survival has resulted in a 
resurgence of interest in developing newer therapeutic interventions in recent years.45 
Identification of driver oncogenic mutations in serine/threonine kinase BRAF, a critical 
functional component in the RAS-RAF-MEK-ERK-MAP kinase cascade, provided unique 
opportunities in the treatment of malignant melanoma. Vemurafenib and dabrafenib, two 
structurally unrelated inhibitors selectively targeting V600E, a missense mutation, that 
constitutes about 65 % of all malignant melanomas, resulted in improvement of disease free 
survival (DFS) and OS, leading to regulatory approval in 2011 and 2013.46 However, this 
strategy can only address melanomas driven by the activating V600E mutation and suffers from 
resistance mechanisms driven by reactivation of the MAPK pathway, often paradoxically 
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induced by the inhibitors. Combined inhibition of BRAF and MEK can reduce disease 
progression risk by 25 % over BRAF inhibition alone and delay development of resistance, but it 
cannot overcome it altogether.47 
          Immunotherapeutic strategies have been extensively investigated against melanoma in 
recent years. Tremendous excitement was generated as the “checkpoint inhibitors” demonstrated 
improvement in OS and DFS over conventional chemotherapy regimens. Ipilimumab, a 
monoclonal antibody targeting cytotoxic T-lymphocyte antigen 4 (CTLA-4), received FDA 
approval in 2011, followed by approval of Pembrolizumab and Nivolumab, antibodies against 
programmed cell death 1 (PD-1), in 2014.48 However, new challenges rapidly emerged as a high 
proportion of patients demonstrated transitory or no responses against checkpoint inhibitors, 
while long-term survival and cure was further achieved in a small subset of patients. It is thus 
crucial to identify the right patient subset that may benefit from immunotherapy however no 
biomarker can currently predict clinical outcomes.49 
          The CTLA-4 monoclonal antibody Ipilimumab and the BRAF kinase inhibitor 
vemurafenib changed the treatment landscape of metastatic melanoma. However, chemotherapy 
is still a relevant tool to clinicians because most patients do not respond to immunotherapy, and, 
further, not every patient carries the V600E mutation on BRAF. Even if a patient harbors the 
mutation and can be treated with the kinase inhibitor, drug resistance develops rapidly, and 
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1.5.1 Chemotherapy 
          As previously mentioned, Dacarbazine has been the standard of care for management of 
metastatic melanoma ever since its regulatory approval in 1976. The drug has a response rate of 
about 10–20 %; however, its OS benefit had never been validated in a randomized Phase III 
clinical trial. Temozolomide, an analog of dacarbazine, was not found to provide a significantly 
better response rate or OS when compared with dacarbazine in a European Phase III trial.50 Apart 
from alkylating agents, other cytotoxic classes of drugs, like nitrosoureas, microtubule toxins, 
and taxanes, have been investigated for melanoma. These agents provided no significant OS 
benefit over dacarbazine. DNA-crosslinking agents like cisplatin also did not demonstrate a 
promising effect in melanoma. In one randomized Phase II trial, cisplatin was combined with 
WR-2721 (a chemoprotective agent for normal tissues against radiation therapy), alkylating 
agents, and platinum compounds. Cisplatin had a response rate of 16.3 % in single-arm treatment 
against a rate of 23.3 % in the combination arm. However, toxicity was not mitigated and rather 
was enhanced with the combination regimen, and no additional OS benefit was presented.  
          Immunological agents have been combined with chemotherapy, but the results have been 
less than satisfactory. IFN-α and IL-2 have been explored in combination with chemotherapeutic 
regimes in multiple clinical trials and Meta-analyses revealed that while the combination of 
immunological agents and cytotoxic drugs can significantly improve response rates, it provides 
no survival benefit. Furthermore, the toxicity in the combination regimens dampens the overall 
improvement in the response. Moreover, the combination of IFN-α with chemotherapy drugs 
was found to be associated with hematological toxicities.51 
          Angiogenesis has been established as one of the well-defined processes for tumor 
proliferation and survival.52 Vascular endothelial growth factor (VEGF) facilitates angiogenesis, 
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and chemotherapeutic resistance of metastatic melanoma is rendered, in part, by VEGF 
overproduction.  Hence, combining chemotherapeutics with angiogenetic inhibitors, like 
monoclonal antibodies targeted against VEGF, is a clinically significant strategy. A combination 
regimen of paclitaxel, carboplatin, and bevacizumab, a monoclonal antibody targeting VEGF, in 
patients with Stage IV melanoma who have not qualified for surgery has been explored in a 
Phase II clinical trial.53 The median progression-free survival (PFS) was about 6 months, while 
the median OS was about 12 months. A similar trial investigated the combination of 
temozolomide and bevacizumab against a combination regimen of nab-paclitaxel (Abraxane), 
carboplatin, and bevacizumab. Patients on the latter regime had a better PFS rate at 6 months 
(52.1 % vs. 32.8 %); however, that did not translate into higher OS (13.9 months vs. 12.3 
months). There is at least one other trial that explored temozolomide and bevacizumab in 
chemotherapy-naïve patients and recorded a significantly higher OS in patients harboring the 
V600E BRAF mutation (12 months vs. 9.2 months). Researchers attempted to address 
chemotherapeutic resistance mediated by apoptotic resistance through a combination of 
chemotherapy with an antisense oligonucleotide against Bcl-2.54 Oblimersen, a Bcl2 antisense 
oligonucleotide, was developed and investigated in combination with dacarbazine. No OS 
benefit was observed in the overall population, although the benefit was significant in patients 
with normal lactate dehydrogenase (LDH) levels. However, no significant benefit in a 
subpopulation of patients with low-normal LDH levels was determined in further studies.55 
 
1.5.2 Targeted therapy 
          The idea of targeted therapy against cancer is focused around the targets on which 
malignant cells must rely for progression, survival, and proliferation. Hyper-activated pathways 
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provide a therapeutic opportunity because progression of cancer cells can have a higher 
dependence on these pathways over normal cells. Kinases, phosphatases, and proteases are 
reasonable tools worthy of clinical investigation, because rationally designed drugs can bind 
selectively on active sites and potentially mediate a therapeutic effect.56 However, NRAS and 
BRAF mutations are not simultaneously presented and implicated to drive pathogenesis in 
metastatic melanoma through the same pathway. 
          Ras farnesyl transferase inhibitors have been one of the earliest classes of drugs 
investigated in clinical trials; however, results have been generally disappointing.57 Although 
tissue analyses showed potent target inhibition in advanced melanoma, no tumor response was 
demonstrated in a Phase II trial. Sorafenib, a broad-spectrum kinase inhibitor targeting both 
CRAF and BRAF, demonstrated a modest response of about 30 % when investigated in 
combination with carboplatin and paclitaxel; however, responses were disappointing as a 
monotherapy. The initial clinical success of vemurafenib and dabrafenib targeting BRAF 
(V600E), with 50 % response rates, was a breakthrough in the management of metastatic 
melanoma. However, initial excitement was rapidly replaced by disappointment as most patients 
suffered relapse, and molecular analyses revealed multiple pathways of acquired resistance, 
primarily by compensation from other pathways. Reactivation of MAPK and ERK has been 
demonstrated as a clinical marker of resistance development.58 Trametinib, an MEK inhibitor, 
has been investigated in combination with BRAF inhibitors, and although PFS improves to 9–10 
months, resistance development cannot be prevented in the long run. The mechanism underlying 
resistance is not clearly understood, although exome sequencing on a small number of patients 
revealed an activating mutation on MEK2. The potential of selective ERK inhibitors has been 
harnessed to address resistance against BRAF inhibition; however, this approach suffers from the 
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actuation of an ERK inhibition-mediated negative feed, leading to RAS and PI3K signaling.59    
Recently, the role of the TME in resistance-acquired, post-BRAF inhibition was suggested by 
Hirata et al. They demonstrated that BRAF inhibition triggers MAPK signaling in tumor-
associated fibroblasts (TAFs), subsequently leading to kinase integrin/focal adhesion kinase 
(FAK) signaling and increasing tolerability of melanoma cells against BRAF inhibition. A 
BRAF and FAK inhibitor combination prevented ERK reactivation and improved tumor control, 
although a complete remission was not observed when investigated in preclinical models.60 
          MEK and ERK reactivation, although common, is not the sole driver of resistance to a 
combination BRAF/MEK inhibitor, and receptor tyrosine kinase overexpression has been 
routinely observed to induce compensation by PI3K-AKT pathways.61 However, targeting the 
PI3K-AKT pathway is difficult because the mammalian target of rapamycin (mTOR) kinase 
inhibition induces reactivation of AKT signaling by feedback loops, and effective targeting 
becomes challenging.62 
          About 15–20 % of melanomas harbor an NRAS mutation, and while there is an active 
interest in developing targeted therapies against BRAF mutation, successful therapies against 
NRAS mutant melanomas are an unmet medical need. NRAS mutant melanomas signal 
primarily through CRAF and not BRAF, and induction of MAPK signaling is triggered when 
treated with inhibitors targeting BRAF mutation.63 The MAPK signaling cascade is still critical 
to NRAS mutant melanomas. Mono-therapy with MEK inhibitors like trametinib or selumetinib 
has been modest, and finding combinatorial additive therapies targeting downstream of NRAS is 
critical. Overall, targeted therapies have been clinically impactful for melanoma management, 
although they suffer from the drawback of resistance development after initial response or a lack 
of translation of target inhibition into disease control. The future of targeted therapies in 
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melanoma management rests on successful translation of the understanding of the biological 
mechanisms of resistance into clinically significant therapeutic combinations.  
 
1.5.3 Immunotherapy 
          The clinical success of checkpoint inhibitors largely facilitates melanoma research, and 
there is considerable interest in understanding the immunology of melanoma and translating it to 
robust therapeutic strategies. The classic two-signal activation model was formulated out of basic 
research on understanding T-cell activation that involved the contribution of both antigens and 
secondary stimuli. The co-inhibitory receptors or the immune checkpoints like CTLA-4 and PD-
1 promote downregulation by preventing T-cell activation.64 Hence, negative regulatory 
mechanisms are a major hurdle in the T-cell response to tumors. The T cells may undergo 
functional inactivation and death in the TME, because PD-1 expressed on T cells engages with 
cancer cells (which would express programmed cell death-ligand 1, PD-L1).65 Hypothesizing 
that the blockade could break tolerance and rescue the immune response, researchers developed 
monoclonal antibodies targeting the immune checkpoints.  
A. Immune checkpoint inhibitors 
          Ipilimumab was the first successful checkpoint inhibitor in the clinics. It functions by 
binding to CTLA-4, thereby actuating down-regulation of the T-cell response. It received 
regulatory approval after demonstrating OS benefits in patients treated previously with 
chemotherapeutic regimens or IL-2. In one of the earliest trials, melanoma patients in Stage III or 
Stage IV who were not eligible for resection demonstrated a 10-month OS when treated with 
Ipilimumab in combination with gp100 peptide vaccine, against an OS of 6.4 months on vaccine 
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single-arm therapy. Interestingly, a recent meta-analysis revealed that about 20 % of patients 
with advanced melanoma may have long-term survival benefits, indicating the possibility of 
remission in a subset of patients. The next-generation antibodies targeting PD-1/PD-L1 entered 
clinical trials following Ipilimumab and pembrolizumab, a monoclonal antibody against PD-1, 
received accelerated approval in 2014. Pembrolizumab was compared against chemotherapy in 
patients non-responsive to Ipilimumab, and the 6-month response rate was approximately twice 
that of the chemotherapy arm. Nivolumab, another antibody targeting PD-1, was compared 
against the investigators’ choice of chemotherapy and demonstrated an objective response in 
31.7 % of the patients, as opposed to 10.6 % in its control arm. However, as with kinase 
inhibitors, the shortcomings of immune checkpoint inhibitors were quickly revealed because a 
large population of patients did not respond to therapy, while no bio-marker could be identified 
for patients who received long-term benefits.  
          With the success of mono-therapies, the exploration of CTLA-4 and PD-1 checkpoint 
inhibitors as a combination regimen was the next rational step. CTLA-4 and PD-1 are believed to 
have distinct regulatory roles, acting in different stages of T-cell activation. Targeting both 
checkpoints induced non-reductant changes in gene expressions and demonstrated a synergistic 
interaction.66 The combination of Nivolumab and Ipilimumab has been demonstrated to provide 
a longer PFS benefit (11.5 months overall and 11.7 months in BRAF-mutant melanoma patients) 
in comparison to Nivolumab or Ipilimumab alone, which offered a PFS of 6.9 and 2.9 months, 
respectively. This was comparable to a dabrafenib and trametinib combination in melanoma 
patients with BRAF mutation (9.3–11.4 months). The trial further observed a similar PFS with 
Nivolumab or Nivolumab combined with Ipilimumab in patients positive for PD-L1. It will be 
worthwhile to look at long-term survival and investigate if PD-L1 expression can be exploited as 
 19  
 
a clinical bio-marker to predict whether a patient is suitable for mono-therapy or combination 
therapy. Currently, other co-inhibitory receptors like Lymphocyte-activation gene 3 (LAG-3), 
mucin-domain containing-3 (TIM3), and T-cell immunoreceptor with Ig and ITIM domains 
(TIGIT) are being explored in clinical trials.67  
B. Therapeutic vaccines 
          A strong association between tumor-infiltrating cytotoxic T lymphocytes (CTL) and 
patient survival drove interest in the development of vaccine strategies to treat cancer. However, 
initial clinical trials did not offer any survival benefit, and in hindsight, this was primarily due to 
a lack of rational strategies.68 Most therapeutic vaccines were aimed at induction of response 
against tumor-associated antigens (TAAs). Effective anti-tumor response, however, requires 
presentation of TAAs to T cells after distinct activation and maturation signals are received by 
antigen-presenting cells. Further, the activated T cells have to expand, travel to tumor sites, and 
infiltrate the immunosuppressive TME to be able to recognize and kill tumor cells. Some of the 
initial trials investigated free peptide antigens with poor pharmacokinetic profiles, administered 
without a delivery system or an immuno-stimulatory adjuvant, which contributed to failure and 
generated cynicism about the future of vaccines as an effective therapeutic strategy. As 
additional knowledge has been acquired about the immunology of cancer, the current focus has 
shifted to combining vaccines with other immunomodulatory agents. A melanoma peptide 
antigen vaccine (gp100) was investigated in combination with IL-2 and demonstrated a response 
rate of 16 % over 6 % and a median PFS of 17.8 months over 11.1 months. Metastatic melanoma 
patients were treated with DCs stimulated with an assortment of melanoma antigens, and the 
survival benefit in the immunized group was 13.6 months, over 7.3 months in the control group. 
However, as with most immunotherapies, only a subset of patients who were immunized 
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responded to the therapy, as demonstrated by a positive CTL response, extending to a longer 
survival benefit (21.9 months vs. 8.1 months). Recently, a tumor vaccine that secretes GM-CSF 
was in Phase III clinical trial.  With the help of Ipilimumab, these patients bearing Stage III or 
Stage IV melanoma showed longer overall survival (17.5 months vs. 12.7 months). 
Unfortunately, PFS was not clearly extended. 
C. Emerging directions in immunotherapy 
          A few other active immunotherapy approaches involving T cells are currently generating 
interest in academic labs and clinics. Adoptive T-cell therapy is one of the most personalized and 
effective treatment methods available for management of metastatic melanoma, involving 
proliferation of tumor-infiltrating lymphocytes (TILs) ex vivo and transferring the TILs back to 
the patient augmented with other immuno-modulators like vaccines.69 When combined with 
lympho-depletion, objective response rates can be dramatic and reach 49–72 % in metastatic 
melanoma patients, further providing durable survival benefits over the long term. However, one 
of the major hurdles that limit this otherwise effective treatment is the economic cost and skilled 
labor associated with this complex, personalized therapy. Chimeric antigen receptors (CARs), a 
class of engineered fusion proteins combining an antibody-derived antigen recognition domain 
and a signaling domain, can bypass immune escape exploited by malignant cells by their MHC-
independent recognition of TAAs.70 However, major clinical success of this modality is 
restricted to hematological cancers like multiple myeloma, and its impact on solid tumors is yet 
to be clinically validated.71 Currently, oncolytic virus is also FDA approved for melanoma 
treatment. An oncolytic virus is a virus that preferentially infects and kills cancer cells. As the 
infected cancer cells are destroyed by onco-lysis, they release new infectious virus particles or 
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virions to help destroy the remaining tumor while not harming normal tissue, as well as initiating 
innate and adaptive anti-tumor immunity.72 
          BRAF inhibition and combination BRAF/MEK inhibition had been reported to be 
associated with higher CD8+ T-cell infiltration and PD-L1 expression.73 Hence, a combination of 
MAPK signaling inhibitors with immune checkpoint inhibitors could be considered a critical 
therapeutic strategy. Treatment with BRAF inhibitors induces an increase in antigen expression 
and decrease of immunosuppressive factors.74 The hypothesis is that the antigen-presenting cells 
could pick up antigen released from dying melanoma cells and cross-present them to T cells, 
therefore combination therapy with checkpoint inhibitors can potentially augment T-cell 
response. However, there are numerous limitations to this approach. For example, autoimmune 
toxicity is a primary concern. In fact, one of the early trials combining vemurafenib and 
Ipilimumab had to be terminated due to liver toxicity.75 Efforts need to be focused to understand 
the immunological modulations followed by treatment with combinations of targeted therapies 
and immunotherapies and translate the knowledge into tailoring the appropriate dosage and 
schedule of therapeutics in subsequent clinical trials. 
 
1.6 Demand of efficient delivery systems: Scope of nanomedicine 
          Nanomedicine involves the development and design of materials at the nanoscale and has 
been extensively investigated in the past few decades for development of efficient delivery 
systems for diagnostics and therapeutics in a multitude of diseases. Resistance to 
chemotherapeutics in melanoma has been attributed to high intra-tumoral pressure induced by 
stromal cells, poor perfusion, drug efflux, and intracellular entrapment, leading to inefficient 
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drug delivery. It is theoretically possible to design NP formulations capable of altering bio-
distribution of therapeutic cargo and mediating better payload accumulation in a target of interest 
by active targeting.76 
          There are many arenas in which NPs can potentially serve as robust delivery platforms. 
With increasing demand for combinatorial drug regimens, it is possible to harness the potential 
of NPs to precisely tailor the ratio of individual drugs and further mediate sequential release. 
Guo et al. demonstrated sensitization of melanoma cells to cisplatin therapy by co-delivery with 
rapamycin, an mTOR inhibitor that mediated microenvironment modulation and synergistically 
affected the efficacy of cisplatin.77 Peptide antigens, when delivered systemically, suffer from 
suboptimal cytosolic delivery to DCs, and high-dose administration may induce significant 
toxicity. Xu et al. managed to co-encapsulate Trp2, a melanoma antigen with immune-stimulant 
CpG, on a lipid-calcium phosphate NP platform and induced a potent CTL response and superior 
tumor inhibition in a murine melanoma model. RNA interference is another key therapeutic 
application where NPs can serve as a potent delivery platform. Beloor et al. explored the 
potential of a polymer-based siRNA delivery platform to efficiently co-deliver a cocktail of 
siRNAs like Bcl-2, VEGF, and c-myc in a mouse xenograft tumor model and demonstrated 
robust tumor control. The Trp2 vaccine discussed earlier was less effective in a late-stage 
melanoma model.78 In a follow-up study, a liposome-protamine-hyaluronic acid-based NP 
platform was exploited to deliver siRNA against transforming growth factor-β (TGF-β), because 
immunosuppressive cytokines like TGF-β were found to be elevated in a TME. Thus, the 
combination of an antigen-specific CTL response was harnessed to a rational modulation of an 
immune microenvironment using an NP-based delivery system.  
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          Despite intensive pre-clinical development, success in the clinical setting has been 
disappointing so far due to rapid reticuloendothelial system (RES) clearance, difficulty related to 
scalability, and toxicity issues. The grand diversion between animal models and human diseases 
has further affected successful translations.79 A considerable number of “multi-functional” NPs 
are currently under investigation in pre-clinical models and early clinical trials, although there is 
a long way to go before translation into a clinical modality.  
 
1.7 Organization of this dissertation 
          In desmoplastic melanoma (DM), a rare histological variant of melanoma, the malignant 
tumor cells are surrounded by rich fibrous tissues, thus compromising the efficacy of therapeutic 
options. The interstitial cells, especially TAFs construct an extracellular matrix-rich structure and 
cytokine crosstalk, thus facilitating aggressive and highly metastatic tumor growth. Moreover, 
the fibrosis raises delivery barriers for effective therapies.  
          In the dissertation work, we grafted murine model of DM mimicking clinical settings. The 
BPD6 melanoma cell (BRAFV600E, PTEN-/-, syngeneic with C57BL/6) -inoculated mice 
sequentially bearing aggressively-grown and highly desmoplastic tumors. The oncogenic 
mutations in the BRAF gene (BRAFV600E mutation is the major common one), which encodes a 
serine/threonine-protein kinase B-Raf, accounts for ~50 % of patient cases. When comparing to 
BRAF-wildtype, the DM tumors are often resistant to conventional chemotherapies. Hence, new 
treatments deemed necessary.  
          Recent advances in immunology and cancer biology, including a better understanding of 
signaling pathways in cancer progression, have promoted cancer immunotherapy as a new way 
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of halting growth and metastasis. Furthermore, developments in nanotechnology provide us with 
new approaches for targeted delivery of therapeutics to malignancy and improved efficacy. Thus, 
this dissertation is built upon DM as a disease model, to further investigate nano-approaches in 
immunotherapy.  
          Immunotherapy harnesses the patient’s immune system to combat cancer. The typical 
strategy is to generate a large number of antigen-specific CTLs to battle against tumor cells by 
vaccination. Herein, we explored a new potent tumor-specific nano-vaccine in its preventive and 
therapeutic efficacy (Chapter 2). Furthermore, we explored targeted nano-delivery of TME-
changing motifs, including FDA-approved anti-cancer chemo-drug Sunitinib (SUN) (Chapter 3) 
and active compounds Fraxinellone (Frax) (Chapter 4), in synergy with efficient vaccines. As a 
major component of suppressive TME, the TAFs are one of the major stroma cells that regulate 
tumor cell proliferation and metastasis and secrete extracellular macromolecules to stiffen the 
extracellular matrix (ECM). As two major dominators within the DM TME, tumor cells and 
TAFs further secrets key molecular controlling fibrosis and inducing DC tolerance, thus dampen 
effective antigen-presentation and the recruitment of effective CTLs. Therefore, mechanism 
study emphasis on interaction between TAFs and cells within TME are further investigated. 
Herein, gene-therapy “trapping” key molecule Wnt5a within TME (Chapter 5) and a design of 
combining chemo- with immune-therapy (Chapter 6) aiming at triggering effective 
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1.8 Key novelties of research 
          A. Deep understanding of TME and immune modulators in DM. 
          B. Clinical translational designs of vaccination and TME-related therapeutic regimens.  
          C. Nano-strategies applied in achieving high drug-loading efficiency, targeted local 
delivery and release of therapeutics, as well as low systemic toxicities of hosts for promising 
anti-tumor efficacy.  
          D. Effective immune-surveillance in DM-bearing host and significant elongation of 
survival.    
 
1.9 Contributions to the dissertation research 
          Dr. Leaf Huang mentored in the designs of all projects, the drafting and revision of all 
papers. All collaborators Dr. Hongda Zhu (chapter 3), Dr. Lin Hou (Chapter 4), Dr. Rihe Liu 
(Chapter 5), Fengqian Chen (chapter 6) participated in performing the experiments, analyzing the 
data, and drafting the manuscripts. All authors have discussed the results and commented on the 
published journals and submitted manuscripts.  
 
1.10 Publications for different parts of this dissertation 
          Chapter 1: The majority of this chapter has been published in Advanced Drug Delivery 
Reviews. (Q Liu, M Das, Y Liu, L Huang. Targeted drug delivery to melanoma. Advanced drug 
delivery reviews. 2017 Sep 19.) 
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          Chapter 2: The content has been published in Cancer Immunology, Immunotherapy. (Q 
Liu, H Zhu, Y Liu, S Musetti, L Huang. BRAF peptide vaccine facilitates therapy of murine 
BRAF-mutant melanoma. Cancer Immunology, Immunotherapy 2018 Feb;67(2):299-310) 
          Chapter 3: In preparation for publication in Theranostics. 
          Chapter 4: Accepted for publication in Theranostics, 2018. (L Hou*, Q Liu*, L Shen, Y 
Liu, X Zhang, F Chen, L Huang. Nano-delivery of fraxinellone remodels tumor 
microenvironment and facilitates therapeutic vaccination in desmoplastic melanoma) 
          Chapter 5: Published in ACS Nano. (Q Liu, H Zhu, K Tiruthani, L Shen, F Chen, K Gao, X 
Zhang, L Hou, D Wang, R Liu, L Huang. Nanoparticle-Mediated Trapping of Wnt Family 
Member 5A in Tumor Microenvironments Enhances Immunotherapy for B-Raf Proto-Oncogene-
Mutant Melanoma. ACS nano 2018 Jan 31) 















          Cancer immunotherapy primarily depends on tumor-associated antigens, which are 
overexpressed during malignant tumor cell development. The immune system is manipulated to 
recognize tumor-associated antigens and raise a specific immune response against the cancer 
cells. The typical strategy is to generate many antigen-specific T cells to battle the tumor by 
using cancer vaccines.80 Notably, 50 % of human melanomas are driven by BRAF mutations, 
among which BRAFV600E mutation is a majorly common one, characterized by aggressive 
growth and a highly immunosuppressive TME.81 These tumors are often resistant to immune 
vaccination therapy. Therefore, inducing a BRAF-mutation-specific and potent T-cell response 
to endogenous antigens remains challenging. The murine BRAFV600E mutant peptide (mBRAF 
594-602: FGLANEKSI) for the C57Bl/6 haplotype (H2Db) was designed by modifying amino 
acids at the 5 and 9 positions to increase binding affinity using the Rammensee epitope 
prediction model.82 A previous report on type 1-polarized DCs pulsed with affinity-modified 
BRAFV600E peptide showed antigen-specific CD8+ T-cell responses,83 supporting mutated BRAF 
                                                          
2 This chapter previously appeared as an article in Cancer Immunology, Immunotherapy. The original is as follows: 
Q Liu, H Zhu, Y Liu, S Musetti, L Huang. “BRAF peptide vaccine facilitates therapy of murine BRAF-mutant 
melanoma.” Cancer Immunology, Immunotherapy 2018 Feb;67(2):299-310 
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as a potential immune system target. However, cell-based vaccination is both costly and less 
reproducible compared with an injectable chemical dosage of nano-formulation for targeted 
delivery of nano-formulation for targeted delivery to the draining LNs. In this study, we aimed
to use a BRAF-mutant melanoma in a syngeneic mouse model to study tumor growth inhibition 
using a tumor-specific BRAF peptide vaccine delivered by DC-targeting NPs.  
          Our lab has established a nano-formulation called lipid-calcium-phosphate (LCP) NPs for 
delivering nucleic acids, peptides, and chemotherapeutic drugs.6, 84 The NP core, supported by 
lipid bilayers, may offer efficient encapsulation and delivery of acid and peptides. Injected NPs 
must overcome both kinetic and physical barriers after administration. This is especially true for 
peptides and nucleic acids. After the NP formulation is administered, it must protect the cargo 
molecules from enzymatic degradation by endogenous nucleases. It should also avoid 
aggregation, which can be accomplished by PEGylation. The BRAF peptide, along with CpG 
oligodeoxynucleotides (ODN) adjuvant, was formulated in LCP NPs with mannose modification 
and delivered to the DCs in the LNs. This approach was very effective in inducing an antigen-
specific CTL response in the host and significantly inhibited primary BRAF-mutant melanoma 
growth. Variations in the extent to infiltrated suppressive leukocytes and T cells within the TME 
were also monitored after vaccination. The simple but sophisticated LCP NP design is an 
effective vaccine platform with great translational potential. The BRAF peptide vaccine, which 
has both MHC-I and HLA-restricted properties acts as a potent immunotherapy for BRAF-
mutant melanoma.  
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2.2 Results and discussion  
2.2.1 Affinity-modified BRAF peptide was readily packaged in LCP NPs  
          To achieve more efficient vaccination, we co-delivered NPs encapsulating both the tumor-
specific antigen and an adjuvant to antigen-presenting cells (APCs). CpG ODN, a potent 
adjuvant, could be efficiently encapsulated in LCP NPs; this system was extensively 
characterized and optimized in our lab.85 On the N-terminal of the BRAF peptide, 
phosphorylated serine residues were designed to facilitate CpG ODN encapsulation. CpG ODN 
was co-loaded in LCP NPs using a reverse oil-in-water micro-emulsion, amorphous calcium 
phosphate (CaP) precipitates were formed and then stabilized with DOPA. These particles cores 
were then coated with DOTAP/cholesterol and stabilized with DSPE-PEG and DSPE-PEG-
mannose. The zeta potential, as determined by a Zetasizer, was approximately 15 mV, which was 
indicative of full PEGylation of the LCP NPs. Transmission electron microscope (TEM) images 
were taken to investigate the NP morphology and to confirm the size of the LCP NPs (Figure 2 
a-d). The LCP NPs loaded with the modified BRAFV600E peptide and CpG were spherical with a 
diameter of approximately 30 nm after uranium acetate staining. The encapsulation efficiency 
was about 60 % after optimization. Mannose modification achieved enhanced and prolonged 
accumulation of the NPs in the LNs, whereas the targeted delivery of NPs to draining LNs 
facilitated local DC activation (CD11c+CD86+), as well as local T-cell activation (CD8+CD69+), 
thus boosting immune efficiency (Figure 2 e-f).  
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          Figure 2. Characterization of the LCP NP-based BRAF peptide vaccine. LCP encapsulating the modified 
melanoma-specific antigen (BRAFV600E) and adjuvant (CpG ODN) illustrated efficient antigen loading and DC 
activation. Panels (a) and (b) show TEM images of NP cores and final structure. Size distribution (c) and Zeta 
potential (d) show NP characteristics. Cy5-labeled NPs show enhanced accumulation in draining LNs and uptake in 
proximal DCs (e) after mannose-modified LCP encapsulation, which facilitated local DC activation and T-cell 
activation (f). n = 5, *: p < 0.05, **: p < 0. 01. 
 
2.2.2 BRAF peptide vaccine induced an antigen-specific immune response 
          We proceeded to evaluate therapeutic efficacy of vaccination in the murine BRAF-mutant 
melanoma syngeneic tumor model. CTLs can kill tumor cells, while interferon gamma (IFN-γ)-
producing T cells secrete cytokines to modulate the TME. Therefore, an assay for antigen-
specific CTL response measured the efficacy of vaccine formulation, moreover, measuring IFN-
γ-producing T cells would predict systemic T-cell function upon antigen presentation.78, 86 LCP 
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NPs loaded with the modified tumor-specific BRAF-mutant peptide were subcutaneously 
inoculated in the flank of the mice. CTL and ELISPOT assays were performed 1 week later to 
examine the antigen-specific T-cell response.  
          As shown in Figure 3a, immunization with LCP-NPs encapsulating the modified BRAF-
mutant peptide or CpG ODN alone boosted a modest (approximately 48 %) efficacy, whereas 
vaccination with empty particles or NP encapsulating BRAFWT peptide (the wildtype (WT) 
group) showed no noticeable BRAF-mutant specific CTL results. Only the combined group with 
tumor specific peptide and adjuvant proved effective (approximately 80 % efficacy), indicating 
robust BRAFV600E-specific responses. 
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          Figure 3. Antigen-specific immune response induced by the BRAF peptide vaccine. (a) In vivo CTL response 
after vaccination, n = 5. (b) IFN-γ production after vaccination was measured with ELISPOT assay system. One 
representative experiment from each group is shown. n = 5, N.S.: no significance, *: p < 0.05, **: p < 0. 01. 
 
          Moreover, consistent with the CTL assay, we found no significant IFN-γ production of 
BRAFV600E-pulsed cells in the spleens or LNs of naïve mice or empty NP-vaccinated mice, 
indicating none-detectable BRAFV600E-specific CTL responses (Figure 3b). IFN-γ release is 
largely boosted only by tumor-specific peptide + adjuvant vaccination. OVA-pulsed or 
BRAFWT–pulsed cells for any group in the spleen or LN also showed no significant IFN-γ 
production. 
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2.2.3 Enhanced T-cell infiltration into TME results in a superior antitumor vaccination 
effect 
          The therapeutic efficacy induced by the BRAF peptide vaccine was evaluated in a BRAF-
mutant melanoma model. As Figure 4 shows, this vaccine showed potent tumor growth 
inhibition compared with other groups. Empty LCP NPs and LCP NPs encapsulating CpG 
showed no significant therapeutic effect, whereas LCP NPs encapsulating the BRAF peptide 
showed modest efficacy, indicating the essential immune function of antigen presenting. 
Furthermore, the most effective anti-tumor action can only be achieved when using an adjuvant. 
Only the combined full vaccination significantly inhibited tumor growth (p < 0.01). Preventive 
vaccination further reduced melanoma risk. Giving two vaccination dosages (on day -14 and day 
-7 boosted), the rate of tumor progression was significantly decreased; the therapeutic 
group/control group (T/C) ratio was 22.3 %. Moreover, two out of ten mice achieved tumor-free 
survival, compared with the PBS control group, suggesting a potential preventive therapy for 
translational application. 
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          Figure 4. Antitumor activity of the BRAF peptide vaccine in murine BRAF-mutant model. Mice were 
subcutaneously inoculated with either 2 × 105 (a) or 1 × 106 (b) BPD6 cells on day 0. Vaccination with 5 % glucose 
(The PBS group), empty LCP (The Empty group), LCP-CpG (The CpG group), LCP-BRAF peptide (The BRAF 
group), or LCP-(BRAF+CpG) (The BRAF+CpG group) were given on day 10. Tumor growth was measured every 
2–3 days. Five mice from each group were sacrificed on day 29, and tumors, whole blood, and organs were 
harvested for further study. n = 5, *: p < 0.05, **: p < 0. 01. Preventive vaccination (n = 10) significantly reduced 
tumor growth compared with PBS control (n = 8), with T/C ratio of 22.3 %. Two animals in the vaccinated group 
did not grow tumors (c). 
 
          The vaccine’s enhanced antitumor effect was accompanied by an increase in CD8+ T-cell 
population in the tumors, as determined by both flow cytometry analysis and  
immunofluorescence staining (Figure 5). Tumor tissue slices from mice treated with the BRAF 
peptide vaccine showed extensive T-cell infiltration into the tumor region (Figure 5a). The 
tumors were further collected and dispersed into single cells. CD8+ T-cell (CD8+CD45+) and T-
cell activation (CD8+CD62L-) were analyzed with flow cytometry. The results confirm that the 
CD8+ T-cells significantly increased in number upon activation (Figure 5b). These data suggest 
the possibility that tumor-antigen-presenting APSs would significantly enhance CD8+ T-cell 
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activation and proliferation. The antigen-specific CD8+ T-cell killing induced potent cell death 
within the TME, as indicated by terminal deoxynucleotidyltransferase-mediated nick end 
labeling (TUNEL) assay (Figure 5c). 
 
          Figure 5. Enhanced T-cell infiltration into TME-induced potent CTL killing. (a) Tissue sections from murine 
BRAF-mutant model with different treatments were stained for CD8+ (red) and DAPI (blue), then analyzed by 
immunofluorescence microscopy. Scale bars indicate 200 μm. Arrow indicated infiltrating CTLs. (b) The percentage 
of CD8+ T-cell (CD8+CD45+) and its activation (CD8+CD62L-) within tumor regions were quantified by flow 
cytometry. (c) TUNEL assay indicating apoptotic cell death. Scale bars indicate 300 μm. Arrows indicate apoptotic 
regions.  Numbers in the panel indicate average values of three samples per group, quantified by Image J. *: p < 
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2.2.4 Changes of tumor-infiltrating immune cells and collagen within the TME 
          To further elucidate the effect of BRAF peptide vaccination in improving T-cell 
infiltration, the changes of the related immunosuppressive subsets such as regulatory T cells 
(Tregs) and myeloid-derived suppressor cells (MDSCs) were evaluated, which contribute to a 
complicated interplay network with CD8+ T-cell antitumor activity within the collagen-rich 
BRAF-mutant murine model.87 The accumulation of these immunosuppressive cells was 
measured by flow cytometry. As shown in Figure 6a-b, the percentages of Tregs and MDSCs in 
the BRAF peptide vaccine group were much lower than in other groups. Macrophages are 
another important component of the suppressive tumor immune microenvironment. As shown in 
Figure 6c, vaccination could efficiently stimulate macrophages to an advantageous tumor-
suppressive M1 macrophage (M1) state. Vaccination significantly increased cytokine production 
of IFN-γ and Interleukin-4 (IL-4) and decreased anti-inflammatory C-C motif chemokine 2 
(CCL2) and Interleukin-6 (IL6) production (Figure 6e). The BRAF control group alone is 
insufficient to build up Type 1 T helper (Th1) type immunity. Interestingly, it correlated with 
increased Tregs and MDSCs. Tumor profiling of cytotoxic T-cell (CD8+CD45+), T-cell 
activation (CD8+CD62L-), MDSCs (CD11b+Gr1+), Tregs (CD4+Foxp3+), and the M1 
(F4/80+Ly6C+) to M2 macrophage (M2) (F4/80+CD206+) ratio indicated a strong correlation 
between high levels of MDSCs and Tregs present in TME with loss of T-cell function 
(activation). Furthermore, a significant decrease in collagen after vaccination indicated a change 
of the TME morphology that favored further CTL infiltration (Figure 6f). Although we found no 
significant increase in infiltrating CD4+ T cells after vaccination (Figure 6d), there was an 
overall significant remodeling of the suppressive TME in favor of immunotherapy. 
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          Figure 6. Change of TME. The percentage of MDSCs (a), Treg cells (b), M1-to-M2 ratio (c) and CD4+ T 
cells (d) within tumor regions were quantified by flow cytometry. Rt-PCR elucidated inflammatory cytokine profile 
within TME (e). Masson’s trichrome staining (f) indicating change in collagen after different treatments. Numbers in 
the panel indicate average values of three samples per group, quantified by Image J. n = 5. *: p < 0.05, **: p < 0. 01. 
Scale bars indicate 300 μm. 
 
2.2.5 Toxicity evaluation  
          There was no significant loss in mice body weights, which might indicate none detectable 
treatment toxicity. No significantly noticeable morphological changes occurred in major organs 
(Figure 7). Additionally, serum biochemical value analysis demonstrated normal liver (aspartate 
aminotransferase (AST), alanine aminotransferase (ALT)) and kidney (creatinine, blood urea 
nitrogen (BUN)) function. Whole blood cell counts remained constant within normal ranges for 
all the groups, suggesting that no systemic anemia or inflammation occurred after treatments.  
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          Figure 7. Safety profile of the BRAF peptide vaccination. (a) Body weights of mice in each group. (b) Whole 
blood and serum toxicity evaluation. (c) H&E morphology evaluation. The BPD6-bearing mice were divided into 
five groups with different treatments. Body weights were evaluated every 2-3 days. Mice were euthanized at the 
endpoint with blood and major organs collected for blood serum, and H&E tests. Scale bars indicate 300 μm. n = 5. 
N.S.: p > 0.05. 
 
2.3 Conclusion 
          Management of advanced melanoma is still a major challenge, and the development of a 
better understanding of melanoma biology is essential to design new therapeutic strategies and 
address present challenges associated with existing therapies. In the present work, vaccination 
using NP-delivery effectively treated aggressive growth of BRAF-mutant melanoma. In 
summary of current strategy: on one side, by predicting peptide-MHC class I binding using 
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artificial neural networks (the NetMHC 4.0 developed by Technical University of Denmark),88, 89 
we identified the murine BRAFV600E peptide FGLANEKSI as a strong binder with binding 
affinity of 104.92 nM and 0.07% rank (strong binders are defined as having %rank<0.5, and 
weak binders with %rank<2). On the other side, In vivo studies demonstrated that a single 
vaccination can induce a strong antigen-specific CTL response and potent tumor growth 
inhibition for approximately 2 weeks. Again, our LCP NPs provided enhanced vaccination 
efficacy. LCP, as a Ca2+ reservoir, could effectively modify the intracellular calcium dynamics 
that drive DC maturation for antigen presentation in a timely manner.90 This advantage allowed 
the DCs to orchestrate cytokine production and antigen presentation to induce a potent immune 
response.  
          CD8+ T-cell-mediated immunity was one crucial mechanism for enhanced antitumor 
immunity.91 BRAF peptide vaccination induced a local enhancement of tumor-specific T-cell 
infiltration, thus facilitating immune response activation, resulting in a long-term sustained 
effect. After vaccination, cytotoxic T cells increasingly infiltrated TME derived inflammatory 
cytokines such as IFN-γ and IL-4 and therefore amplified macrophage polarization. The 
inflammatory TME facilitated further Ly6C+ monocyte differentiation into M1-like functional 
phenotypes (F4/80+Ly6C+). These M1 state macrophages were recruited predominantly to the 
site of cancer. These key effector cells in the TME boosted local tumor antigen uptake and 
provided protection against tumor cells. Vaccination, when given at an early stage of tumor 
progression (tumor volume approximately 50 mm3 or smaller), would effectively skew immune 
reactions towards Th1 type. Our data showed a significant decrease in anti-inflammatory 
cytokines such as CCL2 and IL6. The Th1 type TME promoted effective CTL infiltration rather 
than activation of Tregs. These cytokine mediators regulated the expansion, migration, and 
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activation of immune suppressive cells in a combinatorial manner. The attraction of CCL2 to 
MDSCs is well documented.92 Increased IL6 signaling also promotes MDSCs proliferation once 
infiltrated. These vaccine data suggested a potential immunotherapy by blocking IL6 or CCL2 
within TME at an early stage of melanoma progression. Although there was no significant 
increase in TME infiltrating CD4+ T cells after vaccination, one approach to improve efficacy is 
to co-load BRAF class II peptides into the same NP delivery system, thereby enhancing the T 
helper cell memory response. Overall, the modified TME would further enable syngeneic mono-
antibody or chemotherapeutic nano-therapy, providing a promising strategy of combining 
immune therapy with chemotherapy. Thus, targeting TME-changing motifs along with efficient 
vaccination is a viable future research direction. One proposed project is to apply BRAF peptide 
vaccination on genetically engineered BRAF-mutant murine model, and plan to test this on a 
humanized murine model.  
          Dysplastic nevi, also known as unusual-looking benign (noncancerous) moles, are 
common among Caucasians.93 These atypical moles greatly increase the risk of developing 
melanoma, even if there is no family history of melanoma.94 The BRAF peptide vaccine, which 
can be designed as human leukocyte antigen (HLA)-restricted, may thus be developed as a 
preventive vaccination for use alongside regular exams. Theoretically, NP platforms can be 
exploited for combinatorial therapy by designing multimodal particles to further clinical 
translation.95 
 
2.4 Materials and Methods 
2.4.1 Materials 
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          Dioleoylphosphatydic acid (DOPA), (±)-N,N,N-trimethyl-2,3-bis(z-octadec-9-ene-
oyloxy)-1-propanaminium chloride (DOTAP), 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-[amino(polyethylene glycol)-2000 (DSPE-PEG-2000) and 3-(N-
succinimidyloxyglutaryl)aminopropyl, polyethyleneglycol-carbamyl distearoylphosphatidyl-
ethanolamine (DSPE-PEG-NHS) were purchased from Avanti Polar Lipids (Alabaster, AL). H-
2Db restricted peptides original BRAFV600E (FGLANEKSI), BRAFWT (FGLANVKSI), modified 
BRAFV600E peptide (pSpSSFGLANEKSI), and control peptide OVA (SIINFEKL) were 
purchased from Peptide 2.0 (Chantilly, VA). PEG-DSPE-Mannose was synthesized from DSPE-
PEG-NHS and 4-Amino phenyl-mannopyranoside. CpG ODN 1826 (5’-
TCCATGACGTTCCTGACGTT-3’) and Cy5-labeled ODN (5’-
CAAGGGACTGGAAGGCTGGG-3’) were purchased from Sigma Aldrich (St. Louis, MO).  
2.4.2 Cell Lines 
          Murine BRAF-mutant melanoma cell line BPD6 (BRAFV600E, PTEN-/-, syngeneic with 
C57BL/6) was obtained from Brent Hanks (Duke Cancer Institute, Durham, NC) and cultivated 
in RPMI-1640 Medium (Invitrogen, Carlsbad, CA) supplemented with 10 % FBS (Invitrogen) 
and 1 % Penicillin/Streptomycin (Invitrogen) at 37 °C and 5 % CO2. 
2.4.3 Preparation and Characterization of Vaccine Formulation 
          The LCP NP was synthesized in a water-in-oil reverse micro-emulsion.96 Ca phase was 
formed by mixing 600 μL of 2.5 M CaCl2 with or without peptide and/or CpG ODN in a 20 mL 
Cyclohexane/Igepal CO-520 (71:29, V: V) solution (oil phase). The oil phase was formed by 
mixing 600 μL of 12.5 mM Na2HPO4 (pH = 9.0). We stirred both phases for 5 min then added 
400 μL of 20 mM DOPA for 25 min. We then added 40 mL of ethanol and collected cores by 
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centrifugation. Ethanol washes were followed before collection of the cores. Final LCP NPs 
were formed by mixing 1 mL CaP cores, 100 μL of 20 mM DOTAP, 100 mL cholesterol, 10 mL 
DSPE-PEG-2000, and 10 μL DSPE-PEG-mannose. After removal of chloroform under reduced 
pressure, final particles were dispersed in 100 μL of 5 % glucose. Transmission electron 
microscopy (JEOL 100CX II TEM, JEOL, Japan) was used for particle characterization. Particle 
size and zeta potential were measured with a Malvern Zetasizer Nano ZS in water (Malvern, 
United Kingdom). DC accumulation of DSPE-PEG-mannose modified LCP NPs in the draining 
LNs was investigated by using LCP NPs containing a Cy5-labeled oligonucleotide and flow 
cytometry analysis of NP uptake in CD11c+ DCs. 
2.4.4 Tumor Growth Inhibition 
          Female C57BL/6 mice (6–8 weeks old) were purchased from Charles River Laboratories 
(Wilmington, MA). All animal studies were approved by the IACUC Committee at the 
University of North Carolina at Chapel Hill (UNC). On day 0, mice were inoculated 
subcutaneously with 1×106 BPD6 cells on their lower flank. Once the tumor volume reached 
approximately 50 mm3 (0.5 × length × width × height), mice were then randomized into five 
groups (n = 5-7) as follows: Untreated group (PBS group), Empty LCP NP (Empty group), CpG 
LCP NPs (CpG group), BRAF LCP NPs (BRAF group), and BRAF + CpG LCP NPs (BRAF + 
CpG group). Vaccination with LCP NPs was performed on day 10. We monitored tumor size 
(using digital calipers) and animal weight every 2–3 days. Mice were sacrificed before tumors 
reached 20 mm in one dimension. At the endpoint, tumors, major organs, and blood samples 
were harvested and tested. We evaluated antitumor efficacy by comparing relative tumor volume 
(RTV) value and T/C ratio. RTV = Vt/V0, Vt and V0 represent the tumor volume measured at 
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each timepoint interval and Day 0. T/C (%) = RTV of therapeutic group / RTV of control group 
× 100 %. T/C≤42 %, active, T/C ≤10 %, highly active. 
2.4.5 In Vivo CTL Assay 
          In vivo CTL was conducted per a previously published protocol.78 Mice were vaccinated 
with different formulations on the lower flank. Seven days later, the mice were intravenously 
injected with a mix of 5×106 splenocytes, half of which were pulsed by BRAFV600E peptide (10 
μM) while the other half were pulsed by OVA peptide (10 μM). The BRAFV600E pulsed cells 
were labeled with 4 μM carboxyfluorescein succinimidyl ester (CFSE) and OVA pulsed cells 
with 0.4 μM CFSE. These two population were referred to as CFSEhigh (BRAF
V600E pulsed cells) 
and CFSElow (OVA pulsed cells). After 18 h, splenocytes were collected and analyzed by flow 
cytometry. CFSEhigh and CFSElow, as well as in vivo BRAF
V600E specific lysis was calculated.97 
The experiments were conducted in triplicate. Specific lysis was calculated as follows. 
          % specific lysis = (OVA*x-BRAF)/(OVA*x) × 100 %, 
          where x = BRAF/OVA from naive mice. 
2.4.6 ELISPOT Assay for IFN-γ Production 
          Mice were vaccinated with different formulations of treatment. Seven days later, spleen 
and draining LNs were collected into single cells and seeded on the capture antibody-coated 96-
well plate. IFN-γ production was measured with BDTM ELISPOT assay system (BD 
Pharmingen, San Diego, CA) per the manufacturer's instructions.86  
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2.4.7 Flow Cytometry Assay 
          Immune cell populations were analyzed by flow cytometry. Briefly, Tumor tissues or LNs 
were collected using collagenase A at 37 °C for 40-50 min. Single cells were harvested in PBS 
and stained with fluorescein-conjugated antibodies. Penetration buffer (BD, Franklin Lakes, NJ) 
was added for any intracellular cytokine staining. 
2.4.8 Immunofluorescence Staining 
          Staining was performed following tissue deparaffinization, antigen retrieval, 
permeabilization, and bovine serum albumin (BSA) blocking. Primary and secondary antibodies 
conjugated with fluorophores (BD, Franklin Lakes, NJ) were incubated overnight at 4 °C. Cell 
nuclei were counterstained with DAPI (Vector Laboratories Inc., Burlingame, CA). Images were 
collected using fluorescence microscopy (Nikon, Tokyo, Japan) and analyzed using Image J 
software. Three randomly fields were selected. 
2.4.9 TUNEL Assay 
          Assay performed following DeadEnd Fluorometric TUNEL System (Promega, Madison, 
WI) instructions98 and imaged using fluorescence microscopy. Fluorescently stained FITC 
(green) positives were defined as TUNEL-positive nuclei. Three fields were randomly selected 
and quantified. 
2.4.10 H&E Morphology Evaluation and Blood Chemistry Analysis   
          At the endpoint of the tumor inhibition study, mice with different treatments were all 
subjected to toxicity assays. Both whole blood and serum were collected. We collected and 
compared whole blood cellular components and tested for indicators of renal and liver function 
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such as creatinine, BUN, serum AST and ALT. Organs were collected and send out for H&E 
staining by UNC histology facility.  
2.4.11 Statistical Analysis  
          We used Prism 5.0 Software to conduct one-way ANOVA and a two tailed Student’s t-test 
and compared the data with those for the PBS control group. P-values less than 0.05 were 
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CHAPTER 3 
NANO-SUNITINIB REMODELING OF TME FACILITATES VACCINATION 
 
3.1 Introduction  
          Melanoma vaccines could induce a tumor-specific immune response to inhibit micro-
metastasis in its early stages when the suppressive effects of an advanced tumor are not yet an 
obstacle. In the previous work, a LCP NP as a nano-based carrier to efficiently deliver a tumor-
specific antigen, the BRAFV600E peptide, and CpG ODN (a Toll-like receptor 9 agonist) adjuvant 
elicited a robust antigen-specific cytotoxic T-cell response and potent tumor growth inhibition 
against the established DM (BRAF-mutant) model in its early stages.99 However, it remained 
difficult to control tumor growth effectively once the tumor progressed to a later stage, likely due 
to presence of the immune-suppressive TME. The tumor immune-suppressive microenvironment 
limits effector T-cell activity, which is a major hurdle for an effective vaccine therapy, thus 
contributing to tumor progression.80 SUN malate is an oral broad-spectrum tyrosine kinase 
inhibitor. SUN has antiangiogenic and tumor apoptosis properties, which also shows 
immunomodulatory features.100 It has become an attractive drug to explore for treating 
melanoma.101, 102 In our previous work, the aminoethylanisamide (AEAA)-modified polymeric 
NPs were utilized as the drug delivery system for loading in-dissolvable drug such as SUN base 
(SUNb-NP) or rapamycin, enhanced the antigen-specific immune response and exhibited 
effectively anticancer activity in BRAF-wildtype melanoma model.103 Compared with wildtype 
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BRAF, i.e., the murine B16F10 model, BRAF-mutant melanoma is characterized by more 
aggressive growth and by the existence of a highly immune-suppressive desmoplastic
TME. In clinical trials, such patients with BRAF-mutant melanoma were largely incapable of 
achieving long-lasting remissions from novel immunotherapies, for example, with the cytokine 
IL 2 therapy. The major reason why this type of tumor has relatively low response to 
immunotherapy might be limited by T-cell transportation and loss of tumor antigen presentation 
due to immune-suppressive TME.17, 99 There are still much challenges in TME remodeling in the 
advanced BRAF-mutant melanoma. Herein, we hypothesized that SUNb-NP may work 
synergistically with our NP vaccine for therapy of advanced DM. The combination therapy may 
remodel the immune-suppressive microenvironment, achieve enhanced antigen-specific CTL 
response and increase antitumor effect on late-stage tumor. Data were collected and under peer-
review in Molecular therapy. (H Zhu*, Q Liu*, L Miao, S Musetti, L Huang. Remodeling 
Immune Suppressive Microenvironment of Desmoplastic Melanoma to Facilitate Vaccine 
Immunotherapy) 
 
3.2 Results and discussion 
3.2.1 Characterization of SUNb-NP and LCP-BRAF peptide vaccine 
          Polymeric micelles provide an advantageous platform to deliver hydrophobic drugs to 
tumor.104 Here, SUN base was encapsulated into targeted AEAA-modified poly-lacticglycolic-
acid poly (ethylene glycol) (PLGA-PEG-AEAA) micelles per the previously described 
protocol,103 drug loading (DL) and encapsulation efficiency (EE) of SUNb-NP was 11.6 ± 0.4 % 
and 73.5 ± 2.4 %, respectively. SUNb-NP was spherical with uniform size distribution (Figure 8 
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A and C) and showed smaller size than the blank polymer micelles (NP) (85.7 ± 2.3 nm & 116.4 
± 3.3 nm, respectively) owing to hydrophobic interactions between SUN and the hydrophobic 
cores of polymeric micelles (Table 1). The smaller size of SUNb-NP could enhance vessel 
permeability through the enhanced permeability and retention (EPR) effect and avoid rapid RES 
elimination.105 Figure 8D showed that SUNb-NP had excellent stability in vitro. The cytotoxicity 
of SUNb-NP slightly enhanced compared to SUN solution since the micellar nanoparticles 
increased cellular uptake above that of the free drug (Figure 8E). 
 
          Figure 8. Characterization of SUNb-NP and LCP-BRAF peptide vaccine. (A) Size distribution of SUNb-NP. 
(B) TEM images of LCP NP-based BRAF peptide vaccine. (C) TEM images of SUNb-NP after negative staining. 
(D) In vitro stability of SUNb-NP at 4 °C. (E) Cytotoxicity of SUN solution and SUNb-NP against BPD6 cells after 
48 h. The error bars in the graphs represent standard derivations (n=5). 
 
Table 1. Characterization of SUNb-NP (n=3) 
 Blank NP SUNb-NP 
Size (nm) 116.4±3.3 85.7±2.3 
Zeta (mV) -17.0±0.3 7.0±0.2 
 49  
 
          The LCP NP was established for the delivery of nucleic acids and peptides.106 It is 
particularly suitable for delivery of a peptide antigen together with a nucleic acid adjuvant to the 
DCs, because the NP vaccine can effectively modify the intracellular calcium dynamics and 
drive the maturation of dendritic cells for antigen presentation in a timely manner.107, 108 The 
BRAF peptide and CpG oligonucleotide adjuvant were encapsulated into LCP NPs using the 
method previously described. TEM analysis showed the NPs were spherical and had a diameter 
of around 30 nm after negative staining with uranium acetate (Figure 8B). Encapsulation 
efficiency was about 60 % for both the BRAFV600E peptide and CpG. 
3.2.2 In vivo anti-tumor efficacy 
          A mannose-modified LCP NP encapsulated the BRAF peptide vaccine could induce a 
favorable antigen specific CTL response and anti-tumor efficacy in early stage of murine DM 
model (less than 200 mm3 in tumor volume), but it exhibited only a partial antitumor effect in 
advanced stage.99 In this study, the therapeutic efficacy induced by SUNb-NP combination with 
the BRAF peptide vaccine was evaluated with advanced stage of DM model (300 ~ 400 mm3 in 
tumor volume). In the tumor growth curve shown in Figure 9, vaccine monotherapy exhibited 
only a partial antitumor effect. Interestingly, SUNb-NP group showed improved tumor growth 
inhibition efficacy than the vaccine group (p < 0.01, SUNb-NP vs vaccine, n=5-8), and combo 
group achieved the highest anti-tumor efficacy among all groups. The result indicated the tumor-
specific immune function elicited by the vaccine could be boosted by SUNb-NP. Furthermore, an 
overall survival analysis showed that the median survival for the combo group was 41 days, as 
opposed to 27, 28 and 33 days for PBS, vaccine and SUNb-NP groups, respectively (Figure 9B), 
and achieved long-lasting overall response and superior therapeutic effect (p < 0.001, n=10~18). 
The inhibition ratios based on the tumor weight (Figure 9C) were consistent with tumor volume 
 50  
 
measurement. The TUNEL apoptosis assay in Figure 9D and E also indicated that SUNb-NP 
could significantly enhance the tumor-specific immune response and induce higher cellular 
apoptosis.  
 
          Figure 9. Anticancer efficacy in advanced DM model. Mice were subcutaneously inoculated on day 0 with 
1×106 BPD6 cells. Vaccination with LCP-BRAF peptide vaccine was s.c. injected at a dose of 200 μg /kg on day 12 
and 20; SUNb-NP was administered i.v. from day 12 and injected every other day at a dose of 20 mg/kg with 5 total 
administrations, respectively. Body weight and tumor size were detected every two days. Blood samples, major 
organs and tumor tissue were harvested on day 24. (A) Tumor volumes of mice via function of time. The arrows 
indicate the time of drug administration (blue for vaccine and red for SUNb-NP, n=5-8). (B) Survival of mice in 
different treatment groups (n=10-18). (C) Tumor inhibition ratio. (E) TUNEL-positive cells in tumor sections 
stained using commercial apoptosis detection kit (green). DAPI (blue) stained the cell nuclei, and the white scale bar 
represents 100 μm.  Three selected randomly images were quantified by Image J (in D). *p < 0.05, **p < 0.01, ***p 
< 0.001. 
 51  
 
          No significant loss in body weight (Figure 10A) demonstrated minor toxicity of 
treatments. No significantly noticeable morphological changes in the major organs (Figure 10D) 
and normal ranges in serum biochemistry (Figure 10 B and C) suggested no systemic toxicity 
occurred after treatments. 
 
          Figure 10. Safety evaluations. (A) Body weight change of BPD6 tumor-bearing C57BL/6 mice after 
treatments. (B) Liver, kidney function assays and (C) whole blood cell analysis after treatment. (D) H&E-stained 
heart, liver, spleen, lung, and kidney sections from BPD6 tumor-bearing C57BL/6 mice after treatment. The white 
scale bar represents 100 μm. Results were expressed as the mean ± S.D. (n = 4-5). 
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3.2.3 Pharmacokinetics and bio-distribution of SUNb-NP 
          As shown in Figure 11 and Table 2, the area under curve (AUC) value of 3H-labeled 
SUNb-NP after i.v. administration was 2.2 times higher than that of SUN solution. As Figure 
11B shown, SUN accumulation in tumors of SUNb-NP group was ~3 fold higher than SUN 
solution at 2 and 4 h after treatment. Bio-distribution study clearly showed a dominant 
accumulation of 3H-labeled SUN polymer micelles in the tumor (as of targeted delivery) and 
liver (as of major systemic clearance route) after i.v. administration (Figure 11C). The results of 
pharmacokinetics and bio-distribution studies indicated that AEAA-modified polymer micelles 
could selectively deliver SUN to the tumor and achieve higher bioavailability. 
 
 
          Figure 11. Pharmacokinetics and bio-distribution of SUN. (A) In vivo pharmacokinetics of 3H-labeled SUNb-
NP and SUN solution in BPD6 tumor-bearing C57BL/6 mice after treatment. (B) Tumor accumulation of 3H-labeled 
SUNb-NP and SUN solution at t = 2, 4 and 24 h after treatment. (C) Organs (heart, liver, lung, kidney, spleen) and 
tumor accumulation of 3H-labeled SUNb-NP and SUN solution at post-injection 2 h. The dose of 3H-labeled SUN 
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Table 2. In vivo pharmacokinetic parameters of 3H-labeled SUNb-NP and SUN solution in tumor-bearing 
C57BL/6 mice (n = 5) 
 3H SUN solution 3H SUNb-NP 
K (h-1) 0.10±0.03 0.01±0.01 
AUC0-t (mg.h/mL) 632.2±326.5 1381.9±442.6 
AUC0-∞ ((mg.h/mL) 688.1±367.3 1698.3±406.2 
T1/2 (h) 7.5±0.8 5.3±0.6 
 
3.2.4 TME remodeling by SUNb-NP 
          Structural changes in the TME. Here, the change of the vessel distribution and morphology 
in tumor was measured using CD31 (a blood vessel marker) immunofluorescence staining. As 
shown in Figure 12 (1st row), vessels were abundantly distributed in the tumor of PBS and 
vaccine group (red). High interstitial fluid pressure within the TME leaded to thin and elongated 
vessel structure (indicated by arrows), which greatly impeded the transport of drug from vessels. 
Interestingly, the vessels in the combination therapy treatment group showed a round 
morphology (indicated by arrowhead), as well as significantly decreased vessel density (Figure 
12B). We have also tested the NP penetration into the tumor by using Dil-loaded PLGA NPs 
(Figure 12A, 4th row). The PBS and vaccine group exhibited weak fluorescence due to poor 
tumor permeability, but SUNb-NP alone and combined treatment with vaccine elicited stronger 
and more widespread red fluorescence. The 1,1′-dioctadecyl-3,3,3′,3′-
tetramethylindocarbocyanine perchlorate (DiI) fluorescence intensity increased markedly in the 
combination therapy group (p < 0.05 compared with vaccine or SUNb-NP group, Figure 12E), 
which indicated the combo group displayed the highest permeability in the tumor. Tumor-
associated collagen and elastin in tumor tissues was characterized with the expression of α-
smooth muscle actin (α-SMA, a TAF marker).109 Representative immunostaining showed that 
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both the expression of α-SMA content and fibroblast population were decreased in SUNb-NP 
group and combined treatment group (Figure 12A, 2nd row and C). SUNb-NP combined with 
the vaccine almost removed the fibroblast population in cancerous tissue, indicating SUN 
significantly modulated TME modification through depleting TAFs. The over-expressed 
collagen in tumors could impede the function of antitumor immune cells and enhance tumor cell 
migration.110 The morphology and content of collagen were observed using Masson’s trichrome 
staining. BPD6 melanoma contained a collagen-rich stromal structure compared with BRAF-
wildtype melanoma B16F10. There was a significant decrease in collagen content after BRAF 
vaccination treatment in early tumor stages. Here, the fibrous structures using collagen staining 
(in blue) significantly decreased and almost disappeared in the SUNb-NP treated group and 
combined treatment group (Figure 12A, 3rd row and D). Overall, these data indicated that 
SUNb-NP combined with BRAF vaccination elicited the most significant changes of the TME 
morphology in such way that should favor further CTL infiltration. 
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          Figure 12. Structure changes in TME. (A) CD31+ antibody (red) visualized tumor vasculature (1st row, 
arrows and arrowheads indicated the elongated vessels or round vessels, respectively); α-SMA antibody (red) 
characterized TAFs in tumors (2nd row); Collagen fibers was stained with Masson’s trichrome (blue, 3rd row); 
Tumor permeability of Dil-loaded NP (red, 4th row). DAPI (blue) stained the cell nuclei, and the white scale bar 
represents 200 μm. To quantify the data in the images, three selected randomly images were analyzed using Image J 
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          Change of immune cells within the TME. Structural changes in the TME also favor the 
infiltration of immune cells into the tumor.91 The enhanced antitumor effect in three treatment 
groups was accompanied by an increase in CD8+ T-cell population in the collagen-rich BPD6 
model, as measured by immunofluorescence staining and flow cytometry (Figure 13A and B). 
Vaccination increased CD8+ T-cells, but also led to an increase in immunosuppressive cells 
(MDSCs and Tregs), which could impair the T-cell activation and result in poor anti-tumor 
efficacy. As shown, the percentages of Tregs and MDSCs111 in BRAF vaccine monotherapy 
group was higher than other groups, which was an important factor for the partial anti-tumor 
efficacy of vaccine alone treatment. However, the percentages of Tregs and MDSCs were 
significantly lower in the SUNb-NP group and combination therapy than the vaccine 
monotherapy group (p < 0.001), indicating the superior ability of SUN to remodel the 
suppressive TME in favor of immunotherapy.  
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          Figure 13. Change of tumor-infiltrating immune cells in TME. (A) CD8+ T cells, MDSCs and Tregs cells 
using immunofluorescence staining, scale bar represents 100 μm. (B, C, D) The percentage of CD8+ T-cell, MDSCs 
and Tregs cells within tumor regions were analyzed using flow cytometry. *p < 0.05, **p < 0.01, ***p < 0.001, n = 
3. 
 
          Cytokine expression in the TME. As shown in Figure 14, the cytokine expression after 
treatment with BRAF vaccine alone resulted in both escalated Th1 and Th2 cytokine expression. 
The high level of Interleukin-10 (IL10), IL6 and TGF-β were responsible for the poor anti-tumor 
efficacy of vaccine alone treatment group at the advanced stage of tumor growth.112 However, 
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combination therapy group significantly increased cytokine production of IFN-γ and IL-2, and 
decreased Type 2 T helper (Th2) cytokine expression, which would facilitate tumor antigen 
presentation and enhance cytotoxic T-cell-mediated tumor-specific killing, halting tumor 
progression.113 
 
          Figure 14. RT-PCR elucidated inflammatory cytokines within the TME. *p < 0.05, **p < 0.01, *** p < 0.001, 
n = 5. 
 
3.2.5 Signaling pathway determination 
          To explore the underlying mechanism of SUNb-NP on remodeling the TME, expression 
levels of several signaling molecules such as Stat3, AKT and PD-L1 were examined using 
western blot analysis. In Figure 15A and B, the p-Stat3 levels were not reduced in the vaccine 
monotherapy, whereas BRAF vaccine together with SUNb-NP efficiently decreased the p-Stat3 
level in the tumor. SUNb-NP alone showed only a modest reduction. A similar decreased pattern 
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in p-AKT expression was detected in the combination therapy. Reduction of p-Stat3 and p-AKT 
should associate with reduced tumor growth.101 As shown, tumor PD-L1 expression level in mice 
treated with BRAF vaccine alone and SUNb-NP, respectively, exhibited a significant inhibition, 
though the combination therapy did not enhance the downregulation. The results indicated that 
down-regulated check point PD-L1 could enhance antigen-specific CTL killing of the tumor 
cells. 
 
          Figure 15. Oncogene expression levels. The level of p-Stat3, p-AKT and PD-L1 in tumor were examined by 
western blotting. (A) Relative band intensity was quantified by Image J (B, C, D). *p < 0.05, **p < 0.01, ***p < 
0.001, n = 3. 
 
3.3 Conclusion 
          Our previous work proved that SUN encapsulated into targeted PLGA-PEG-AEAA 
micelles could specifically remodel the immune suppression in BRAF-wildtype melanoma 
model (B16F10) and enhance the antigen-specific immune response. Compared with B16F10 
model, the BRAF-mutant melanoma had richer the dense collagen matrix, which induced high 
interstitial fluid pressure and obstructed the therapeutic efficacy of drugs. Immune-suppressive 
TME often exists in advanced malignancy grades, which support immunologic escape, drug 
resistance, tumor recurrence and metastasis. Considering the many formidable barriers, we 
provided a possible approach to synergistically combine SUNb-NP with vaccine therapy for the 
advanced DM.  
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          Why the combination treatment group could boost tumor-specific immune response and 
achieve the improved antitumor efficacy compared to vaccine monotherapy group? As shown in 
this study, SUNb-NP could normalize vasculature in tumor and significantly reduce the collagen 
and tumor-associated fibroblasts through depleting TAFs. High interstitial fluid pressure within 
the TME often leads to thin and elongated micro-vessel structure, which greatly impede the 
transport of drug from vessels. The normalized vasculature in the tumor should enhance the 
delivery of drug and the infiltration of lymphocytes into the tumor. In addition, the over-
expressed collagen in tumors can inhibit the function of antitumor immune cells and enhance 
tumor cells migration. Structural changes in the TME also favored the infiltration of immune 
cells into the tumor. CD8+ T-cell mediated immunity is one crucial mechanism for enhanced 
antitumor immunity. To further elucidate SUNb-NP and vaccination in improving CD8+ T-cell 
infiltration, we also evaluated the changes of the related immunosuppressive cell subsets such as 
Tregs and MDSCs, which contributed to a complicated interplay network with CD8+ T-cell 
antitumor activity within the collagen-rich DM model. The vaccination increased CD8+ T cells 
and induced a local enhancement of tumor-specific T-cell infiltration. It also led to an increase in 
immunosuppressive cells (MDSCs and Tregs), which could impair the T-cell activation and 
result in poor anti-tumor efficacy. SUNb-NP combination therapy treatment could reduce the 
MDSCs, Tregs and improve CD8+ T-cell infiltration, indicating the superior ability of SUN to 
remodel the suppressive TME in favor of immunotherapy. 
          Immune-suppressive cells in tumor express cytokines to shape the TME. Th1 cytokines 
including IFN-γ, IL2 and Th2 cytokines such as IL6, IL10 and TGF-β present to elicit or inhibit 
anti-tumor immunity respectively. Thus, cytokine profiles of Th1 increase or Th2 loss reflect the 
pharmacological action of effective treatments on the suppressive cells during tumor growth. Our 
 61  
 
data showed that combination therapy group significantly increased cytokine production of IFN-
γ and IL-2 and decreased Th2 cytokines expression, which would facilitate tumor antigen 
presentation and promote effective CTL infiltration, halting tumor progression. 
          Expression levels of several signaling molecules such as Stat3, AKT and PD-L1 could 
explore the underlying mechanism of SUNb-NP on remodeling the TME from immune-
suppressive to immune-responsive. Phosphorylated Stat3 and AKT represent the activated form 
of these proteins, which would further play an important role in tumor cell apoptosis and tumor 
immune evasion. Reduction of phosphorylated Stat3 activity could enhance the antitumor effects 
due to expression of activated p-Stat3 reduce tumor cell death, which was consistent with our 
tumor growth inhibition result. Meanwhile, Stat3 is involved in the accumulation of tumor–
associated MDSC and Tregs, which plays an important role at the suppressing immune 
responses. Our results demonstrated that the decreased p-Stat3 expression by SUN could reduce 
MDSC and Tregs. IL-6 mediating signaling could also activate Stat3, supported by the decreased 
level of IL-6 in the tumor tissue among SUNb-NP and combo group in our study. A similar 
decreased pattern in p-AKT expression was detected in the combination therapy. The inhibitory 
cytokines secreted by tumor cells for instance TGF-β, IL-10 and the inhibitory molecules such as 
PD-L1 expressed by TAFs could induce T-cell suppression. The results indicated that SUNb-NP 
and the combination therapy down-regulated the inhibitory cytokines and enhanced antigen-
specific CTL killing of the tumor cells. 
          In conclusion, SUNb-NP combined with the vaccine can remodel immune suppressive 
microenvironment in the advanced DM to facilitate vaccine immunotherapy without detectable 
side effects. If BPD6 and B16F10 models represent typical BRAF mutation and wild-type 
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melanoma, respectively, our current and previous study strongly demonstrate the clinical 
potential of SUNb-NP for all melanomas, especially when combined with a tumor vaccine.   
 
3.4 Materials and Methods 
3.4.1 Reagents  
          DOPA, DOTAP, and DSPE-PEG2000 were purchased from Avanti Polar Lipids 
(Alabaster, AL). PEG-DSPE-mannose was synthesized using DSPE-PEG-NHS (Avanti Polar 
Lipids, Alabaster, AL) and 4-amino phenyl-mannopyranoside (Sigma-Aldrich, St. Louis, MO). 
Cholesterol was obtained from Sigma-Aldrich (St. Louis, MO). H2Db restricted peptides 
including the original BRAFV600E (FGLANEKSI), BRAFWT (FGLANVKSI), modified 
BRAFV600E peptide, the ‘BRAF’ (pSpSSFGLANEKSI), and control peptide OVA (SIINFEKL) 
were obtained from Peptide 2.0 (Chantilly, VA). CpG ODN 1826 (5’-
TCCATGACGTTCCTGACGTT-3’) was purchased from Sigma Aldrich (St. Louis, MO). SUN 
base and SUN malate were purchased from Selleckchem (Houston, TX) and Sigma-Aldrich (St. 
Louis, MO) respectively. 3H-Labeled SUN TFA salt (20 Ci/mmol) was obtained from ViTrax 
(Placentia, CA). Acid-terminated poly (lactic/glycolic acid, 50:50) (PLGA) was purchased from 
DURECT (Pelham, AL). PLGA-PEG and PLGA-PEG-MBA were synthesized using PLGA, 
mPEG3500-NH2.HCl, tBOC-PEG3500-NH2.HCl (JenKem Technology, Allen, TX) and 
aminoethylanisamide (Sigma-Aldrich, St. Louis, MO) as previously described and 1H NMR 
confirmed the structure. 
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3.4.2 Animals and cell lines 
          Female C57BL/6 mice (6–8 week) were purchased from Charles River Laboratories 
(Wilmington, MA). All animal studies were carried out under the protocols which were approved 
by the IACUC committees at the University of North Carolina at Chapel Hill. Murine BRAF-
mutant melanoma cell line BPD6 (BRAFV600E, PTEN-/-, syngeneic with C57BL/6) was obtained 
from Dr. Brent Hanks (Duke Cancer Institute) and cultured in RPMI-1640 Medium (Invitrogen, 
Carlsbad, CA) containing 10 % (v/v) fetal bovine serum (Invitrogen, Carlsbad, CA) and 1 % 
Penicillin/Streptomycin at 5 % CO2 and 37 °C. 
3.4.3 Preparation and characterization of the formulations 
          The BRAF peptide encapsulated LCP NP vaccine was formulated by reverse micro-
emulsion technique as previously described.96 SUN base was loaded into polymeric micelles 
nanoparticle using the solvent displacement method.77 Five mg SUN base and 30 mg PLGA-
PEG/ PLGA-PEG-AEAA /PLGA polymers (weight ratio 7:2:1) were added in 600 μL 
tetrahydrofuran (THF). Under stirring, the mixed solution was dropwise added into 5 mL water. 
Removing of THF using reduced pressure, the SUNb-NP was further purified by centrifuging 
(6,000 g × 15 min) to remove un-encapsulated drug. SUNb-NP containing 
3H-labeled SUN base 
were prepared using the method described above, with the dose of 3H-labeled SUN fixed at 5 
μCi/mL. TEM (JEOL 100CX II TEM, JEOL, Japan) and Malvern Zetasizer Nano ZS (Malvern, 
Worcestershire, United Kingdom) were used to characterize micelles nanoparticles. UV 
spectrophotometer (BeckmanCoulter, Atlanta, GA) was measured for drug loading. DL and EE 
of SUNb-NP were calculated according to the previously formulas. The particle size and drug 
content were monitored for stability evaluation during storage at 4 °C. 
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3.4.4 In vitro cytotoxicity studies 
          The cytotoxicity of SUNb-NP and SUN malate (SUN solution) against the BPD6 cells 
were evaluated using MTT assay in vitro. The SUN solution (10 mg of SUN malate in 1 mL 
DMSO) and SUNb-NP were diluted to the designed series concentration of SUN (from 0.625 to 
50 μg/mL) with culture medium. The BPD6 cells were seeded in 96-well plates at 5×103 
cells/well and added into series concentration of SUNb-NP or SUN solution. The cell viability 
was performed using MTT assay after incubation for 48 h. IC50 value of SUNb-NP or SUN 
solution was calculated using GraphPad Prism software. 
3.4.5 In vivo anticancer efficacy 
          Murine DM model was built by inoculating subcutaneously with 1×106 BPD6 cells on the 
right flank of mice. Once tumor volume grew to 300~400 mm3 (length × width × width ×0.5), 
mice were divided into 4 groups randomly as follows (n=5-8 per group): (1) Untreated control 
group (PBS); (2) LCP-BRAF peptide vaccine at 200 μg BRAF peptide /kg (vaccine); (3) SUNb-
NP at 20 mg SUN base/kg (SUNb-NP); (4) LCP-BRAF peptide vaccine at 200 μg BRAF peptide 
/kg plus SUNb-NP at 20 mg SUN base/kg (Combo). For the vaccination group and combo group, 
vaccination with LCP NPs was s.c. injected on day 12 and 20. SUNb-NP was administered i.v. 
from day 12 and injected every other day with 5 total administrations. Body weight and tumor 
size were detected every two days. Blood samples, major organs and tumor tissue were obtained 
and tested for toxicity evaluation on day 24. Survival of murine BRAF-mutant melanoma model 
in different treatment groups (n=10~18 per group) was executed under same treatment as in 
tumor inhibition study.  
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3.4.6 In vivo pharmacokinetics and bio-distribution 
          Pharmacokinetics and bio-distribution studies of SUNb-NP were evaluated using 
3H-
labeled SUN polymer micelles on DM model. A dose of 20 mg/kg SUNb-NP or SUN solution 
containing 3H-labeled SUN TFA salt at 50 μCi/kg was i.v. injected, when tumor volume grew to 
~ 300 mm3. After injection 15 min, 30 min, and 1, 3, 4, 8, 20, and 24 h, blood samples were 
gathered from caudal vein. Under same treatments, major organs and tumor tissue were collected 
when the mice were sacrificed 2, 4, and 24 h post-i.v. injection. Briefly, the samples (100 mg 
tissues or 20 mg blood) were digested by NCS® II Tissue Solubilizer (Amersham Biosciences 
Corp. NJ-) at 60 °C overnight, then added 200 μL of H2O2 (30 % in water) and vortexed to 
remove potential pigmented quenching agents. The sample was added to 4 mL scintillation 
cocktail (Thermo Fisher Scientific Inc., MA) and analyzed with a liquid scintillation counter 
(Beckman coulter LS6500). The pharmacokinetics and bio-distribution were evaluated using 
percentage of the injected dose in blood samples or tissue (% ID/g). All tests were performed 3 
times. 
3.4.7 Tumor permeability 
          For the imaging of micelle nanoparticle distribution and tumor permeability, DiI as probe 
was loaded in polymer micelles according as described in section of formulation preparation. 
DiI-loaded NP was administered i.v. with a single dose of 0.5 mg/kg on the tumor-bearing mice 
which were under same treatment as in tumor inhibition study. The tumor tissues were collected 
24 h post-injection. To visualize micelle nanoparticle penetration, the tumor was lyophilized and 
sectioned. Images were collected by fluorescence microscopy (Nikon, Tokyo, Japan) and 
analyzed using Image J software. Three randomly fields were selected. 
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3.4.8 TME remodeling 
          Parameters including TME markers (CD31, α-SMA, collagen and immune cell) were used 
to illuminate TME remodeling process. Vessels were stained with CD31 using tumor frozen 
sections. First antibody was added and incubated overnight at 4 °C, following incubation with 
fluorophore-conjugated secondary antibody (BD, Franklin Lakes, NJ) for 1 h at room 
temperature. Tumor-associated fibroblasts (TAF) and collagen were characterized by α-SMA 
and Masson Trichrome kit respectively. The change of immune cell subsets such as antitumor 
cytotoxic T cell (CD8+ molecular markers), Tregs and MDSCs in TME were visualized using 
immunofluorescence staining. Staining was performed with paraffin section following tissue 
deparaffinization, antigen retrieval, permeabilization, and BSA blocking. T cells, Tregs and 
MDSCs were defined using FITC-conjugated rat-anti-mouse CD8a, FITC-conjugated rat-anti-
mouse CD4 and PE-conjugated rat-anti-mouse Foxp3, FITC-conjugated rat-anti-mouse CD11b 
and PE-conjugated rat-anti-mouse Gr1 respectively. Collagen was visualized according to 
Masson Trichrome kit’s instructions. Apoptotic tumor cells were characterized using the TUNEL 
assay kit (Promega, Madison, WI) and performed following TUNEL System instruction. Nuclei 
were double stained with DAPI (Vector Laboratories Inc, Burlingame, CA). Images were 
observed by fluorescence microscopy and analyzed using Image J software. Three randomly 
fields were selected. 
3.4.9 Flow cytometry analysis 
          Immune cell populations in tumor tissue were analyzed using flow cytometry. Fresh tumor 
tissues from in vivo anticancer efficacy experiment were collected with 1 mg/mL collagenase A 
(Invitrogen) and 200 μg/mL DNAase I (Invitrogen) at 37 °C for 40-50 min to generate single 
cells suspension. Single cells in PBS were stained with fluorescein-conjugated antibodies, 
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intracellular cytokine staining need to add penetration buffer (BD, Franklin Lakes, NJ). Flow 
cytometry was performed 3 times for each group. The results were analyzed by CellQuest 
software (BD Biosciences, San Jose, CA). 
3.4.10 Western blot analysis 
          The expression level of several signaling proteins in tumor tissue was evaluated using 
western blot. Tumors lysates were prepared and analyzed, then equal amounts protein of 
treatment group was separated by 10 % SDS-PAGE electrophoresis and transferred to 
polyvinylidene difluoride membranes (Bio-Rad) for immunoblotting as document described 
method.114 Primary antibodies against p-AKT, AKT, p-Stat3, Stat3 and PD-L1 (1:500-1,000 
dilution, Cell Signaling, Beverly, MA) were directed, GAPDH (Cell Signaling, Beverly, MA) 
was detected as loading control. After washing, the membrane was incubated with horseradish 
peroxidase conjugated secondary antibody (1: 1,000 dilutions, Cell Signaling, Beverly, MA) and 
developed using the Pierce ECL Western Blotting Substrate (Thermo, Rockford, IL). The 
expression level of each protein was quantified with ImageJ software, and performed in triplicate 
in each group. 
3.4.11 Statistical analysis 
          A two-tailed Student's t-test and one-way ANOVA were utilized to analyze in GraphPad 
Prism 5.0 Software (San Diego, CA). Data were shown as mean ± S.D., Values were indicated 
significantly difference when *p < 0.05; **p < 0.01 and ***p < 0.001. 
 
 
 68  
 
CHAPTER 4 
NANO-FRAXINELLONE REMODELING OF TME FACILITATES VACCINATION 
 
4.1 Introduction  
          The stroma of the DM includes TAFs, T cells, B cells and immunosuppressive cells. TAFs 
are one of the most prominent stromal cell types. It has been reported that TAFs are the receivers 
as well as the inducers of tumorigenic activation signals. Emerging evidence suggests that TAFs 
can modulate the immunosuppression of TME through diverse mechanisms, thereby supporting 
tumor progression.115, 116 For example, TAFs can suppress CTL-driven antitumor immunity and 
mediate immune suppression by modulating myeloid cells, such as tumor associated 
macrophages (TAMs), MDSCs, and tolerogenic DCs. TAFs can also mediate epithelial-
mesenchymal transition (EMT) of carcinoma cells, thereby contributing to the progression of 
cancer. Additionally, some growth factors secreted by TAFs like TGF-β play an important role in 
promoting the carcinogenic process.117 As a result, a bi-directional activation between cancer 
cells and TAFs has been identified as the leading cause to form the malignant phenotype of 
cancer.115 Taken together, TAFs are the potential target for treatment of desmoplastic melanoma 
and targeting TAFs will render both malignant and stromal compartments more responsive to 
immunotherapies. Encouragingly, our previous investigation on modifying TAFs through 
delivery of apoptosis-reducing ligand has proved effective to treat desmoplastic cancers.108, 118 
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          In recent years, we have studied natural products which target TAFs, especially on the 
interaction loop between TAFs and cancer cells. The focus of this work is on TGF-β, one of the 
key mediators for fibroblast activation and tissue fibrosis.119 Frax, a compound isolated from the 
root bark of Dictamnus dasycarpus, is reported to resolve liver fibrosis by reducing CUG-binding 
protein 1 (CUGBP1) expression and consequently regulating TGF-β and IFN-γ signaling.120 
Other studies have examined Frax for its actions such as anti-inflammatory, neuroprotective, 
antinociceptive, and vasorelaxation activities.121, 122, 123 However, the effect of Frax on TAFs in 
TME has not been studied. Therefore, as a part of our research on TAFs modification, we 
investigated the anti-fibrotic properties of Frax in TME. To enhance the targeting ability, AEAA 
was added on the surface of formulation.124 
          As accumulating investigations have proved the importance of TME modulation in 
alleviating the offensive behavior of melanoma,125, 126 we hypothesize that targeted delivery of 
Frax to the tumor site will lead to deactivation of TAFs and reduce tumor load. Nevertheless, 
remodeling TME alone might affect tumor growth partially. To further improve anti-cancer 
activity, vaccination in DM is proposed to be combined herein. In this study, a synergistic 
therapy combined Frax and tumor-specific peptide vaccine was hypothesized to regulate the 
TME and negate its suppressive surroundings, thus increasing the anti-tumor immune response, 
inhibiting tumor growth and prolonging the survival duration.  
 
4.2 Results and discussion 
4.2.1 Preparation and characterization of Frax NE 
 70  
 
          Frax is so hydrophobic that it is very difficult to be loaded into traditional drug delivery 
systems. It is well-known that nanoemulsion (NE) is a colloidal particulate system, which is 
manufactured to improve drug solubilization and enhance therapeutic efficacy. As a result, Frax 
was formulated in the NE.127, 128 In NEs, the combination of surfactants with oils offers a 
superior advantage over co-solvent system or other nanocarriers in terms of drug-loading 
capacity for hydrophobic compounds. To avoid the toxicity of traditional small molecular 
surfactants, we used the biocompatible lecithin from soybean as the emulsifier herein. To 
achieve tumor targeting ability, AEAA was used as the targeting group on the NE, as our 
previous studies have confirmed that AEAA is the sigma receptor ligand, which is overexpressed 
on cancer cells and TAFs.124, 129 Moreover, the preparation procedure of Frax NE was much 
simpler than that of other nano-systems, and thus endowing it with translational potential. 
          Frax NE was prepared by the method of ultrasonic emulsification, which is very efficient 
in constructing this formulation. The Frax NE concentrated solution appears opalescence with a 
yellow color, and the average particle size was 148.1 ± 1.3 nm. The morphology of NE by TEM 
analysis was shown in Figure 16, revealing spherical shape and uniform droplet. The 
concentration of Frax in the NE was 2 mg/mL, the encapsulation efficiency was about 90 % and 
Frax NE was found to be stable for about 20 days of storage at room temperature. There was no 
significant difference in diameter size, appearance and dilution ability, which indicated that Frax 
NE was chemically and physically stable. 
 71  
 
 
          Figure 16. Preparation and characterization of Frax NE in vitro and in vivo. (A) TEM image and in vitro 
stability of Frax NE. (B) IVIS image and quantitative analysis of DiI-labeled Frax NE with or without targeting 
ligand in BPD6 tumor bearing mice. (C) Quantitative analysis for tumor accumulation of Frax in vivo using LC/MS. 
(D) PK analysis of Frax NE in vivo using LC/MS. (E) Cellular uptake of DiI-labeled Frax NE in TME, measured by 
flow cytometry. (n = 3, * P < 0.05, ** P < 0.01, *** P < 0.001) 
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          To investigate the accumulation of NE in tumors, the biodistribution of DiI-loaded NE 
with or without AEAA modification was recorded using IVIS imaging (Figure16B). 24 h post-
injection, the higher fluorescence signal in tumors was observed even without targeting ligand. 
This enhanced distribution of DiI-labeled NE at tumor site was attributed to the EPR effect. By 
contrast, AEAA-modified DiI-loaded NE demonstrated higher tumor targeting ability, and semi-
quantitative biodistribution analysis in major organs was also performed. The ratio for 
fluorescence intensity to tissue weights of AEAA-modified NE was significantly increased at 
tumor region and decreased at other organs as compared to that of non-targeted NE. 
          Furthermore, the plasma concentration-time and tissue distribution profiles of Frax were 
characterized after intravenous administration of Frax NE (30 mg/kg) and oral administration of 
Frax suspension, respectively. As shown in Figure 16C and D, data fitting results displayed that 
the pharmacokinetics behavior of Frax NE fitted a two-compartment model, the value of total 
AUC was 139.88 ± 4.5 μg*h/mL, and t1/2 was 6.03 ± 0.67 h. This suggested that Frax NE can 
circulate for a longer time in the blood than Frax oral suspension. Notably, the Frax accumulated 
in the tumor was dramatically greater than that of the oral control. The MRT (0→∞) values of 
Frax for Frax NE was 2.9-fold compared with the control, which indicated that the injected NE 
were targeted to and stayed in the tumor tissue for an extended time. 
          After confirming the targeting ability of Frax NE, especially with the AEAA-modification, 
the DiI-loaded NE accumulation in various cell populations within the tumor was further 
performed by flow cytometry. Based on the results (Figure 16E), we found that approximately 
22.3 % of NE in the TME was taken up by the tumor cells (MART1 positive) and 20.4 % was 
absorbed by TAFs (FAP positive) 24 h post-injection. In most cases, the uptake of nanoparticles 
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results from the binding with cell surface, and thus more AEAA-modified NE entered cells with 
overexpressed sigma receptor regardless of size compared to non-targeted NE, as expected. 
4.2.2 Evaluation of therapeutic efficacy and changes in TME after Frax NE treatment 
          The antitumor efficacy of Frax was investigated after we have confirmed the tumor-
targeting ability of Frax NE. Therapy began when tumor sizes reached 200 mm3 to form the 
stromal-vessel structure. The tumor volume curve (Figure 17) demonstrated that Frax treatments 
can significantly inhibit tumor growth compared with PBS group. In addition, Frax NE exhibited 
higher antitumor effect, even though the dosage of Frax oral suspension was 4 times higher than 
Frax NE. Moreover, the inhibition ratios of these two Frax formulations were calculated based 
on the tumor weight at the endpoint (Figure 17B). IRs for Frax NE and Frax oral were 35.3 ± 
2.5% and 51.0 ± 3.5%, respectively, which agreed with the results of tumor inhibition 
measurements.  
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          Figure 17. Tumor inhibition effects and TME changes in vivo after treatment with Frax. (A) Tumor volume 
change as a function of time. The dosage of Frax by oral administration is 4 times higher than that of Frax NE by 
intravenous injection. Frax was administrated p.o. or i.v. every other day for 5 times (small arrows under the axis 
represent the day of dosing). (B) Tumor weight at the end of the experiment (day 23). Inhibition ratio (IR) is 
calculated. (C) Confocal analysis for α-SMA and CUGBP1 from tumor tissue sections. (D) Comparison of different 
immune cells in TME between BPD6 tumor bearing mice with and without treatment using flow cytometric 
analysis. (E) The survival data from treatment and without treatment groups. Numbers shown in white indicate the 
average % of each cell type in the tumor. The statistical analyses were calculated by comparison with the control 
group if not specifically mentioned. Data show mean ± S.D.. (n = 5-8, * P < 0.05, ** P < 0.01, *** P < 0.001) 
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          Because Frax was reported to treat liver fibrosis,120 we initially examined the changes of 
TAFs as well as the CUGBP1 levels in tumor tissue samples. CUGBP1, standing for CUG-
binding protein 1, was reported to be involved in posttranscriptional regulatory networks, TGF-
β/IFN-γ balancing, fibro-genesis and tumorigenesis.130 It is also the target of Frax. As can be 
seen in Figure 17C, α-SMA positive TAFs were significantly reduced in Frax NE group 
compared with untreated PBS group, and the morphology of TAFs also changed from compact 
ribbons to small dots. Noteworthy, the CUGBP1 expression was decreased with downregulating 
fibrosis.  
          We have showed Frax NE could suppress tumor growth and formation of TAFs, but the 
reason for these effects needed to be further studied. Firstly, we confirmed that empty NE 
without Frax had no influence on tumor growth by using MTT and tumor volume observation 
(data not shown). Therefore, we looked for the alterations of immune cell populations in the 
TME. In tumor-bearing hosts, the immune suppressive cells such as MDSC as well as regulatory 
B cells (Bregs), and PD-L1 play crucial roles in immune suppression, and converse of their 
function is important for immunotherapeutic treatment.131 As seen in Figure 17D, the percentage 
of MDSC (CD11b+Gr1+), Bregs (CD1d+CD19+) and PD-L1 in leukocytes in the Frax NE group 
were much lower than the PBS group, measured by flow cytometry of whole tumor tissue. On 
the contrary, CTLs and natural-killer (NK) cells increased significantly, which suggested that the 
change of the TME morphology might facilitate T cell infiltration and innate immune response. 
There was no significant difference for memory T cells between PBS group and Frax NE group. 
Although we have found Frax NE could inhibit tumor growth, possibly due to the remodeling of 
TAFs and TME as aforementioned, the survival duration was not prolonged, and tumors grew 
back after drug withdrawal (Figure 17E). 
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4.2.3 Frax NE improves the antitumor effect and reprograms TAFs when combined with 
BRAF peptide vaccine in stroma-rich melanoma 
          To improve the antitumor efficacy of Frax NE and increase the survival rate, combination 
therapy was taken into consideration. As Frax NE could remodel TAFs and reduce intra-tumor 
suppressive cells in the TME, we hypothesized that combination therapy with a vaccine that 
induces antigen-specific CTL response would be successful, especially in advanced BRAF-
mutant melanoma. Our group has developed a BRAF peptide vaccine previously,99 and it could 
be introduced into combo group herein. 
          Compared with PBS group, all treatment groups showed reduced tumor growth rates 
(Figure 18A). As expected, the combo group exhibited the best anti-cancer effects, suggesting 
the advantages of combination therapy. Meanwhile, in an overall survival analysis after the final 
day of treatment, median survival was also elevated in combo group (Figure 18B), conveying 
not only a potent therapeutic effect but also a long-lasting overall response.106 
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          Figure 18. Tumor inhibition effects and TME changes in vivo after treatment with Frax NE combined with 
vaccine. (A) Tumor inhibition curve of BPD6 tumor bearing mice using different formulation treatment (PBS, 
Vaccine, Frax NE and Combo). Frax (red arrow) was administrated i.v. every other day for 5 times at the dose of 30 
mg/kg. For the vaccine alone and combo therapy groups, vaccination (blue arrow) was administrated on day 9 and 
boosted on day 15 subcutaneously. (B) The survival proportions of the treated groups. (C) Masson’s trichrome stain 
for collagen. (D) Quantitative analysis of α-SMA and CUGBP1 to evaluate the effects of different treatments on the 
inhibition fibroblast by confocal microscopy. (E) Changes of cytokines in TME using quantitative RT-PCR. (F) 
Western blot analysis of BPD6 tumor protein levels after different treatments. The statistical analyses were 
calculated by comparison with the control group if not specifically mentioned. All data show mean ± S.D.. (n = 8-
10, * P < 0.05, ** P < 0.01, *** P < 0.001) 
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          To investigate the mechanism of anti-tumor effects, we firstly used Masson’s Trichrome 
staining to study the morphology and collagen content of tumors after treatment. In Figure 18C, 
collagen deposition and fibrosis were observed abundantly in tumor sections of untreated group. 
By contrast, Frax NE and Combo treatment significantly ameliorated the pathological changes. 
Simultaneously, percentage of α-SMA and CUGBP1 was quantitatively analyzed by Image J 
under confocal imaging (Figure 18D), which displayed the similar trends as aforementioned. 
However, α-SMA in vaccine only and PBS group were alike, while CUGBP1 in whole tumor 
increased partially. Moreover, the relative mRNA expression of CUGBP1 was a further evidence 
of our staining analyses (Figure 18E, left panel). 
          We wondered about underlying relationship between treatment and TAFs after confirming 
that Frax might have an influence on changes of TAFs. As it is commonly accepted that the 
majority of TAFs are transdifferentiated from resident fibroblasts in response to TGF-β,132, 133 the 
TGF-β expression and downstream portions of TGF-β signaling pathway, involving P-SMAD2 
and α-SMA were examined. Data demonstrated that treatment with Frax alone or combined with 
vaccine resulted in reduced TGF-β expression, but it was also noteworthy that vaccination 
significantly increased the expression of TGF-β in the TME on a RNA level (Figure 18E, right 
panel), which would inhibit the development of anti-tumor immunity.134 
          Western blotting (Figure 18F) revealed that P-SMAD2 level dramatically reduced in 
tumors in Frax NE and Combo groups, but vaccine monotherapy increased this protein partially 
compared to PBS treated group. Decreased α-SMA and CUGBP1 expression after treatment 
agreed with the results previously. 
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4.2.4 Apoptosis of neighboring tumor cells caused by combination therapy of Frax NE and 
BRAF peptide vaccine inducing antigen-specific immune response 
          To study the potential effects from the histological cross-sections, tumor cell apoptosis 
was quantified via a TUNEL assay (Figure 19A). All the three treatment groups displayed a 
greater number of apoptotic cells, than PBS group, and the combo group exhibited the highest 
level of cell apoptosis (46.6 ± 2.7 %). These findings correlated with the tumor inhibition data as 
above, which was possibly due to the immune cells killing induced potent cell death within the 
TME. 
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          Figure 19. Enhanced T-cell infiltration into TME-induced potent CTL killing. (A) TUNEL staining of tumor 
sections after different treatment. (B) IFN-γ production after treatment was measured with ELISPOT assay system. 
(C) In vivo CTL response after treatment with either Frax NE, vaccine or combo was measured through CFSE 
high/low staining of splenocytes collected from naïve mice which were pulsed with BRAFV600E peptide (CFSEhigh 
cells) or with OVA control peptide (CFSElow cells), respectively. An equal mixture of both pulsed cells was injected 
into the vaccinated mice via tail vein. 18 h after injection, mice were euthanized and splenocytes were collected, 
washed and analyzed via flow cytometry. (D) Changes of immune cells quantified by flow cytometric analysis in 
lymph node. (E) Confocal and flow cytometric analysis of immune cells infiltration in TME. Numbers shown in 
white indicate the average % of each cell type in the tumor. The statistical analyses were calculated by comparison 
with the control group if not specifically mentioned. All data show mean ± S.D.. (n = 6, * P < 0.05, ** P < 0.01, *** 
P < 0.001) 
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          To further determine whether the antitumor potency was caused by a robust immune 
response, antigen-specific CTL response and IFN-γ production ELISPOT assay were performed. 
ELISPOT assay results in Figure 19B confirmed the eliciting IFN-γ release capacity of vaccine 
as our published paper.99 Moreover, Frax NE also boosted modest efficacy, and combo group 
exhibited the most sufficient stimulation to secret IFN-γ. For the CTL assay (Figure 19C), mice 
immunized with BRAF peptide showed partial (approximately 43.6 %) efficacy, whereas mice 
receiving combination therapy proved the most effective (about 57.2 %), indicating that 
combination therapy can induce a potent in vivo CTL response compared to monotherapy. 
          It is well known that as an essential component of vaccination, DCs are required to home 
to secondary lymphoid organs to prime T cell responses.135, 136 We detected the DCs and T cell 
population by flow cytometric analysis (Figure 19D), and data revealed that three treatment 
groups all promoted DC activation, with an increase of 0.5 - 1-fold compared with PBS group. 
Among these, combo group possessed the greatest capacity to facilitate DC activation and 
induced the highest level of CD8+ T cells within LNs. Memory T cells and activated NKs, which 
might play a critical role in the initiation of T-cell responses by contributing to DC maturation, 
demonstrated the similar trend as above, within LNs (data not shown). These results confirmed 
that manipulating the DCs could induce T-cell activation and proliferation.137 
          Along with the increase of active DCs and T cells in LNs, immune boosting cells such as 
CD8+ T cells, memory T cells and NK cells were found to be increased in tumors, which was 
determined by both immunofluorescence stating and flow cytometry (Figure 19E). As can be 
seen from the tumor slices, small amounts of T cells were observed in the tumor region, but they 
were in the border of tumor tissue. In comparison, both vaccine and Frax NE group showed 
boosted T cells penetration in the TME, but the most extensive T-cell infiltration was found in 
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the combo group. Interestingly, memory T cells in the tumor region were not altered much in the 
Frax NE, while the markedly enhancement was found in the other two groups, especially in the 
combo group. Significantly, NKs that participated in the early immune response against the 
tumor and contributed to the adaptive immune response were elevated 3-8 folds after treatment, 
and combo group had nearly 14 % of NKs within TME. In agreement with the staining results, 
flow cytometry analysis confirmed our observation. It was found that IFN-γ within whole tumor 
also increased on the mRNA level and in leukocytes cell level (data not shown). 
4.2.5 Remodeling TME and enhanced immune cell infiltration result in the superior 
antitumor effect of combination therapy 
          Collectively, we have seen Frax NE combined with BRAF peptide vaccine has triggered 
the best immunotherapeutic efficacy, including improved tumor inhibition, T-cell penetration, 
NKs activation and IFN-γ secretion. Together with results that collagen deposition and TAFs 
decreased remarkably in TME, antitumor effects were probably due to remodeling of the 
immunosuppressive TME. Therefore, immunosuppressive cells within the TME such as MDSCs, 
Bregs and TAMs, which were the dominating myeloid infiltrates, were examined by 
immunostaining of tumor sections and flow cytometry. 
          As shown in Figure 20A, the percentage of MDSCs in Frax NE and combo group were 
much lower than the control group, whereas more MDSCs were found in vaccine-only group 
(measured by immunostaining and flow cytometry). Meanwhile, the ratio of TAMs exhibiting 
M1 signatures (tumor-suppressing) to M2 signatures (tumor-promoting) significantly increased, 
which was modulated by TAFs in the TME. In addition, PD-L1 immune checkpoint on 
leukocytes accordingly decreased (measured by flow cytometry, data not shown).  
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          Figure 20. Changes of tumor-infiltrating immune cells and cytokines in TME. C57BL/6 mice were inoculated 
with 1×106 BPD6 cells on day 0. Vaccine was injected on day 9 and 15; Frax NE were i.v. administered on days 9, 
11, 13, 15 and 17 at a dose of 30 mg/kg alone or combined with vaccine, respectively. Mice were sacrificed on day 
23 and tumors were harvested for immunostaining evaluation, flow cytometry and quantitative RT-PCR assay to 
detect the MDSC (A) and Bregs (B). CCL2 and IL6 mediate MDSC recruitment. CXCL13, IGF-1 and FGF-2 
facilitate B cells within TME to differentiate into Bregs. Numbers showing in white indicate the average % of each 
cell type in the tumor. The statistical analyses were calculated by comparison with the control group if not 
specifically mentioned. All data show mean ± S.D.. (n = 6, * P < 0.05, ** P < 0.01, *** P < 0.001). 
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          According to the reports that IL-6 and CCL2 produced by TAFs mediated MDSC 
recruitment and differentiation of macrophages into pro-tumor M2 phenotype,138, 139 the mRNA 
expression of IL6 and CCL2 was checked by quantitative RT-PCR (Figure 20A). Treatment 
resulted in reduction of these two Th2 cytokines which are critical for immunosuppression, thus 
inhibiting tumor progression. Although IL6 in Frax NE and combo group exhibited a little higher 
expression than vaccine, it still did not change the overall tendency compared to PBS group. It 
was worth mentioning that IFN-γ, the Th1 cytokine which was more effective in eliciting anti-
tumor immunity, was also dramatically elevated on mRNA level, especially in combo group 
(RT-PCR, data not shown).  
          Interestingly, we noticed that a large amount of Bregs appeared in TME. Bregs, originated 
from normal B cells, were attracted by tumor cells and converted into Bregs by highly expressed 
TGF-β within TME. Bregs can induce the generation of MDSCs and promote tumor cells to 
form a suppressive milieu.140 However, Frax NE and combo treatment significantly 
downregulated the Bregs, indicating that Frax NE could remodel the immunosuppressive TME 
in favor of therapy (Figure 20B). As C-X-C motif chemokine 13 (CXCL13), which is 
predominantly secreted by TAFs and cancer cells, played a vital role in attracting B cells into 
microenvironment,141 we detected this chemokine through flow cytometry and RT-PCR analysis. 
As expected, CXCL13 level within TME was much lower in Frax NE and combo group, 
compared with PBS group, and after vaccine treatment, it was also partially reduced.             
          Furthermore, Insulin-like Growth Factors (IGF-1, produced by tumor stroma-derived cells) 
and Fibroblast Growth Factor (FGF-2, produced by tumor cells) expression, two important 
growth factors involved in tumor associated B cells in crosstalk with tumor cells,117 were both 
suppressed compared with PBS group. As reported, FGF-2 plays a key part in conversing normal 
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B to tumor-associated B cells and could induce B cells to generate inflammatory factors and 
cytokines, most notably IGF-1. On the other hand, IGF-1 can form heterogeneous tumor 
subpopulations possessing cancer stem cell-like properties. Therefore, Frax might have an 
important part in disturbance of this interaction. 
          Meanwhile, C-X-C motif chemokine 12 (CXCL12), also known as stromal-derived factor 
1 (SDF-1), is a key chemokine inhibiting T-cell infiltration.142 Inhibiting of CXCL12/CXCR4 
axis has become a promising TME-modulating strategy that improves the checkpoint inhibitor 
efficacy.106 We found CXCL12 significantly decreased on mRNA transcriptional level (RT-PCR, 
data not shown), thus further facilitating effective immune killing of cancer cells.  
4.2.6 Safety evaluation for the different treatments 
          Safety evaluation is an important aspect for development of immunotherapy. The body 
weight of the above regimens did not cause loss throughout the tumor inhibition experiment 
(Figure 21A). Administration of all formulations showed no significant changes in ALT, AST, 
creatinine, or BUN levels, suggesting that there was no severe damage to renal and hepatic 
functions. Further analysis of blood cell levels demonstrated no signs of change compared with 
control healthy mice (data not shown). Moreover, the H&E staining results also indicated no 
morphological differences in major organs after treatment (Figure 21B). 
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          Figure 21. Safety evaluation of vaccine, Frax NE and Combo. (A) Body weight change. (B) H&E 
morphology evaluation of major organs after treatment. ns: P > 0.05. 
 
4.3 Conclusion 
          TAFs are believed to be essential for synthesis and deposition of the ECM by producing 
various collagens as well as fibronectin and can act like a mutagen that increases the tumorigenic 
ability of cancer cells.143 In addition, TAFs are a rich origin of different secreted factors such as 
cytokines, chemokines (e.g., IL6, CXCL12, CXCL13), and growth factors including TGF-β, 
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FGF as well as VEGF, which mediate the communication between the cancer cells and TAFs.115 
Nowadays, it has been generally accepted that TGF-β can transform normal fibroblasts into 
TAFs and regulate pivotal biological functions in cancers, rendering TGF-β more attractive in 
the field of cancer immunotherapy.144, 145 Taken together, a natural product Frax, which was 
recently reported to treat liver fibrosis by inhibiting TGF-β signaling and triggering IFN-γ 
signaling,120 was considered in our investigation to remodel TME by targeting TAFs. 
          Notably, Frax NE herein indeed demonstrated antitumor efficacy in DM model, which is 
extremely formidable to cure. Unfortunately, there are only a few reports about pharmacology of 
Frax, most of which are focused on the anti-bacterial, anti-inflammatory and neuroprotective 
properties.121, 123, 146 We noticed that as a component of Dictamnus dasycarpus root bark, the 
anticancer activity was mentioned nebulously in some introduction of projects, books or Chinese 
patents. But the molecular mechanism of Frax in cancer has not been characterized. As 
aforementioned, Wu etc. reported that Frax could reduce the mRNA and protein expression of α-
SMA by inhibiting CUGBP1, which balancing the TGF-β/IFN-γ signaling pathways, for the 
therapy of liver fibrosis. Accumulating evidences have indicated that TGF-β/SMAD signaling is 
the most crucial pathway in the pathogenesis of fibrosis. Moreover, several studies showed that 
paracrine secretion of TGF-β can activate stromal fibroblast and produce immune-suppressive 
effects to modulate the TME for the benefit of melanoma growth. Therefore, we questioned 
whether Frax inhibited tumor growth by such mechanism. We found that protein expression of α-
SMA and CUGBP1 in NIH-3T3 cell line (which were activated with 10 ng/mL TGF-β 
mimicking TAFs in vitro147) were both downregulated by Frax NE in a dose-dependent manner. 
But Frax NE only had a slight influence on BPD6 tumor cells even with a high dosage, which 
indicated that our formulation primarily focused on TAFs, not tumor cells (data not shown).      
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          Furthermore, Frax NE also reduced mRNA expression of TGF-β and its downstream 
protein SMAD2 phosphorylation in BPD6 tumor bearing mice after treatment, accompanied by 
decreased protein expression of α-SMA and CUGBP1. It was accordant with the process of well-
established TGF-β/SMADs signaling pathway. Briefly, TGF-β1 binds with its receptor II 
(TβRII) and activates the TGF-β receptor type II-kinase, resulting in phosphorylation of SMAD2 
and SMAD3, which then associate with the SMAD4 to form a heteromeric complex to regulate 
transcription of target gene, relating to fibrosis.148 These findings suggested that Frax NE might 
play a crucial role of inhibiting TGF-β signaling to suppress TAFs in the TME, possibly 
regarding downregulation of CUGBP1. Recently, some studies revealed that CUGBP1 is 
overexpressed in cancer tissue and accompanying with its binding target transcripts, they will 
function to control cellular growth as well as homeostasis. So, we hypothesize that disruptions by 
Frax in this network might also interfere the development of tumor, and the in-depth mechanism 
is explored in our ongoing research.  
          Meanwhile, our results displayed that Frax NE triggered IFN-γ production and 
downregulated IL6 as well as TNF-α expression. IFN-γ, an immunomodulatory cytokine 
secreted by immune cells such as CD4+ Th1 cells, CD8+ T cells and NKs, can act on TAFs and 
change their promoting effects on tumor growth by inhibiting activation and proliferation of 
fibroblasts.149 On the contrary, IL6 and TNF-α are pro-inflammatory cytokines that can induce 
generation of free radicals and damage DNA, potentially leading to tumor initiation and 
enhancement of tumor invasive properties.150 Changes of these cytokines also provide us the 
elucidation for the antitumor efficacy of Frax NE. It is worth mentioning that Kim et al. and Wu 
et al. both confirmed the anti-inflammatory effect (inhibit the release of IL6 and TNF-α) of Frax 
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associating with NF-κB signaling pathway, which regulates the transcription of most 
inflammatory factors.121, 123 
          Many treatments for cancer, especially aiming at TAFs, continue to evolve, including 
TGF-β inhibitors (antisense oligonucleotides, monoclonal antibodies and small molecules) and 
IFN-γ.151, 152 Anti-TGF-β therapy aims to not only tumor cells but also the TME, thus generating 
systemic effects on tumorigenesis. However, long-time use of these medications can cause 
severe side effects (vascular problems and multi-organ inflammatory disease) and its clinical 
failure is mainly due to the poor pharmacokinetics and low specificity. We found that Frax NE 
improved its pharmacokinetics profile and did not produce any adverse reactions at the tested 
dosage levels in mice, although administered for a long time. Therefore, our fibroblast-targeting 
Frax NE could be able to interrupt the interaction between TAFs and the tumor, thus resulting in 
the modulation TME, and if combined with vaccine, the suppression of tumor growth, and 
prolongation of host survival would be enhanced. 
          In summary, we successfully developed Frax NE, a TAFs-targeted formulation of anti-
fibrosis TCM, which could interfere the crosstalk between TAFs and tumor cells, changed 
cytokine profiles as well as stromal structures, and dramatically decreased MDSCs and Bregs in 
the TME, thereby remodeling the immunosuppressive microenvironment. After combination 
with vaccine, the enhanced synergistic antitumor efficacy was achieved through abrogating 
tumor-associated immune suppression and promoting immune cells infiltration, such as CTLs, 
NK cells and memory T cells. Hence, our investigations provided an immunotherapeutic strategy 
for the treatment of advanced DM. 
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4.4 Materials and Methods 
4.4.1 Materials 
          Frax was purchased from Shanghai Tauto Biotech Co. Ltd (Shanghai, China). Lecithin 
from soybean was purchased from Santa Cruz Biotechnology, Inc (Dallas, Texas). DOPA, 
DOTAP, DSPE-PEG-2000, and DSPE-PEG-NHS were purchased from Avanti Polar Lipids 
(Alabaster, AL). Pluronic F68 was provided by BASF (Florham Park, NJ). DSPE-PEG-
aminoethyl anisamide (DSPE-PEG-AEAA) was synthesized based on the previous reported 
methods.153 Briefly, 4-methoxybenzoyl chloride and 2-bromoethylamine hydrobromide were 
mixed at room temperature for 6 h. Then, DSPE-PEG-NH2 was added into above solvent and 
stirred in oil bath for 24 h. Finally, the reactant was washed and lyophilized for further use.  
4.4.2 Cell lines and animals 
          Murine BRAF-mutant melanoma cell line BPD6 (BRAFV600EPTEN-/-, syngeneic with 
C57BL/6) was provided by Brent Hanks (Duke Cancer Institute, Durham, NC) and cultivated in 
DMEM Medium (Invitrogen, Carlsbad, CA) containing 1% Penicillin/Streptomycin (Invitrogen) 
and 10 % bovine calf serum at 37 °C with 5 % CO2. Female C57BL/6 mice (6–8 weeks old) 
were ordered from Charles River Laboratories (Wilmington, MA). All animal handling 
procedures were approved by the University of North Carolina at Chapel Hill’s Institutional 
Animal Care and Use Committee. 
4.4.3 Preparation and characterization of Frax loaded AEAA-modified NE (Frax NE) 
          Frax NE was prepared by ultrasonic emulsification method. In brief, Frax was firstly 
dissolved in dimethyl sulfoxide (DMSO) (no more than 1% in total formulation) and mixed with 
lecithin from soybean and sesame oil. Subsequently, Pluronic F68 solution (100 mg/mL) 
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containing targeting ligand DSPE-PEG-AEAA was added into the drug mixture as above drop 
by drop under stirring. After stirring for 5 min at room temperature, the resultant mixture was 
ultrasonicated on ice bath for 5 min to produce NE. The particle size and morphological 
examination of Frax NE was determined by a Malvern ZetaSizer Nano series (Westborough, 
MA) and a JEOL 100CX II TEM (JEOL, Japan), respectively. The encapsulation efficiency of 
AEAA-modified NE is measured using HPLC (Shimadzu LC-20AT, Kyoto, Japan). In vitro 
stability was evaluated by determining the diameter size by DLS (Malvern, United Kingdom) at 
room temperature. 
          To investigate the targeting ability of this NE, DiI-labeled NE with or without AEAA were 
prepared by the same method as above without addition of Frax but with 0.5 % DiI added. After 
intravenous injection of DiI-labeled NE for 24 h, mice were euthanized, and tumors as well as 
major organs (heart, liver, spleen, lung and kidney) were collected. The bio-distribution was 
visualized and quantitatively measured with IVIS® Kinetics Optical System (Perkin Elmer, CA). 
The excitation wavelength was set at 520 nm, while the emission wavelength was 570 nm.  
          Additionally, intra-tumoral cellular uptake by cells of interest (tumor cells and TAFs) was 
evaluated by flow cytometry. Briefly, tumor tissues were dissociated with 1 mg/mL collagenase 
(Invitrogen), and 200 μg/mL DNAase (Invitrogen) in DMED/2 % FBS for 40 min to generate a 
single-cell suspension. Tumor cells were stained with PE-conjugated MART1 antibody (Melan-
A antibody, sc-20032 PE, Santa Cruz Biotechnology), and TAFs were stained with FAP 
antibody (anti-Fibroblast activation protein antibody, abT28244, Abcam). The cells were then 
subjected to flow cytometric analysis, and the ratios of DiI-loaded NE distributed in different cell 
populations were calculated. 
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          Furthermore, LC/MS instrument (Shimadzu LCMS-2020, Kyoto, Japan) was also utilized 
to quantitatively analyze the accumulation of Frax NE in tumor site at predetermined times (1, 3, 
8, 12, 24 h) and study the pharmacokinetics profile. Separation of analytes was carried out on 
Thermo Scientific C18 column (100 mm × 4.6 mm, 2.6 μm) (Thermo Fisher Scientific, 
Waltham, MA USA), the flow rate was set to 0.2 mL/min, and column temperature was 35 ℃. 
4.4.4 Tumor growth inhibition 
          The stroma-rich desmoplastic melanoma model was established as previously reported. 
Mice were inoculated subcutaneously with 1×106 BPD6 cells on their lower flank. When the 
tumor volume reached about 200-300 mm3, mice were separated into the following groups (n = 
6): Untreated group (PBS), Frax oral suspension group (Frax oral, 120 mg/kg), and Frax NE 
group (Frax NE, 30 mg/kg). As the control, Frax oral was prepared by suspending Frax directly 
in a 0.5 % of carboxymethylcellulose (CMC) solution with grinding. Frax was administrated p.o. 
or i.v. every other day for 5 times, and the tumor volumes were monitored by caliper every 2 
days and calculated as (a×b2)/2, where “a” represents the larger diameter and “b” represents the 
smaller one. At the endpoint of tumor inhibition study, we sacrificed the mice, and tumors were 
harvested and weighed. The inhibition ratio (IR) was defined as IR (%) = ((Wc-Wt)/Wc) × 100, 
where Wc and Wt are the average tumor weights for the control group and each treatment group, 
respectively. 
          To evaluate the combination therapy with BRAF peptide vaccine, BPD6 tumor bearing 
mice (tumor volume reached about 200-300 mm3) were randomly divided into four groups (n = 8 
- 10): Untreated group (PBS), Frax NE group (Frax NE, 30 mg/kg), BRAF peptide vaccine group 
(Vaccine, (BRAF peptide + CpG) 100 μg/mice) and Frax NE combined with BRAF peptide 
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vaccine group (Combo). BRAF peptide vaccine was prepared as described previously. For the 
single vaccine and combo therapy groups, vaccination was administrated on day 9 and boosted 
on day 15 subcutaneously. Intravenous injections of Frax NE were also given every 2 days for a 
total of 5 doses. Tumor volume was measured as above, and mice were sacrificed before tumor 
volume reached 2000 mm3 under animal safety protocol.  
          Long-term survival was also monitored on BPD6 bearing mice with different treatments (n 
= 8, in each treatment group). Kaplan-Meier curves and Median Survival were quantified and 
calculated using GraphPad. 
4.4.5 Immunofluorescence staining and Masson trichrome staining  
          Tissue section staining was executed following the procedure of deparaffinization, antigen 
retrieval, permeabilization, and 1 % BSA blocking. Primary antibodies with or without 
fluorophores conjugation were incubated at 4 ℃ overnight. The samples used non-conjugated 
primary antibodies was treated with secondary antibodies for 1 h at room temperature on the next 
day. Nuclei were counterstained with DAPI (Vector Laboratories Inc., Burlingame, CA). Images 
were acquired using fluorescence microscopy (Nikon, Tokyo, Japan) and five fields were 
selected at random for quantitative analysis by Image J software. 
          The Masson Trichrome assay was performed to detect collagen among tumor tissue. 
Tumor slides were stained using a Masson Trichrome Kit by the UNC Tissue Procurement Core. 
4.4.6 Flow cytometry analysis 
          Immune cell populations in tumor and LNs were detected by flow cytometry. In brief, 
tumors were treated with collagenase A and DNAase for 40 min at 37 ℃. Then, single cells in 
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treated tumors and LNs were collected in FACs buffer. For intracellular staining, the cells were 
treated with penetration buffer (BD, Franklin Lakes, NJ) as the manufacture’s instruction 
suggested. Different kinds of immune lymphocytes were stained with different kinds of 
fluorescein-conjugated antibodies.  
4.4.7 Western blot analysis 
          Western blot was performed on proteins extracted from the tumor tissues after treatment or 
cells in the lysis buffer. The extracted proteins were separated by 4 – 12 % sodium dodecyl 
sulfate polyacrylamide gel electrophoresis (SDS-PAGE electrophoresis) (Invitrogen) and 
transferred onto polyvinylidene difluoride (PVDF) membranes (Bio-Rad, Hercules, California). 
The membranes were incubated with the indicated antibodies at 4 ℃ overnight. Primary 
antibodies were directed against P-SMAD2 (Cell signaling, 3108S), α-SMA (Abcam, ab124964), 
CUGBP1 (Abcam, ab129115) and GAPDH (Santa Cruz Biotechnology, sc-25778). Membranes 
were then incubated with a horseradish peroxidase coupled secondary antibody, and signals were 
observed using the Pierce ECL Western Blotting Substrate (Thermo, Rockford, IL). The relative 
expression level of protein was quantified with Image J software. 
4.4.8 Quantitative real-time PCR assay  
          Whole RNA was obtained from tumor tissues using an RNeasy kit (Qiagen, Valencia, 
CA), and cDNA was reverse-transcribed using the SuperScript First-Strand Synthesis System for 
RT-PCR (Invitrogen, Grand Island, NY). 100 ng of cDNA was amplified with Taqman Universal 
Probes Supermix System (Bio-rad, Hercules, CA) and mouse-specific primers. Primers for 
mouse TGF-β, CUGBP1, CCL2, IL6, CXCL13, IGF-1, FGF-2 and CXCL12 were purchased 
from ThermoFisher Scientific (Waltham, MA USA). The GAPDH RNA expression was used as 
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inner control. Reactions were conducted using a 7500 Real-Time PCR System, and the data were 
analyzed with the 7500 Software. 
4.4.9 TUNEL assay 
         Slides were deparaffinized and stained using a TUNEL assay kit (Pierce, Madison, WI) 
according to the manufacturer’s instruction. Cell nuclei that were stained with FITC (green) were 
defined as TUNEL-positive nuclei. The images were acquired using fluorescence microscopy 
(Nikon, Tokyo, Japan) and quantitatively analyzed on Image J. 
4.4.10 Safety evaluation 
          Body weights of mice were measured every other day starting from the treatment. At the 
endpoint, the mice were sacrificed, blood was collected, and plasma was obtained by 
centrifugation at 4000 rpm for 5 min. BUN, creatinine, AST and ALT levels were detected as 
indicators of renal and hepatic function. Whole blood was also gathered for the measurement of 
myelosuppression by counting the Red blood cells (RBC), white blood cell (WBC), platelets 
(PLT), hemoglobin (HGB) and hematocrits (HCT). Major organs, such as heart, liver, spleen, 
lung and kidney were fixed and used for H&E staining by UNC histology facility to evaluate the 
organ-specific toxicity. 
4.4.11 Statistical analysis 
          Results were expressed as mean ± S.D., and statistically evaluated by Student’s test or 
one-way analysis of variance (ANOVA). P values smaller than 0.05 were significant. 
 
 
 96  
 
CHAPTER 5 
NANO-MEDIATED WNT5A TRAPPING ENHANCES IMMUNOTHERAPY3 
 
5.1 Introduction  
          Despite considerable advancement in the study of cancer biology and drug discovery, it is 
still a major undertaking to cure most advanced melanoma patients. Even with conventional 
anticancer chemotherapy, the first line response rate remains low.6, 154 Based on clinical evidence 
of chemotherapy, the definition of immunogenic cell death (ICD) was derived, revealing how 
tumor-specific immune responses shape the therapeutic outcome.155 ICD refers to the apoptosis 
of tumor cell that does release tumor associated antigens, and sequentially stimulate a specific 
immune response against such antigens. The ICD, in turn, will improve the immunogenic 
potential as a form of DC vaccines. Therapeutic vaccination can be clinically successful as a 
monotherapy; however, in DM the immunosuppressive TME placed a major hurdle for treatment 
efficacy.83, 99 Herein, ICD-mediated vaccination should be combined with a co-treatment that 
overcomes immune evasion to achieve desired therapeutic efficacy. 
          It has been reported that in advanced melanoma patients, expression of the soluble Wnt 
family member 5A (Wnt5a) ligand induces a paracrine signaling pathway that drives local DC 
                                                          
3 This chapter previously appeared as an article in ACS Nano. The original is as follows: Q Liu, H Zhu, K Tiruthani, 
L Shen, F Chen, K Gao, X Zhang, L Hou, D Wang, R Liu, L Huang. “Nanoparticle-Mediated Trapping of Wnt 
Family Member 5A in Tumor Microenvironments Enhances Immunotherapy for B-Raf Proto-Oncogene-Mutant 
Melanoma.” ACS nano 2018 Jan 31. 
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tolerization and fibrotic TME.156 Interestingly, melanoma-derived Wnt5a promotes tumor growth 
and metastasis, which correlates with the inhibition of antitumor adaptive T-cell responses. We
hypothesize that compared with wild-type tumor, BRAF-mutant melanoma correlates with 
increased Wnt5a release. Furthermore, Wnt5a represents a critical mediator of tumor immune 
evasion and immunotherapy resistance, and the inhibition of this soluble mediator will augment 
the efficacy of vaccination.   
          In this work, we designed and generated a fusion protein that specifically and potently 
binds to and disrupts the biological functions of Wnt5a. For local TME ‘trapping’, plasmid 
containing the Wnt5a trap cDNA was formulated and specifically delivered to the DM murine 
model in a syngeneic host by using a cationic nanocarrier, the lipid-protamine-DNA (LPD) NPs. 
We found that the administration of the trap along with immunogenic cell death-mediated 
vaccination generated robust innate and adaptive immune responses, resulting in significant 
tumor regression in the murine model. Moreover, this combination therapy delayed tumor 
metastasis and improved long-term survival, providing a strong rationale for pursuing this 
strategy in clinical studies.  
 
5.2 Results and discussion 
5.2.1 ICD induced by low dose DOX 
          For effective cytotoxic T cell killing, we introduced low dose DOX to induce 
immunogenic cell death within the tumor, thus aiding in activating immune microenvironment. 
DOX is a small molecule drug that has been used as a first line chemotherapy for the treatment 
of melanoma. It has been reported that low dose of Dox induced ICD in various cancer cell lines 
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including wild-type melanoma (B16F10).157 To determine the best dosing strategy of DOX-
induced ICD, MTT assay was performed (Figure 22A). Followed by calreticulin (CRT) 
exposure and high mobility group box 1 (HMGB1) release as standard markers for drug-induced 
(0.2 mM DOX) tumor cell immunogenicity, ICD was detected on BPD6 cell line in vitro (Figure 
22B).  
 
          Figure 22. ICD induced by low dose DOX. (A) MTT result on BPD6 cell line in vitro. n = 5. (B) 
Fluorescence imaging detecting ICD markers: CRT and HMGB1 on BPD6 cells treated with low dose of DOX. Cell 
nuclei were stained with Hoechst 33432. Scale bar indicates 10 μm. (C) ELISpot test depicting IFN-γ secreted by re-
stimulated splenocytes of mice treated with or without low dose DOX. n = 3. (D) Flow cytometry analysis shows 
ICD induced increase in: intra-tumoral inflammatory cells (CD8+CD45+) and activation of CD8+ T cell within 
TME. n = 3. (E) HMGB1 and CRT immunofluorescence staining in tumors slide sections, treated with or without 
low dose of DOX. n = 3. Scale bar indicates 300 μm. (F) Mean days of mouse survival in PBS and low dose DOX 
treated groups. n = 8-10. Data present mean ± SE. n.s.: p > 0.05, **: p < 0. 01. 
 
          Low dose DOX efficiently induced IFN-γ production under antigen re-stimulation in vitro, 
analyzed by ELISpot assay, indicating strong systemic immune response against the tumor-
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specific antigen mimicking in vivo settings (Figure 22C). Thus, low dose DOX (0.544 mg/kg) 
was given i.p. to mice, at an early point of desmoplastic tumor growth, as to induce ICD and the 
release of tumor antigens for effective DC presentation and cytotoxic T cell recruitment. After 
DOX treatment, we found induced intra-tumoral inflammatory cells and activated CD8+ T cell 
greatly increased within whole tumor (Figure 22D). DOX therapy significantly increased 
HMGB1 and CRT in vivo, as stained in tumor sections (Figure 22E), which further confirmed 
ICD production in vivo, and demonstrated an effective way of boosting systemic immunity. 
Although the DOX treatment showed modest tumor growth inhibition, we found no significant 
prolongation of host survival, necessitating further investigation into remodeling the 
immunosuppressive TME. 
5.2.2 Wnt5a is a key molecule controlling the immunosuppressive desmoplastic TME 
          Wnt5a is a member of the Wnt family that plays pivotal roles in activating several 
noncanonical Wnt signaling pathways. In normal tissues, such pathways mainly regulate major 
developmental processes, including stem cell self-renewal, proliferation, differentiation, and 
polarity.158 It has been reported that homozygous Wnt5a-ko-mice died postnatally, associated 
with significant lower dermal lymphatics and multiple defects including skeletal and internal 
organs.159 Wnt5a-defient mice resulted in reduction of Wnt/β-catenin signaling, which would 
impair osteoblast differentiation and enhance adipocyte differentiation.156, 160 Moreover, the 
abnormal activation or inhibition of Wnt5a signaling has been demonstrated in controlling tumor 
progression, more specifically, in an immunosuppressive manner.156 In melanoma, previous 
studies have demonstrated that Wnt5a promotes differentiation of monocytes into tolerogenic 
DCs, thus hindering antigen presentation and effective T-cell mediated killing. Furthermore, 
tolerogenic DCs mediate Treg cell differentiation in the presence of TGF-β. More recently, 
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Wnt/TGF-β signaling pathway has been further investigated, in the present of upregulating Yes-
Associated Protein 1 (YAP)/transcriptional coactivator with PDZ-binding motif (TAZ) signaling, 
thus directly linked to physiological morphology of fibrosis (Figure 23A). 
 
          Figure 23. Wnt5a is a key molecule controlling the immunosuppressive desmoplastic TME. (A) Figure 
legend depicting Wnt5a functions on both DCs and Fibroblasts within TME. Wnt5a is highly expressed among 
BRAF-mutant melanoma, compared to BRAF-wild-type, in both clinical (panel B, TCGA database, n = 368) and 
murine samples (panel C, Western blot, n = 3). (D) High level of Wnt5a correlates with poorer patient overall 
survival. n = 29. (E) Masson’s trichrome staining illustrating BRAF-mutant melanoma with desmoplastic collagen-
rich TME (black arrows), compared to wild-type in both human and mouse specimens. Scale bar indicates 300 μm. 
n = 3. *: p < 0.05, **: p < 0. 01. 
 
          We first confirmed that high expression level of Wnt5a was present in melanoma tissue of 
both patients and murine models (Figure 23B and C), with significantly difference (p = 0.0097 
from TCGA analysis) between BRAF-mutant and wild-type tumors. Western blot analysis 
further confirmed this difference in murine melanoma cell lines, i.e. B16F10 (BRAF-wild type): 
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BPD6 (BRAF-mutant). In melanoma patients, excessive Wnt/β-catenin level has been associated 
with poorer response to immune checkpoint therapies.161 Our analysis based on the TCGA 
database further confirmed a strong correlation (p = 0.005) between higher Wnt5a expression 
with shorter patient overall survival (Figure 23D).  
          In this work, we used the BPD6 model that highly resembles aggressive clinical melanoma 
for therapeutic studies.162 Compared to the wildtype, BRAF-mutant melanoma demonstrated a 
desmoplastic collagen-rich TME in both murine and human specimens (Figure 23E). Since 
Wnt5a plays an important role in mediating immunosuppressive desmoplastic morphology, we 
hypothesized that effective local and transient inhibition of Wnt5a would remodel the 
suppressive TME and facilitate immunotherapy without systemic disruption of the multifaceted 
roles of Wnt5a in normal organ functions.  
5.2.3 Local distribution and transient expression of Wnt5a trap  
          To efficiently compete with endogenous Wnt5a receptors and ‘trap’ Wnt5a locally within 
TME, we developed a trimeric trap that binds to mouse Wnt5a with a Kd in the range of medium 
nano-molars (Figure 24B). Wnt proteins are secreted glycoproteins that bind to the N-terminal 
extracellular cysteine-rich domain (CRD) of the Frizzled (FZD) receptor family. Quantitative 
measurement of the interactions between different isoforms of Wnt ligand and FZD receptor is 
challenging due to the lipid modification of Wnt that makes expression, purification and 
crystallization of active Wnt ligands difficult. The problem is further complicated by the 
significant promiscuity where a certain FZD receptor binds to multiple Wnt ligands.   
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          Figure 24. Local distribution and expression of Wnt5a trap. (A and B) Development and characterization of 
Wnt5a Trap protein. (A) SDS-PAGE of the Wnt5a trap in the presence (lane 2) and absence (lane 1) of reducing 
agent DTT. (B) The binding affinity between Wnt5a and FZD7-based trap measured by MST. (C) Bio-distribution 
of DiI-loaded LPD NPs among tumor and organs. n = 3. (D) Expressions of His-tagged Wnt5a trap in different 
organs were quantified by ELISA and compared with the injection of free trap protein. n = 5. (E) Fluorescent 
imaging depicting effective local Wnt5a trapping in tumor slide sections. Numbers indicate Wnt5a expression 
(yellow). Scale bar indicates 300 μm. (F) Mean days of mouse survival.  n = 8-10. Data present mean ± SE. n.s.: p > 
0.05, **: p < 0. 01. 
 
          We chose the CRD of FZD7 to develop a Wnt5a trap for the following considerations. 
First, FZD7 is one of the highest expressing FZD receptors in DCs, and tolerogenic DCs are the 
major immune cells we want to target in the work. Second, in the process of tumor progression, 
FZD7 is found most commonly upregulated among the whole FZD family. This finding is 
confirmed in various types of cancer, include colorectal cancer, triple negative breast cancer, etc. 
Third, FZD7 plays a vital role in the interaction between cancer stem cell and tumorigenesis. 
Therefore, an affinity molecule based on the CRD of FZD7 has the potential to serve as a decoy 
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to trap Wnt5a while at the same time competitively reduce the numerous biological functions of 
this highly expressing FZD receptor. Since the oligomeric status of Wnt ligands Wnt5a was 
implicated in the literature, we designed a trimeric Wnt5a trap with multi-valency and avidity 
feature by genetically fusing the CRD of FZD7 with a robust trimerization domain from cartilage 
matrix protein (CMP-1) that is very abundant in mouse and human cartilage.106 The strong 
hydrophobic and ionic interactions among this trimerization domain result in a parallel, 
disulfide-linked, and rod-shaped trimeric structure with high stability. Since the trimeric trap is 
formed through self-assembly of three identical monomers, it only requires a relatively small 
gene to encode the monomeric trap, making the gene to be delivered much shorter and easier to 
encapsulate.  
          To construct such an original Wnt5a trap, the optimized coding sequence for the 
monomeric trap was cloned into the expression vector pcDNA3.1, driven by a CMV promoter. 
To facilitate trap secretion after expression, a strong signaling peptide from human serum 
albumin preproprotein was incorporated at the N-terminus, whereas an FLAG/His (6×) tag was 
also brought in at the C-terminus, thus to facilitate protein purification and in vivo expression 
analysis.  The recombinant Wnt5a trap was expressed in and purified from 293 T cells. The 
theoretic MW of the monomeric trap should be around 26 kDa but significant glycosylation is 
expected, as shown in Figure 24A with higher MW. We characterized the binding strength and 
specificity of the FZD7 CRD and Wnt5a. As shown in Figure 24B, the resulting FZD7-based 
trap should bind to Wnt5a with a Kd in the range of medium nano-molars. 
          The LPD NP formulation, which preferentially delivers macromolecules including plasmid 
DNA for tumor immunotherapy, has been well established in the Huang lab.108 To prepare LPD, 
plasmid DNA encoding for Wnt5a trap protein was condensed with cationic protamine to form a 
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slightly anionic complex core. The core was further coated with the preformulated cationic 
liposomes (DOTAP, Cholesterol and DSPE-PEG), and modified with tumor targeting ligand 
DSPE-PEG-AEAA. The size (~100 nm), the spherical shape, as well as homogenous distribution 
of LPD NPs were confirmed by TEM images consistent with DLS size distribution (data not 
shown). Through IVIS imaging, DiI-loaded NPs were found mainly distributed in the tumor 24 h 
after i.v. injection into mice (Figure 24C). Although liver may take up NPs, it was significantly 
lower than tumor (p < 0.01). Within the liver, NPs of size ~100 nm mainly internalized by 
Kupffer cells under phagocytosis, but PEGylated NPs are taken up less efficiently than more 
charged NPs.163 Kupffer cells are non-parenchymal cells within the liver that are very difficult to 
transfect, even with Lipofectin® (superior to other lipids for transfection), the transfection 
efficiency remains low.164 The Wnt5a trap expression within other major organs was minor and 
transient. This is presumably due to the efficient targeting effect of AEAA against sigma 
receptor 1 that is highly expressed on the surface of melanoma cells.  
          By introducing His-tag into the C-terminus of plasmid map, the expression of the Wnt5a 
trap against Wnt5a was assessed through ELISA, and further compared with the injection of 
purified trap protein (Figure 24D). His-tag ELISA showed the expression of trap was transient 
within one week. Consistent with IVIS imaging, tumor is the major trap producing organ with 
the help of AEAA targeted local NP delivery. Compared to direct injection of trap protein, the 
half-life of plasmid delivery was significantly prolonged. As illustrated in Figure 24D, free 
protein trap was cleared rapidly, with significantly lower concentration among all organs at each 
timepoint being monitored. Within the tumor, the AUC value for trap expression using NP 
delivery of plasmid DNA was 2.3-fold higher than that of the free protein trap. Presumably, the 
trap binding with Wnt5a prevents the Wnt5a binding with anti-Wnt5a antibody, thus the local 
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concentration of Wnt5a measured in the tumor was significantly reduced (Figure 24E), 
indicating that the locally expressed and secreted Wnt5a trap neutralized Wnt5a in situ. 
Nevertheless, we found no significant elongation in the host survival, compared to the PBS 
control (Figure 24F), suggesting that remodeling of TME by trapping Wnt5a alone was 
insufficient for effective tumor therapy.  
5.2.4 Combination of DOX-induced ICD and Wnt5a trapping significantly inhibited tumor 
progression 
          Effective tumor immunotherapy is often achieved by combination with the stimulation of 
the immune system, i.e. with a vaccine, or by remodeling the TME. As demonstrated above, 
neither ICD induced by low dose DOX (a form of vaccine) nor Wnt5a trap (a TME modulator) 
could produce significant host survival prolongation in this aggressive melanoma model. 
Therefore, we explored whether a combination of both therapies could bring in a synergistic 
therapeutic effect.  
          Indeed, with the help of low dose DOX, the local Wnt5a trapping strategy greatly inhibited 
tumor growth (Figure 25A). Significantly, the median survival of the mice treated with ICD/trap 
combo therapy was prolonged from approximately 45 days to 65 days (Figure 25B). To address 
the action mechanism, we performed treatment by pre-depletion of CD4+ or CD8+ T cells. As 
shown in Figure 25C, the therapeutic effect was partially abolished by the pre-treatment with 
either anti-CD8 or anti-CD4 antibody, whereas it was not affected when an isotype matched IgG 
control was used in the pre-treatment. TUNEL assay demonstrated a large increase of apoptotic 
cells within TME, indicating local tumor cell death (Figure 25D). There was also a significant (p 
< 0.01) decrease in collagen content (by Masson Trichrome staining) of the tumor with the 
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combination therapy (Figure 25E). In either case, DOX treatment alone or Wnt5a trap alone had 
brought only a partial effect.  
 
          Figure 25. Combination therapy significantly inhibited tumor progression. (A) Tumor inhibition of 
combination therapy, compared with untreated or monotherapy groups. n = 8. (B) Long term survival monitored 
over two months. n = 8-10. (C) Tumor bearing mice were pretreated with 3 daily injections of anti-CD8 and/or anti-
CD4 antibody (300 µg/mice) to deplete the CD8+ and/or CD4+ T cells in vivo. Isotype IgG was used as control. 
The efficacy of combination therapy with or without different T cell depletion was compared by monitoring tumor 
burden after treatment cycles. n = 5. (D) TUNEL assay depicting apoptotic region within tumor slide sections. n = 3. 
(E) Masson’s trichrome staining depicting collagen distribution within TME. n = 3. Scale bars indicate 300 μm. *: p 
< 0.05, **: p < 0. 01, ***: p < 0. 001. 
 
5.2.5 Treatment-induced remodeling of the TME  
          To investigate whether the immunosuppressive microenvironment of the tumor was indeed 
remodeled after the combination therapy, we analyzed the immune cells in the tumor by flow 
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cytometry. As illustrated in Figure 26A, the efficient tumor inhibition could be attributed to the 
remodeling of the immunosuppression of TME,165 including significant increased CD103+ DCs 
(required for antigen transportation, T cell priming, as well as induction of intact anti-tumor 
immunity166), increased DC maturation (CD8+CD11c+), enhanced effector T cells infiltration 
(CD45+CD8+) and activation (CD8+CD62Llow), and the reduction in the suppressive immune 
cells such as MDSCs, M2 macrophages and PD-L1+ cells (CD274+). Meanwhile, immune 
cytokines such as IL-12α, TNF-α and IFN-γ were dramatically increased at detected 
transcriptional level (Figure 26C), indicating a Th-2 to Th-1 phenotype switch to an immuno-
stimulatory TME. The switch would greatly facilitate tumor antigen presentation (with a specific 
increase in IL-12α) and result in an intensified cytotoxic T cell mediated tumor-specific killing, 
as demonstrated by extensive IFN-γ production in ELISpot assay (Figure 26B). IFN-γ is 
produced mainly by CTLs mediating adaptive immune responses. The ELISpot assay used in our 
study detected and enumerated antigen-reactive T cells that secrete IFN-γ in vitro upon re-
stimulation by tumor-specific antigen, mimicking systemic immune response in vivo.  
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          Figure 26. Remodeling of TME. (A) Flow cytometry analysis of immune functioning cells within TME. n = 
3. (B) ELIspot assay depicting IFN-γ production under different treatments. n = 3. (C) RT-PCR analysis of both pro-
inflammatory and anti-inflammatory cytokines within TME. n = 6. *: p < 0.05, **: p < 0. 01, ***: p < 0. 001. 
 
5.2.6 Combination therapy demonstrated long-lasting suppressed tumor metastasis  
          Over two months of survival study, we kept monitoring tumor metastasis in major organs. 
Consistent with the clinical observation, we found that liver and lung were the major metastatic 
sites in the untreated murine model.167 The observed long-term efficacy could be due to many 
factors. For one, innate immunity alone would be sufficient, particularly natural killer (NK) cells, 
has been reported to prevent metastasis in nude mice which are immune deficient. Secondly, the 
significant tumor inhibition would restrict cancer cell spreading, possibly via suppressing the 
EMT by down-regulating pro-metastatic markers, such as CCL7/CCR3 or CCL21/CCR7 cross-
talks.168, 169 
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          Nevertheless, at late stage of tumor inhibition, the recruitment of both CD8+ and CD4+ T 
lymphocytes for an efficient systemic immune response would help in tumor restriction and 
reducing metastasis. CD8 T cells are critical in direct anti-tumoral activities. In our study, 
effective DC activation (CD11c+MHCII+) was observed, CD8+ T cells and CD69+CD8+ T cells 
were also found increased within LNs (Figure 27C), as well as within TME (Figure 27A, CD8+ 
and CD62LlowCD8+ T cells). Memory CD8 T cells (CD8+CD44+) were also found significantly 
increased within TME (Figure 27D). For CD4 T cells, we found a significant increase in 
memory CD4 T cells (CD4+CD62L+) within TME (Figure 27A) and LNs (B). Furthermore, 
CD4+ T cells were sorted (at the endpoint of tumor inhibition study) from spleens of mice 
subjected to either Combo therapy or PBS as control. Among which, antigen-specific CD4 cells 
undergo in vitro proliferation when re-stimulated with tumor cell lysate containing tumor 
antigens (Figure 27E). The division of these antigen-reactive cells (Q1 population) was 
significantly increased, indicating a generation of memory CD4 immunity in vitro mimicking in 
vivo settings. 
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          Figure 27. Combination therapy demonstrated long-lasting overall immune response. (A) Immunofluorescent 
staining for memory CD4 T cells within TME. n = 3. Scale bar indicates 100 μm. (B) and (C) Flow cytometry 
analysis of T cells and DCs functions within draining LNs. n = 3. (D) Immunofluorescent staining for memory CD8 
T cells within TME. n = 3. Scale bar indicates 100 μm. (E) In vitro CD4+ T cell proliferation assay depicting 
division of antigen-reactive cells (Q1) between groups. n = 3. *: p < 0.05, **: p < 0. 01. 
 
5.2.7 Safety evaluation of the combination therapy 
          We evaluated the safety and side toxicity of the therapies by performing extensive 
toxicological pathology analysis. It has been reported that Wnt5a plays an important role in the 
liver. Wnt5a, also participates in hepatic stellate cell activation through Wnt/Ca2+ pathway and 
may serve as a therapeutic target in the treatment of liver fibrosis.170 Thus, the homeostasis of 
Wnt5a is directly associated with proper liver functions and worth further investigation. Minor 
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and transient Wnt5a trapping might be beneficial. Throughout the trapping therapeutic window 
and tumor inhibition study, we found no significant morphological damage was caused in the 
liver, neither in other major organs, including kidney, lung, spleen, and lung. Compared with 
non-tumored control group, mice under different treatment of therapies demonstrated none 
noticeable systematic toxicities (Figure 28). No significant body weight changes were found in 
any of the treatment groups (Figure 29A). The serum biochemical parameter analysis and the 
whole blood cell counts remained within the normal ranges for all the groups, suggesting no 
systemic anemia or inflammation occurred after treatments, nor major liver disfunctions noticed 
(Figure 29B). 
 
          Figure 28. H&E morphology under different therapies.  At the endpoint of tumor inhibition study, mice were 
humanely euthanized, major organs were collected, sectioned, and stained for H&E analysis. Non-tumored mice 
were also examined as control. Scale bar indicates 300 μm. 
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          Figure 29. Toxicity evaluation of therapies. (A) Mice body weight changes under tumor inhibition study. (B) 
Whole cell counts and serum biochemical marker analysis of tumor bearing mice. Fresh whole blood and serum 
were collected at endpoint of study. Non-tumored mice were also examined as control. n = 5. n.s.: p > 0.05. 
 
5.3 Conclusion 
          Among human melanoma, the activation of tumor cell intrinsic Wnt/β-catenin pathway 
mediates the deficiency in T cell priming tumor-associated antigens in vivo, followed by 
resistant to anti-PD-L1 and anti-CTLA4 blockage therapy. Owing to its diverse functions, Wnt5a 
signaling in immunosuppression and cancer progression is varied and complex with mechanism 
still elusive, and whether it plays a role in cancer promotion or suppression depends on specific 
cancer types. The persistent activation of Wnt5a and its downstream signaling pathways in 
BRAF-mutant type is particularly mortal. So far, systemically applied monoclonal antibodies 
(mAbs) against Wnt5a are not yet available for patients. Moreover, without specific targeting, a 
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disruption in the functioning of Wnt5a molecule among normal tissues may lead to imbalance in 
immunologic tolerance and result in severe inflammatory diseases.171 In our established 
Wnt5ahigh DM mouse models, the advantage of our approach is to locally normalize, rather than 
systemically deplete, the expression of Wnt5a within TME under a transient therapeutic window. 
Compared to systemic large-size (~150 kDa) mAb therapies which have been reported with 
subsequent multiple autoimmune diseases,172 the local and transient expression of a small-size 
(~26 kDa) Wnt5a ‘trap’ by tumor-specific NP delivery offers great advantages in both 
therapeutic efficacy and safety. Basically, what we have established is a “Wnt5a KD” tumor 
model in a transient way. The Wnt5a trap used in this work is based on the CRD of FZD7. Since 
FZD7 is also implicated in the interaction with other Wnt ligands, it is possible that levels of Wnt 
ligands other than Wnt5a (i.e. Wnt3a) were also reduced in TME.173 
          Conclusively, the local and transient Wnt5a trapping efficiently remodels the fibrotic 
immunosuppressive TME, recovers DC functions, and facilitates T cell infiltration, providing a 
promising platform for the treatment of DM. This is especially true when combined with a 
commonly accepted chemotherapy that can further stimulate immune responses, or other forms 
of tumor-specific vaccination. Currently, we are further investigating into formulation scale-up, 
prolonged safety evaluation, as well as any potential side effects associated with change in 
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5.4 Materials and methods 
5.4.1 Materials 
          DSPE-PEG-2000, DOPA and DOTAP were purchased from Avanti Polar Lipids 
(Alabaster, AL). The DSPE-PEG-AEAA was synthesized according to previous publication of 
our lab. DOX, cholesterol and protamine were purchased from Sigma-Aldrich (St. Louis, MO). 
DiI was purchased from ThermoFisher Scientific (Waltham, MA). 
5.4.2 Cell lines and animals 
          Murine BRAF-mutant melanoma cell lines BPD6 was kindly provided by Brent Hanks 
(Duke Cancer Institute) and cultivated in RPMI-1640 Medium added with 10 % FBS and 1 % 
Penicillin/Streptomycin (Invitrogen, Carlsbad, CA) at 37 °C and 5% CO2. Six-week-old female 
C57BL/6 mice were purchased from Charles River Laboratories. All animal regulations and 
procedures were accepted by Institutional Animal Care and Use Committee, University of North 
Carolina at Chapel Hill. 
5.4.3 Antibodies  
          InVivoMAb anti-mouse CD8α of clone 53-6.7 and anti-mouse CD4 of clone GK1.5 were 
purchased from BioXcell (West Lebanon, NH). Primary antibodies, fluorescent conjugated 
primary and secondary antibodies used for immunostainings (IF), western blots (WB), and flow 
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Table 3. Antibody list 
Antibodies Company Catalog Application 
Anti-CD8 (PE-conjugated)   BD 553032 flow cyt, IF 
Anti-CD4 (FITC-conjugated) BD 561828 flow cyt, IF 
Anti-CD11b (FITC-conjugated) BD 553310 flow cyt 




Anti-CD103 (PE-conjugated)   
Hoechst 33342 











BD PharmingenTM  











































GAPDH Santa Cruz I3015 WB 
 
5.4.4 Wnt5a expression in TCGA human patients and survival analysis 
          The TCGA SKCM (Skin Cutaneous Melanoma)) cohort data was downloaded from the 
Broad Institute Genome Data Analysis Centers (GDAC) by using its fbget tool to directly access 
the GDAC FireBrowse API interface. All the samples are either “TP” or “TM” type. For Wnt5a 
expression analysis, we noticed a significant difference in Wnt5a expression levels between 
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“TP” and “TM” types. The results shown are based on all “TM” type samples, as the majority of 
the samples are “TM”. The same trend was observed for the “TP” samples. The p-value was 
calculated with a t-test. For the survival analysis, we chose to use the “TP” samples, since these 
patients were diagnosed at earlier stages than the “TM” patient and their survival data is thus 
relatively more accurate. The survival time was calculated as days to death for deceased patients, 
and the days to last follow-up for alive patients. Data were represented as scatterplot of Wnt5a 
mRNA expression level vs days of survival for human primary solid SKCM tumor samples. 
Kaplan-Meier curves and Median Survival were quantified and calculated using Prism 5.0 
Software. P-value less than 0.05 was considered significantly difference. *: p < 0.05, **: p < 0. 
01, ***: p < 0. 001. 
5.4.5 Construction of Wnt5a trap gene 
          To construct the Wnt5a trap plasmid (pWnt5a trap), the codon-optimized coding 
sequences of the N-terminal extracellular cysteine-rich domain (CRD) of mouse FZD7 (residues 
33-180) and the C-terminal trimerization domain of cartilage matrix protein (residues 458-500) 
were used for assembling the trap gene. A flexible hinge region with optimized length was 
introduced between the Wnt5a-binding CRD and the trimerization domain. The final sequence 
for the monomeric Wnt5a trap codes for a secretion signaling peptide, Wnt5a-binding FZD7 
CRD, hinge peptide, trimerization domain, FLAG tag, and His (6×) tag, respectively. The 
complete cDNA was cloned into pcDNA3.1 between Nhe I and Xho I sites and the accuracy was 
confirmed by DNA sequencing.  
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5.4.6 Expression and purification of recombinant trap protein 
          293T cells were cultured until 70-80 % confluence. To transfect the cells, 24 μg pTrap (or 
pcDNA3.1 negative control) and 40 μL lipofectamine were added to each 10-cm plate. The 
serum concentration was reduced after transfection. The 293T cells were monitored each day to 
ascertain their survival. Ten mL supernatant was harvested after 24, 48, and 72 h, and kept at 
4 °C for further purification. The supernatants were concentrated with 10 kDa MWCO spin 
filters to 200 μL and subjected to His-Mag-Ni-Sepharose beads to purify His (6×)-tagged trap 
protein. The purified proteins were analyzed on 10 % SDS-PAGE gel. 
5.4.7 Binding kinetics 
          The binding affinities of FZD-CDR-based proteins to Wnt5a were accessed with 
Microscale Thermophoresis (MST). In brief, Wnt5a-binding protein was first fluorescently 
labeled by using RED-tris-NTA dye. Ten μL of the labeled protein was then supplied to 10 μL of 
serially 2-fold diluted mouse Wnt5a using a PBST buffer (PBS with 0.05 % Tween 20). The 
resulting samples were subsequently loaded into capillaries, and the thermophoresis of each 
sample was measured using Auto Red laser power and medium MST power on Monolith NT.115 
(NanoTemper Technologie, Munich, Germany). 
5.4.8 Preparation and Characterization of LPD  
          LPD NPs were synthesized according to published procedures from Huang lab.118 Briefly, 
DOTAP and cholesterol (1:1, mol/mol) liposomes were prepared by a hydration-extrusion 
method. LPD cores were self-assembled as adding 100 μL of 20 μg protamine in DI water to 100 
μL of 50 μg Wnt5a trap plasmid. After incubation for 10 min at room temperature, 60 μL of the 
liposomes were added. We then introduced 10 μL DSPE-PEG and 10 μL DSPE-PEG-AEAA at 
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60 °C for 15 min. Finally, 20 μL 20 % glucose solution was added to adjust the osmotic pressure. 
NP size and NP surface charge were measured by a Malvern ZetaSizer Nano series 
(Westborough, MA). Followed by negatively staining, NPs were imaged with a JEOL 100 CX II 
TEM (JEOL, Japan).  
5.4.9 Tumor growth inhibition, metastasis suppression and survival analysis 
          On day 0, mice were inoculated subcutaneously with 1 × 106 BPD6 cells on lower flank 
area. Once tumor volume reached ~200 mm3 (0.5 × length × width × height), mice were then 
randomized into 5 groups (n = 5~8) as follows: Untreated group (the PBS group), Control 
plasmid trap (the pGFP group), Low dose DOX (the DOX group), Wnt5a trap (the Wnt5a trap 
group), and Combination of low dose DOX with Wnt5a trap (the Combo group). DOX group 
was i.p. treated (0.544 mg/kg) on day 10 and 12. Control or Wnt5a trap was i.v. treated (50 µg 
plasmid/mouse) on day 10, 12, 14 and 16. Tumor size (digital caliper) and animal weight were 
monitored every 2–3 days. Mice were sacrificed before tumors reached 20 mm in one dimension. 
At the endpoint, tumors, major organs and blood samples were harvested and tested. Long-term 
survival was also monitored for over two months. Kaplan-Meier curves and Median Survival 
were quantified and calculated using Image J. At the endpoint of survival monitor, metastasis 
study was performed as major organs were harvested, fixed and processed with H&E staining for 
pathology observation. 
5.4.10 Bio-distribution of LPD NPs 
          DiI-labeled LPD NPs were synthesized with liposomes containing approximately 0.05 % 
of hydrophobic dye DiI. Mice were intravenously injected with DiI-labeled LPD NPs and 
sacrificed after 24 h. Tumor and major organs were collected accordingly and subject to IVIS® 
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Kinetics Optical System (Perkin Elmer, CA) (excitation/emission = 520/560 nm) for imaging 
and quantifications. 
5.4.11 Expression of Wnt5a trap 
          Mice bearing BPD6 allografts were intravenously injected with LPD NPs containing 50 μg 
plasmid. Mice were humanely sacrificed at 1, 2, 4, 8 days post final dosage. Tumor and major 
organs were harvested, and total protein were purified and quantified with BCA Protein Assay 
Kit (Pierce, Rockford, IL). Expression of Wnt5a trap was quantified with ELISA (Cell biolabs, 
INC., n = 5) using anti-His antibody against the His-Tag engineered at the C-terminus of Wnt5a. 
Trap protein was also directly intravenously injected into mice and compared with the plasmid 
counterpart.  
          Tumor bearing mice treated with pGFP were sacrificed two days after final dose. Liver, 
lung, and tumor were further sectioned by a cryostat (H/I Hacker Instruments & Industries, 
Winnsboro, SC) to quantify the distribution of LPD NPs within these tissues. Accumulation and 
distribution of NPs among these tissues were quantified to compare (n = 3).   
5.4.12 Flow cytometry assay 
          Immune cell populations were analyzed by flow cytometry. Briefly, Tumor tissues or LNs 
were collected by collagenase A at 37 °C for 40-50 min. Single cells were harvested in PBS and 
stained with fluorescein-conjugated antibodies. Penetration buffer (BD, Franklin Lakes, NJ) 
were added for any intracellular cytokine staining. 
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5.4.13 In vitro CD4+ T cell purification and proliferation  
          At the endpoint of tumor inhibition study, the CD4 positive T cells were sorted from whole 
spleen of mice among PBS or Combo groups. Sorted cells were stained with 5 μM CFSE, pulsed 
with DOX-treated cell lysate and cultured with RBC-depleted splenocytes as well as 25 U/mL 
IL-2 + 5 µg/mL soluble CD28 in vitro (0.5 x 105 cells/well in 96-well plate, with 200 µL 
compete culture medium) for 3-4 days. All cells before/after culture were subject to flow 
cytometry for quantification of CD4+CFSE+ cell population. The percentage of CD4+ cell 
proliferation (Q1 population) was quantified by CFSE staining via flow cytometry, and the 
divisions of antigen-reactive cells were statistically compared between groups, quantified by 
Flowjo software.  
5.4.14 Immunofluorescence staining 
          Staining was performed on paraffin-embedded sections from tumor tissues. Briefly, all 
tissues for paraffin-embedding were resected, rinsed in PBS, and placed in 4 % PFA for over 48 
h at 4 °C. Immunofluorescence staining was performed by deparaffinization, antigen retrieval, 
permeabilization, and blocking in 1 % BSA. All antibodies conjugated with fluorophores were 
incubated overnight at 4 °C, followed by nuclei counterstained with Prolong® Diamond 
Antifade Mountant with DAPI (ThermoFisher Scientific). Stained slides were imaged with Zeiss 
880 Confocal microscopy (Germany). Three randomly microscopic fields were selected and 
quantified by Image J software. 
5.4.15 ICD determination 
          ICD dosing was determined by in vitro CRT exposure and HMGB1 release. Briefly, BPD6 
cells treated with low dose of DOX were harvested, PBS washed and fixed in 0.25 % PFA. 
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Primary and secondary antibodies were diluted in blocking buffer and added to collected samples 
for 30 min each. Cells were then mounted, and nuclei were stained with Hoechst 33432 
(ThermoFisher Scientific), followed by Confocal imaging. For intracellular staining of HMGB1, 
cells were permeabilized with 0.1 % Triton X-100 for 10min before blocking.  
5.4.16 Quantitative real-time PCR (RT-PCR) assay 
          Total RNA was extracted from the tumor tissues following protocol of RNeasy® 
Microarray Tissue Mini Kit (Qiagen, Hilden, Germany). We then reverse-transcribed cDNA with 
iScript cDNA Synthesis Kit and amplify cDNA with iScript Reverse Transcription Supermix for 
RT-PCR (Bio-Rad, Hercules, CA). RT-PCR primers, all mouse specific, are listed in Table 4. 
RT-PCR reactions were performed with 7500 Real-Time PCR System and subject to analysis 
with 7500 Software, compared to and normalized by GAPDH endogenous control. 
 
Table 4. Primer list for real-time PCR 
Antibodies Applied Biosystems/Ref 
Mouse IFN-γ Mm01168134_m1 
Mouse IL12α Mm00434169_m1  
Mouse TNF-α  
Mouse TGF-β  
Mouse CCL2  
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5.4.17 TUNEL assay 
          Assay performed following DeadEnd Fluorometric TUNEL System (Promega, Madison, 
WI) instruction and imaged with fluorescence microscopy. Fragmented DNAs of apoptotic cells 
were fluorescently stained with FITC and defined as TUNEL-positive nuclei. Slides were 
mounted, and nuclei were stained with Prolong® Diamond Antifade Mountant with DAPI 
(ThermoFisher Scientific), followed by imaging under Confocal microscopy. Three fields were 
randomly selected and quantified. 
5.4.18 H&E staining and blood toxicity analysis   
          At the endpoint day of tumor inhibition study, tumor bearing mice under different 
treatments were humanely sacrificed, whole blood, serum, and major organs were harvested. 
Organs were collected for H&E staining by UNC histology facility. Indicators of renal and liver 
function such as creatinine, BUN, serum AST and ALT were tested based on blood and serum.  
5.4.19 Patient tumor samples 
          H&E sections from paraffin-embedded biopsies of BRAF-mutant melanoma patients were 
obtained from Department of pathology, Xinhua Hospital, China according to an approved 
patient sample management protocol. Informed consent was obtained from patient before 
evaluation. 
5.4.20 Statistical analysis  
          One-way ANOVA and a two tailed Student's t-test were performed in Prism 5.0 Software. 
Data were compared with PBS control group. P-value less than 0.05 was considered significantly 
difference. 
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CHAPTER 6 
NANO-MEDIATED CHEMO-IMMUNO THERAPY ARRESTED TUMOR PROGRESSION 
AND INDUCED DORMANCY 
6.1 Introduction  
          In DM, the interstitial cells especially TAFs construct an extracellular matrix-rich structure 
and cytokine crosstalk, thus facilitating aggressive and highly metastatic tumor growth. 
Moreover, the fibrosis raises delivery barriers for effective therapies.108, 174 In this work, we 
confirmed tumor cells and TAFs as major dominators within TME. Such domination resulted in 
the recruitment of immune cells - especially MDSCs, Tregs and TAMs - that collectively form 
the suppressive immune microenvironment.165 Consequentially, the highly immunosuppressive 
TME supports “tumor immunoediting”, thus inducing the tumor progression and further the drug 
resistance.175 
          The field of onco-immunology recently validates that conventional cancer therapies may 
achieve a sustained patients outcome by arising innate and adaptive immunity against tumor.176, 
177 For such purpose, specialized chemo-drugs which empowering ICD and immune-stimulatory 
side effects have been employed.178 Such “Chemo-immuno therapy” offers new therapeutic 
options for conventional drugs. The common mechanism of inducing ICD by reported chemo-
drugs (mitoxantrone (MIT), DOX, oxaliplatin, bortezomib) involves the induction of 
endoplasmic reticulum (ER) stress,179 but their potency requires enhancement. Thus, in addition 
to target depletion of the dominators (tumor cell and TAFs) within the TME and more 
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importantly, to effectively trigger ICD in DM, we screened drugs that could work synergistically. 
Our hypothesis was that the synergy will significantly reduce the effective drug dose if the drugs
could be delivered together at an optimal dose ratio. We further hypothesized that improved ICD 
could induce long lasting anti-tumor immunity which would elicit prolonged progression free 
survival of the host. To achieve the highest anti-cancer efficacy, we used a nanoparticle (NP) 
delivery system that specifically targets and triggers drug-release to deliver sufficient drugs with 
high concentration and with the synergistically optimal combination ratio at the tumor site. This 
chemo-immuno therapy strategy holds promise to prime robust innate and adaptive immune 
responses, arrest cancer progression and induce tumor dormancy. Data were collected and under 
peer-review in ACS Nano. (Q Liu, F Chen, L Hou, L Shen, X Zhang, D Wang, L Huang. 
Nanocarrier-Mediated Chemo-Immuno Therapy Arrested Cancer Progression and Induced 
Tumor Dormancy in Desmoplastic Melanoma) 
 
6.2 Results and discussion 
6.2.1 The design of chemo-immuno therapy 
          DM presents a highly fibrotic TME in comparison to non-desmoplastic subtypes. Figure 
30A depicts a typical collagen-rich morphology (predominantly produced by TAFs) in DM, 
compared with relatively non-desmoplastic ones, in both human patients and preclinical mouse 
models. Importantly, the metastatic rate of clinical primary melanoma significantly increased 
from 44.56 % (non-desmoplastic) to 50.45 % (desmoplastic subtypes). Among which, lung and 
distant lymph nodes (LNs) are the major identified loci (analyzed from The Cancer Genome 
Atlas (TCGA), data not shown).  
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          Figure 30. The design of chemo-immuno therapy. (A) Masson’s trichrome staining illustrating desmoplastic 
melanoma with collagen-rich TME (blue-stained collagen, black arrows highlighted), compared with relatively non-
desmoplastic samples from patients and mouse tumor specimens. Scale bar indicates 300 μm. (B) Flow cytometry 
analysis showing major cell populations within TME. (Tumor cells: MART1+; TAFs: FAP+). (C) A total of 25 
candidate drugs were screened using MTT assay. MIT and CEL were selected among lowest IC50. n = 5. (D) 
Cytotoxicity and combination index of MIT, CEL, and optimized ratios of MIT+CEL on both BPD6 cells 
(desmoplastic melanoma cells) and 3T3-T cells (TGF-β activated fibroblast, mimicking TAFs in vivo). 24 h 
incubation. n = 5–8. (E) ICD induced by MIT and MIT+CEL (combination ratio of 5:1) on tumor cells. 
Fluorescence imaging detecting ICD markers: CRT and HMGB1. Cell nuclei were stained with Hoechst 33432. 
Scale bar indicates 10 μm. n = 3. 
 
          In study of desmoplastic TME, we performed a whole tumor profiling assay (Figure 30B, 
using flow cytometry) on murine tumor model, where the presence of ~23 % tumor cells and 
~17 % TAFs were found. To target depletion of these two dominators of tumor mass, as well as 
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inducing tumor ICD, we designed a cancer-specific “chemo-immuno therapy”. A total of 25 
candidate drugs were screened with MTT assay in vitro. Among these were 4 well-reported ICD-
inducing chemo-drugs and 21 active compounds from traditional Chinese medicine (TCM) 
extracts (for full list, see Materials section). As illustrated in Figure 30C, MIT and celastrol 
(CEL) were among the most effective (IC50<50 μM) in both the desmoplastic melanoma cell line 
(BPD6) and a model TAF cell line (TGF-β activated NIH 3T3 cells, referred to as 3T3-T). 
MIT, clinically used in treating malignant melanoma,180, 181 can trigger ICD in various cancer 
types.155 CEL, a pentacyclic triterpene extracted from Tripterygium wilfordii (Thunder God 
Vine), which is reportedly an immune-stimulatory, anti-inflammatory and anti-cancer agent,182 
has further elicited potent anti-tumor and anti-fibrosis potential in the murine DM model (Figure 
30D). Such active compounds from TCM has been reported to increase efficacy of chemo-drugs 
as well as to decrease toxicity.129, 183 Thus, we explored the possible synergy between these two 
drugs. 
          As shown in Figure 30D, various combinations of these two drugs were tested for their 
half maximal inhibitory concentration (IC50) and the combination index (CI). In both tumor and 
TAF cell lines, significantly lower IC50 of MIT was achieved after combining MIT with CEL, 
indicating that CEL increased the sensitivity of cells to MIT. For example, IC50 of MIT in BPD6 
cells decreased from 16.0 to 4.5 µM and from 30.8 to 1.5 µM in 3T3-T cells, respectively, when 
tested in a drug ratio of 5:1 (marked in red). IC50 values for CEL were similarly decreased in 
both cell lines. We have also examined the synergistic effect184 among 7 combination ratios of 
MIT to CEL (1:10, 1:5, 1:2, 1:1, 10:1, 5:1, and 2:1). Among these, 5:1 and 10:1 showed strong 
synergy. The strongest CIs were 0.2 in TAF cell line and 0.6 in tumor cell line. Thus, CEL 
enables enhanced cytotoxicity of MIT in a best combination ratio of 5:1 (MIT: CEL=5:1, 
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referred to as MIT+CEL 5:1). Such high therapeutic efficacy achieved at low-doses would allow 
reduction of side-effects and satisfies the prerequisite of ICD-inducing chemo-drugs which 
should be used in a low-dose range.  
          The application of CEL in anticancer therapy has elucidated its role in calcium-mediated 
activation of ER stress.185 When calcium is released from ER and mitochondria, un/mis-folded 
proteins accumulate within the ER. The impaired activities of chaperones (e.g., HSP90) and 
disabled processing of proteins further promote proteasome function, thus initiating cell 
apoptosis and paraptosis. Thus, CEL has demonstrated its great potential in facilitating ICD. 
Upon stress and apoptosis, CRT translocated from ER lumen to the surface of cancer cells, with 
increased release of HMGB1.186 With CRT exposure and HMGB1 release as standard markers 
for drug-induced tumor cell immunogenicity,157 we confirmed that both MIT itself and 
MIT+CEL 5:1 effectively induced ICD in tumor cell line (Figure 30E), indicating the potential 
for synergistic chemo-immuno therapy. It would be beneficial to track the trafficking of each 
drug in tumor cell intracellular organelle distribution, thus to further elucidate the mechanism 
underlying ICD. 
6.2.2 The TME-responsive NP delivery platform 
          Despite the advantages and great promise of combination drugs, obstacles aligned between 
the ideal optimal synergistic ratio and the ratio at the tumor sites. Conventional drugs distributed 
all over the body, with only minor portion insufficiently delivered to the tumor. Thus, we applied 
a TME-responsive NP platform in purpose to enhance precisely-targeted and fast-released 
delivery of drugs, and subsequently induce ICD onsite. 
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          To construct such NP delivery platform as aforementioned, the APS (AEAA-Polymer-
Disulfide bond) NPs were synthesized by Michael addition polymerization (Figure 31A), based 
on the synthesis scheme of disulfide linkages in (β-amino ester) copolymers that was previously 
reported.187 In addition, we synthesized and added AEAA ligand to the copolymers for targeting 
purpose. AEAA is a high-affinity (Kd = 9 nM) ligand for sigma receptors which are over-
expressed on both melanoma and TAFs.124 The signal peaks in Figure 31A (1H NMR spectrum) 
represent functional groups such as PEG-AEAA and tertiary amine, indicating a successful 
synthesis of the APS copolymer. The analysis of characteristic peaks is described in Materials 
section. 
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          Figure 31. The TME-responsive NP delivery platform. (A) Synthesis scheme of the NP and 1H-NMR 
spectrum interpretation result. (B) Graphical structure and composition of APS NP. (C) NP DLS size and TEM 
image. Scale bar indicates 500 nm. (D) The in vitro MIT release from NPs in changing pH and GSH conditions. n = 
4. (E) NP hemolysis assay. n =4. 
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          Based on the optimized combination ratio as described above, MIT and CEL were co-
loaded (5:1, molar ratio) into APS NPs with a solvent evaporation procedure. Its illustrative 
feature (Figure 31B), TEM morphology image and NP size distribution (Figure 31C) are 
shown. Essential characterization of drug-loaded NP and NP itself, including nanoparticle 
particle size, zeta potential, polydispersity index (PDI), drug loading efficacy (DLE) and drug 
encapsulation efficiency (DEE) are listed in Figure 32A. Importantly, the zeta potential reversed 
from a negative charge (pH 7.4) to positive (pH 6.5) due to tertiary amines protonated in the 
copolymer. In blood (pH ~7.4), the negative charge of APS NPs can be leveraged to reduce rapid 
NP clearance in the circulation without interacting with blood components which are mostly also 
negatively-charged. Due to acidic microenvironment (pH ~6.5) in solid tumors, APS NPs 
triggered a charge-reversal process thus attracting their combination with negatively-charged cell 
membrane. In turn, this charge-reversal effect enables NPs to be internalized at the TME and 
minimizes their distribution among normal tissues.188, 189 These features offer excellent 
possibility for inducing local ICD at the tumor site.  
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          Figure 32. The TME-responsive NP delivery platform. (A) Characterization of blank and drug-loaded NPs. 
(B) NP DLS in changing pH and GSH conditions. n = 4. (C) The in vitro CEL release from NPs in changing pH and 
GSH conditions. n = 4. (D) Stability of drug-loaded NP in PBS and 10% fetal bovine serum (FBS), respectively, 72 
h, n = 4. (E) The representative image of hemolysis assay. (F) Cytotoxicity of blank NPs (of different concentration) 
on 3T3-T and BPD6 cell lines (24 h incubation), n = 4. 
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          An effective drug delivery system allows rapid drug release inside the cancer cell. To 
achieve optimal drug ratio promptly, as well as improve anti-cancer efficacy, TME-specific 
glutathione (GSH) property has been employed. The concentration of GSH in the cytosol of 
cancer cells (~2-10 mM) was remarkably higher than that of extracellular matrix and blood (~2-
20 μM).104, 190 Furthermore, GSH level in cancer cells are over 4-fold higher than normal cells.191 
To confirm such TME-responsive property, the synthesized NPs were tested in changing pH and 
GSH conditions. As shown in Figure 32B, the particle size dramatically increased in the 
presence of 10 mM GSH compared with no GSH condition, possibly due to disulfide-bond 
breakage in a reductive manner.192 A pH change from 7.4 to 6.5 further facilitated NP response 
to GSH. Thus, these NPs were unstable in either acidic or reductive conditions. Both are 
favorable properties for anti-cancer drug delivery.193 
          As a result, MIT (Figure 31D) and CEL (Figure 32C) were being triggered to release 
from NPs. In the condition of pH 7.4, MIT and CEL loaded NPs released less than 20 % in 24 h. 
However, at pH 6.5 (simulating the acidic tumor extracellular microenvironment), the drug 
release slightly increased to ~40 % due to ionization of tertiary amines. The slightly acidic 
environment led to NP leakage but did not collapse the NPs. Moreover, in the addition of 10 mM 
GSH (which simulated the reductive environment inside the cancer cells), the release increased 
to ~60 % due to the rupture of disulfide linkage, indicating that the core of NPs had collapsed. A 
combination effect was observed in pH 6.5 and 10 mM GSH condition, where more than 80 % of 
drugs were released. Such high releasing property would help achieve the optimal ratio for drug-
induced ICD at the tumor site. 
          To mimic the blood physiological conditions, APS NPs were added to 10 % fetal bovine 
serum (FBS) or PBS in vitro for 72 h, and no significant change in size was found, suggesting 
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their stability (Figure 32D). To further evaluate the biocompatibility, a hemolysis assay was 
employed investigating the interaction between NPs and red blood cells (RBCs). As shown in 
Figures 31E and 23E, 1 % Triton was used as a positive control which had roughly a 100 % 
hemolysis rate. At pH 7.4, four concentrations of NPs (0.1, 0.5, 1, and 2 mg/mL) were observed 
with less than 10 % hemolysis. However, the hemolysis rate increased at pH 6.5 and 5.0; 
especially in maximum conditions (1 or 2 mg/mL of NP at pH 5.0), the hemolysis rate was close 
to 100 %, indicating strong interactions between NPs and RBCs. Importantly, blank NP itself 
showed no significant cytotoxicity in either tumor cells or TAFs (Figure 32F). To conclude, the 
NP deliver platform responded in accordance to TME-mimicking factors and showed a high 
biocompatibility profile.  
6.2.3 Nanocarrier-mediated chemo-immuno therapy significantly improved anti-tumor 
response and remodeled suppressive TME 
          To achieve sufficient efficacy, we first examined the delivery of MIT and CEL in TME-
responsive NP among DM tumor-bearing mice. Through IVIS imaging, Cy5-loaded NPs mainly 
distributed in the tumor 24 h after i.v. injection (Figure 33A), compared with other major 
organs. Although liver took up NPs, it was significantly lower than the tumors on the per gram 
weight basis (p < 0.01) (Figure 33B). With the help of sigma receptor-targeting, we found that 
most of the NPs were taken up by tumor cells and TAFs within the TME (measured by flow 
cytometry, data not shown). Furthermore, pharmaco-distribution profiles of MIT and CEL were 
characterized after i.v. administration of drug-loaded NPs and free drug suspension, respectively. 
As shown in Figure 33C, the injected NPs offered targeted delivery of MIT and CEL to and 
stayed in the tumor for a significantly increased amount compared with injected free drugs 
(measured by LC/MS). Within the tumor, the area-under-curve values of nano-delivered drugs 
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were significantly higher than those of the free drugs (2.9-fold increase in MIT and 3.8-fold 
increase in CEL). Importantly, the amounts of drugs in the tumor resembled the designed optimal 
ratio in vitro at least in the early time points (at 4 h, ratio was 6.1:1; 8 h was 5.0:1; 12 h was 
4.0:1, 24 h was 3.1:1). In comparison, the free drugs failed to retain such ratio (7.1:1; 13.9:1; 
9.9:1; 8.9:1, respective to 4 measured time points). This result indicated the benefit of using a 
controlled-release nanocarrier system.  
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          Figure 33. Effective therapy significantly improved anti-tumor response and remodeled suppressive TME. 
(A) NP distribution in tumor-bearing mouse. Mice were intravenous injected with Cy5 (3 μg/kg)-loaded NPs and 
measured by IVIS imaging 24 h post-injection. n = 3; (B) Region-of-interest intensity of fluorescence signals among 
tumor and organs. n = 3; (C) Pharmaco-distribution of MIT and CEL within tumor measured by LC/MS, n = 5; (D) 
Tumor inhibition study and tumor weight comparison. Arrows indicate days of drug injection. Dosage: for M+C 
group: ~2 mg/kg of CEL per dose; for M+C NP group: ~160 μg/kg of CEL per dose. Tumors were surgical removed 
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from host at endpoint of study, weighted and compared between groups. n = 10-12; (E) Relative tumor inhibition 
ratio between M+C NP, M NP+N NP group, and single drug NP groups at day 23 after tumor inoculation. n = 5; (F) 
Cell apoptosis measured by TUNEL staining and collagen morphology changes measured by Masson’s trichrome 
staining (left panel), scale bar indicates 300 μm. n = 3. Right panel indicates Cy5-loaded NP penetration within 
TME after different treatments, measured by fluorescence imaging of tumor frozen sections. n = 5. (G) Flow 
cytometry analysis of immune functioning cells within TME. n = 3. *: p < 0.05, **: p < 0. 01, ***: p < 0. 001. 
 
          Through NP encapsulation and delivery, the cytotoxicity of drugs was ~6-fold enhanced in 
comparison to free drugs in combination (measured by IC50, data not shown). Furthermore, on 
animal model bearing DM tumors (Figure 33D), the mice treated with MIT and CEL loaded NPs 
(denoted as the M+C NP group) presented a significant tumor-killing effect, with only ~1/13 
dosage compared to free drugs administrated in combination (the M+C group). As shown in 
Figure 3D, the delivery of low-dose drugs largely inhibited tumor growth. Moreover, tumor mass 
was significantly restrained with lower tumor weight. Such therapeutic strategy also achieved 
best anti-cancer effect in comparison to single drug-loaded NP groups (Figure 33E).  
          DMs are well-known for their immunoediting ability and resistance to immunotherapy. 
The significant tumor inhibition by delivered drug combination, also referred to as “the 
elimination phase” of cancer immunoediting, is mainly resulted from the following factors:  
          1) Effective apoptosis induced by MIT and CEL (shown in vivo by TUNEL assay in 
Figure 3F, and in vitro by quantitative cell apoptotic assay and cell cycle analysis in Figure 34). 
In the cell apoptosis assay, M+C NP caused a dramatic increase in the total apoptosis rate (> 
60 %) in both tumor cells and TAFs (Figure 34A and C). Enhanced apoptosis could be the result 
of the G1 phase shift to the G2/M phase in the cell cycle. As shown in Figure 34B and D, M+C 
NP group also had a higher percentage of G2/M phase cells, suggesting a synergistically 
blockage of cell mitosis compared with all controls. These data indicated an increased level of 
cell apoptosis, possibly due to ICD. 
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          Figure 34. Effective therapy significantly enhanced cell apoptosis and cell cycle arrest. (A) Quantitative cell 
apoptotic assay among BPD6 cells and 3T3-T cells under different treatments for 48 h, measured by flow cytometry. 
n = 3. For each panel, top left (Q1) presents necrotic cells; top right (Q2) presents late apoptotic cells; bottom left 
(Q3) presents live cells; bottom right (Q4) presents early apoptotic cells. (B) Cell cycle analysis measured by flow 
cytometry, 48h, n = 3. (C) Histogram of total apoptosis rate. Total apoptosis rate=Q2+Q4. All data compared with 
MIT+CEL group. (D) Histogram of cell arrest at G2/M phase. All data compared with MIT+CEL group. *: p < 0.05, 
**: p < 0. 01, ***: p < 0. 001. 
 
          2) Change of TME morphology that facilitated further delivery of therapeutics. As shown 
in Figure 33F, collagen deposition and fibrosis were abundant in tumor sections of the untreated 
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group. By contrast, the in vivo tumor model depicted significantly decreased collagen density 
and increased NP penetration under the treatment of M+C NP (Figure 33F, right panel). 
Collagens were predominantly produced by TAFs, which were the target of both MIT and CEL. 
          3) The immune-stimulatory effects that counteracted immune-suppression induced by 
TME dominators. As shown in Figure 33G and Figure 35, the effective elimination of tumor 
cells and TAFs dampened the secretion of immune-suppressive TGF-β, IL6, CCL2 and IL-10 
network. Thus, suppressive immune cell (MDSC, Treg, and TAM) were significantly reduced. 
Antigen presenting cells within TME, mostly dendritic cells (DCs) were normally inhibited in 
antigen-recognition functions and were tolerogenic to immune-stimulators under immune-
suppressive environment.194 After treatment, DC functions were largely recovered with CD103+ 
DC significantly increased, suggesting that the local effective ICD would help release tumor-
associated antigens and facilitated DC maturation with cross-priming ability to CD8+ CTLs. As 
a result, IFN-γ increasingly released to stimulate tumor-specific immunity and inhibit the tumor 
growth. It is known that perforin and granzymes released by CTLs enable non-apoptotic 
pathways of cell death, thus offering an effective treatment of cancer by modulating the immune 
system.195, 196 
 
          Figure 35. Effective therapy remodeled immune profile within TME. RT-PCR analysis of both pro-
inflammatory and anti-inflammatory cytokines changes within TME. n = 6-8. *: p < 0.05, **: p < 0. 01, ***: p < 0. 
001. 
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          To examine the observed therapeutic efficacy in other models of desmoplastic melanoma, 
we established a second DM model using D4M cells (BRAFV600E, syngeneic with C57BL/6 
mice). As shown in Figure 36, like the BPD6 tumor model, these tumors also presented a 
desmoplastic morphology. Following same treatment protocols, the M+C NP group mitigated the 
desmoplastic structure compared with the PBS group, resulting in superior tumor growth 
inhibition as compared with all other controls.  
 
          Figure 36. Second model of desmoplastic melanoma. (A) Masson’s trichrome staining depicting collagen 
morphology change in TME. Scale bar indicates 300 μm. (B) Effectiveness of therapies were compared by 
monitoring D4M tumor growth every 2 days, on day 25 after inoculation, tumor burden was compared and 
quantified. n = 3-5, **: p < 0. 01, ***: p < 0. 001. 
 
6.2.4 Enhancement of long-term immune surveillance, host survival, and anti-metastasis 
efficacy of therapy 
          Clinically, a strong cancer immunoediting implies that the “elimination phase” can be 
hardly completed, thus resulted in a balance between surviving tumor cells and the modified 
immune system. Such balance may last for years for patients. In our animal model, as the tumor 
inhibition study continued, we also noticed a long-term sustained tumor inhibition effect in the 
M+C NP group (Figure 37A). Tumor volume was restrained around 200 mm3 for over two 
weeks after the last dose of treatment, with a significant prolongation of progression-free host 
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survival (Figure 37B). A typical “tumor dormancy” phenomenon suggested the existence of 
endogenous immune surveillance.  
 
          Figure 37. Enhancement of long-term immune surveillance, host survival, and memory immunity. (A) Long 
term tumor inhibition study. Dosing schedule was consistent for all in vivo studies. Arrows indicate days of drug 
injection. M+C group: 2 mg/kg of CEL per dose. M+C NP group: 160 µg/kg of CEL per dose. n = 10-12; (B) Long 
term survival between different treatments. n = 6-8; (C) In M+C NP group, figures depict tumor tissue’s collagen 
staining at different days after tumor cell inoculation. Scale bar indicates 300 μm. n = 3; (D) Tumor tissue 
immunostaining analysis of memory immune cells within TME at endpoint day of survival study. n = 3; (E) In M+N 
NP group, tumor-bearing mice were treated with 3 daily injections of anti-CD8 or anti-CD4 antibody or Isotype 
control (300 μg/mice i.p. started from 10 days after the last dose of therapy, arrows) to deplete either CD8+ or CD4+ 
T cells in vivo. n = 3-4. ***: p < 0. 001. 
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          Tumor dormancy can be categorized into two types: cell cycle arrested at G0-1 phase at 
the cell level, or mostly on a population level represents a balance between tumor cell 
proliferation and death. Herein, the tumors were restrained as a result of several possible key 
factors:  
          1) A turnover of TME morphology. As depicted in Figure 37C, the density of fibrosis 
increased correlatively along with tumor growth (from I to II). The TME was heavily 
desmoplastic at the start of therapy (depicted in II, ~200 mm3 in tumor volume at day 13 after 
tumor cell inoculation), and then subjected to de-fibrosis treatment by targeted co-delivery of 
MIT and CEL aiming at the depletion or deactivation of TAFs (depicted in III, M+C NP group). 
During over two weeks of host survival observation, the morphological structure of the tumor 
was largely reframed. At the endpoint of study, an inner necrosis-rich pattern was found in the 
core area of the residual tumors, along with only a minor level of fibrosis (depicted in IV). 
          2) Increased levels of immune-surveilling cells. Local CTLs and NK cells are crucial 
components, but more importantly tumor-specific memory T cells were significantly recruited 
(Figure 37D). The increased memory CD4+ and CD8+ T cells inside the tumor suggested the 
effectiveness of ICD in vivo. Reasonably, residual tumor cells may express low but persistent 
levels of tumor antigens to be recognized and cleared by the immune system. To address such 
action mechanism, we further depleted CD4+ or CD8+ T cells in mice bearing the dormant 
tumor. As shown in Figure 4E, the sustained tumor restrain effect was abolished by the treatment 
with either anti-CD8 or anti-CD4 antibody, whereas it was not affected when an isotype-matched 
IgG control was used. The result suggested that a strong immune-surveillance might be the main 
reason for such dormancy.  
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          3) High expression of CD69 (Figure 38A). CD69 is a T cell activation marker. Recent 
studies in metastatic melanoma patients have reported that the expression of CD69 positively 
correlates with survival and negatively corelates with metastasis.197 We found CD69 highly 
expressed in the remaining cells within the TME, which would help contributing in metastasis 
inhibition (in both lung and liver) compared to the untreated hosts (Figure 38B).  
 
          Figure 38. Long-term tumor dormancy and anti-metastasis efficacy of therapy. (A) Tumor flow cytometry 
analysis of CD69+ leukocytes within TME at endpoint day of survival study. n = 3; (B) Tumor metastasis in liver 
and lung, observed at endpoint day of survival study between PBS and M+C NP group, measured by H&E staining. 
Scale bar indicates 300 μm; (C) Flow cytometry analysis of CD44+CD133+ tumor cells within TME at endpoint day 
of survival study. n = 3. *: p < 0.05, ***: p < 0. 001. 
 
          4) A high percentage of remaining dormant tumor cells showing the characteristics of 
cancer stem cells (CSCs) (Figure 38C). CSCs are poorly immunogenic and thus avoiding 
immune-surveillance and clearance.198 Moreover, CSCs demonstrate a slow growth rate and are 
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unable to grow into overt tumor mass.199 Any immunogenic daughter cells from CSCs would be 
eliminated by immune-surveilling cells, which further stabilized tumor dormancy. 
          Interestingly, we found that two out of ten mice with remaining dormant tumors eventually 
had their tumors grown back at a late stage (Figure 37B), indicating equilibrium was disturbed 
in favor of tumor-escape. This suggested the possibilities underlying genetic or epigenetic 
changes which further allow tumor progression. Main factors to be investigated in such 
probabilities can be summarized as follows: a) Due to genomic instability, dormant tumor cells 
express new tumor antigens with specific mutations. Such probability may serve as novel target 
for the design of neoantigen vaccines; b) The remaining dormant cells may overexpress immune 
checkpoint ligands, such as PD-L1, gained by gradual increase in resistance. Thus, the 
checkpoint inhibitors and kinase inhibitor might be applied in combination with new targeted 
therapy; c) At a late stage, dormant tumors would induce MDSC or Treg proliferation as well as 
their active suppression of immunity; d) A depletion of T cells or decrease in IFN-γ or IL12 
would also trigger immune-escape mechanisms; e) An over-activation of angiogenesis would 
facilitate tumor progression and even metastasis.  
6.2.5 Safety evaluation for chemo-immuno therapy 
          Safety is an essential aspect for the development of both effective and translational 
therapy. Thus, biosafety-related toxicological pathology analyses were performed. As shown in 
Figure 39A and B, the serum biochemical parameter analysis and the whole blood cell counts 
were remained within normal range, this suggested that the treatment strategy led to none 
detectable systemic anemia nor inflammation. Liver and kidney function markers were remained 
normal. No severe weight loss in hosts were found (Figure 39C). Moreover, the H&E staining 
results also indicated no significant morphological damage among major organs, including 
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kidney, lung, spleen, liver, and lung (Figure 39D). Lack of toxicity of the combination chemo-
immuno therapy was certainly the direct result of low drug doses required. 
 
          Figure 39. Toxicity evaluation of therapies. (A) and (B) are whole cell counts and serum biochemical marker 
analysis of tumor bearing mice. Fresh whole blood and serum were collected at endpoint of study. All indicators 
were among normal biological range. (C) Mice body weight changes under tumor inhibition study. (D) H&E 
morphology under different therapies.  Major organs were collected at endpoint of study and sectioned, stained for 
H&E analysis. Scale bar indicates 300 μm. n = 5. n.s.: p > 0.05. 
 145  
 
6.3 Conclusions 
          In summary, the success described here stems from the strong synergy between MIT and 
CEL in inducing ICD. The combination also targets TAFs to reduce the desmoplasia of the 
tumor. The chemo-immuno therapy significantly remodeled immune-suppressive TME, as well 
as triggered a robust immune memory response. Since only low doses of both drugs were used, 
the treatment was without any toxicity to the host. Low dose drug-synergy is also clinically 
beneficial, especially for patients suffering from chemo-toxicities, but the optimization of such 
synergy needs further investigation. In comparison to personalized vaccines, no matter 
preventive or therapeutic, our strategy offers a broader application to patients subjects in a way 
of priming immune system against cancer.   
 
6.4 Materials and methods 
6.4.1 Materials 
          MIT, DOX, Oxaliplatin, and Bortezomib were obtained from Sigma-Aldrich (MO, USA). 
Active compounds with over 99 % purity, including Dihydroartemisinin, Glycyrrhizin, 
Curcumin, Tetramethylpyrazine, Resveratrol, Epigallocatechin, CEL, Salvianolic acid B, 
Salvianolic acid A, Scutellarin, Oleanolic acid, Dihydromyricetin, Osthole, Berberine, 
Cryptotanshinone, Baicalein, Sinomenine, Lupeol, Wogonin, Cepharanthine, and Adiponectin 
were obtained from Chengdu Mansite Biotech Co. Ltd (Sichuan, China). NH2-PEG-OH (MW 
2k, CAS No. 32130-27-1) was obtained from Biochempeg Scientific Inc. (MA, USA). Synthetic 
materials as previous reported were obtained from Sigma-Aldrich MO, USA).  
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6.4.2 Cell lines and animals 
          Desmoplastic melanoma models were built according to previously published protocol.200 
In detail, murine melanoma cell lines BPD6 and D4M (BRAFV600E, syngeneic with C57BL/6) 
was kindly provided by Brent Hanks (Duke Cancer Institute) and cultivated in RPMI-1640 
Medium added with 10 % FBS and 1 % Penicillin/Streptomycin (PS) (Invitrogen, Carlsbad, CA) 
at 37 °C and 5 % CO2. NIH-3T3 cell line (which were activated with 10 ng/mL TGF-β 
mimicking TAFs in vitro) were cultivated in DMEM Medium also with FBS and PS. Six-week-
old female C57BL/6 mice were purchased from Charles River Laboratories (Wilmington, MA). 
All animal regulations and procedures were accepted by Institutional Animal Care and Use 
Committee of University of North Carolina at Chapel Hill. 
6.4.3 Antibodies  
          InVivoMAb anti-mouse CD8α (clone 53-6.7) and anti-mouse CD4 (clone GK1.5) were 
purchased from BioXcell (West Lebanon, NH).  
6.4.4 ICD determination 
          ICD dosing was determined by in vitro CRT exposure and HMGB1 release. Briefly, BPD6 
cells treated with MIT alone or MIT+CEL (5:1 molar ratio), then harvested, PBS washed and 
fixed in 0.25 % PFA. Primary and secondary antibodies were diluted in blocking buffer and were 
added to collected samples for 30 min each. Cells were then mounted, and nuclei were stained 
with Hoechst 33432 (ThermoFisher Scientific), followed by Confocal imaging. For intracellular 
staining of HMGB1, permeabilization buffer (0.1 % Triton X-100) were applied for 10 min 
before blocking.  
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6.4.5 Synergistic effects of MIT and CEL at various combination ratios 
          Synergy of MIT in combination with CEL were tested using MTT assays. BPD6 and 3T3-
T cells were seeded onto 96-well plates (5×103 cells per well). After overnight incubation, cells 
in each well were incubated with various concentrations of MIT, CEL, or combinations of MIT 
and CEL at a molar ratio of 1:10, 1:5, 1:2, 1:1, 2:1, 5:1, or 10:1 (MIT+CEL). After 24 h 
incubation, cell cytotoxicity was assessed by MTT assay. The synergy of MIT and CEL 
combination treatment was evaluated by calculating the combination index (CI) based on the 
level of synergism (median-effect analysis). The classificatory of synergy are: additive (CI = 1), 
synergistic (CI < 1), or antagonistic (CI > 1). IC50 value was calculated using GraphPad Prism 
software. 
6.4.6 Synthesis and characterization of the drug-loaded AEAA-modified NP (APS NP)  
          The APS copolymers were obtained by previous reported method.187 Briefly, AEAA 
ligand (71.3 % yield) and AEAA-PEG-2,2-bis(acryloyloxymethyl)propionate (AEAA-PEG-
BAP) (91.1 % yield) were first synthesized. Then, all the synthetic materials were dissolved in 
anhydrous DMSO for Michael-type step-polymerization. The reaction was gently stirred in oil 
bath (60 °C) for 60 h under nitrogen protection. To obtain the final products of APS NP, the 
mixture was dropped into excessively cold ethyl ether and dialyzed in a dialysis tube in PBS (p 
H 7.4) with a molecular weight of MW 5000, followed by freeze-drying (78.4 % yield).  
          The APS copolymer was confirmed by 1H NMR (at 500 MHz, Bruker, USA) with 
deuterated chloroform (CDCl3) as the solvent. As shown in Figure, the signals at 3.66 ppm are 
the characteristic peaks for –OCH2CH2– in PEG-AEAA; the four peaks at 5.31, 3.15, 3.10, and 
2.77 ppm correspond to the -NH-CH2-CH2-NH- moieties; the peak at 3.58 ppm is characteristic 
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for the -O-CH3 end group in PEG-AEAA. The signals at 2.69, 1.32, and 1.51 ppm indicate a C–
C single bond in 1,6-hexanediol. The signals at 4.01 and 2.48 ppm were generated by -O-CH2- 
and O-CO-CH2- moieties in the 1,6-hexanediol diacrylate, respectively. The signal at 2.57 ppm 
was generated by the C–C single bond and the tertiary amine in the piperazine ring.   
          APS NP were prepared using the solvent evaporation method. In brief, 10 mg of the APS 
copolymer and MIT+CEL combination (5:1) were dissolved in 1 mL acetonitrile/methanol (1: 1) 
and gently added to 10 mL PBS (pH 7.4). The residual methanol and acetonitrile were water-
bathed (45 °C) for 15 min. The solution was centrifuged at 4,000 rmp (10 min) and filtered by 
0.18 μm filter membranes to remove the unloaded MIT and CEL. The Non-drug loaded blank 
APS NP were prepared by the same process but without loading any cargo. To evaluate the 
redox-sensitivity and pH-triggered charge reversal, the zeta potential and nanoparticle size were 
measured DLS (Malvern, United Kingdom) under different conditions: the normal physiological 
conditions (pH 7.4), the acidic extracellular TME (pH 6.5), and the intracellular reductive 
environment (10 mM GSH). The stability of drug-loaded NPs was recorded for 72 h. DLE and 
DEE of MIT and CEL in NP were quantified using HPLC (Shimadzu LC-20AT, Japan). The 
morphological examination was detected under JEOL 100CX II TEM (JEOL, Japan). The 
particle size changes of the APS NP (1 mg/mL) under reductive (10 mM GSH) and/or acidic 
environments (pH 6.5 or 5.0) were investigated using DLS measurements.  
6.4.7 Controlled MIT and CEL release from APS NP in vitro 
          The release kinetics of MIT and CEL from the NP was investigated in four different 
mediums using the dialysis tube method. The medium consisted of either 1) pH 7.4, 0.01 M PBS 
buffer, 2) pH 7.4, 0.01 M PBS buffer with 10 mM GSH, 3) pH 6.5, 0.01 M PBS buffer, or 4) pH 
6.5, 0.01 M PBS buffer with 10 mM GSH. Tween 80 (0.5 % w/w) were added to all medium, 
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then 1.0 mL of the MIT+CEL-loaded NPs solutions (0.1 mg/mL) were transferred into dialysis 
bags (MW 3500) with 30 mL of such medium. The release of drugs in different mediums were 
measured using HPLC. 
6.4.8 Biocompatibility assay  
          The hemolytic activity was measured at pH 7.4, pH 6.5, and pH 5.0 with red blood cells 
(RBCs). Mice RBCs were extracted from plasma by 2,000 rpm centrifugation for 15 min and 
two washes. Triton X-100 was used as a positive control. The suspensions of RBCs were added 
to copolymer samples (0.1 to 2 mg/mL) or Triton X-100, and then compared between groups. 
6.4.9 Drug distribution assays 
          To investigate the distribution of drug-loaded NP in vivo, Cy5-loaded NP (3 μg/kg) was 
prepared by the same method as previously mentioned.187 Mice were injected with Cy5-loaded 
APS NP and sacrificed after 24 h. Tumors and major organs were collected accordingly and 
subject to IVIS® Kinetics Optical System (Perkin Elmer, CA) for imaging and quantifications. 
          The intra-tumoral cellular uptake of NPs was evaluated using flow cytometer. Briefly, 
tumor tissues were dissociated with 1 mg/mL collagenase and 200 μg/mL DNAase (Invitrogen) 
in DMED/2 % FBS for 40 min to generate a single-cell suspension. Major cell populations 
within TME, such as tumor cells, TAFs, macrophages, MDSCs, Tregs, and DCs were stained for 
quantification. The ratios of Cy5-loaded NP distributed in these different cell populations were 
calculated accordingly. 
          LC/MS instrument (Shimadzu LCMS-2020, Japan) was also utilized to quantitatively 
analyze the accumulation of drugs (delivered by APS NP or delivered i.v. as free drug) in the 
tumor site at predetermined times (4, 8, 12, 24 h) and to study the pharmacokinetics profile. The 
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separation of analyses was by using Thermo Scientific C18 column (100 mm × 4.6 mm, 2.6 μm) 
with flow rate of 0.2 mL/min and 35 ℃ column temperature. 
6.4.10 Assays on tumor growth, metastasis and host survival 
          On day 0, mice were inoculated subcutaneously on lower flank with 1x106 BPD6 cells. 
Tumor growth were measured by digital caliper where volume = 0.5 × length × width × height. 
Mice were randomized into treatment groups (n = 15-20) when tumor volume reach ~200-300 
mm3. Groups were named as follows: PBS treated control (the PBS group), APS NP with no 
drug loaded (the blank NP group), MIT+CEL (5:1) administrated i.v. (2 mg/kg of CEL per dose) 
(the M+C group), MIT+CEL (5:1) formulated into APS NP and administrated i.v. (160 µg/kg of 
CEL per dose) (the M+C NP group), and as single controls, MIT loaded APS NP (the M NP 
group), as well as CEL loaded APS NP (the C NP group). Treatment groups were administrated 
on day 13, 15, 17, 19 after tumor inoculation. Mice weight and health conditions were monitored 
every 2 days. Once tumors reached ~20 mm in one dimension, mice were humanely sacrificed. 
Long-term host survival was monitored and calculated by Kaplan-Meier curves in GraphPad 
Prism software. At the endpoint of survival monitor, metastasis study was performed as major 
organs were collected, fixed in 4 % PFA, and H&E stained for pathology observation. 
6.4.11 Cell cycle assay  
          Briefly, BPD6 and 3T3-T cells were seeded in 6-well plate (1.5 × 105 cells per well) and 
incubated for 48 h. Then, cells were treated with either blank APS NPs (100 mg/mL), MIT, CEL, 
MIT and CEL in combination (the MIT+CEL group), or MIT+CEL-loaded NPs (the MIT+CEL 
NP group) for 48 h. Cells were then collected, fixed, stained with PI staining solution, and then 
 151  
 
measured by flow cytometer (BD Biosciences, USA). For each sample, 10,000 events were 
recorded and compared between groups.  
6.4.12 Apoptosis assay 
          Cell apoptosis assay was performed by Annexin V-FITC/PI double staining. Briefly, cells 
were seeded in 6-well plate (1.5 × 105 cells per well) and incubated for 24 h. Then, cells were 
treated with either blank APS NPs (100 mg/mL), MIT, CEL, MIT+CEL, or MIT+CEL NPs for 
48 h. Cells were stained with Annexin V-FITC assay kit (Biovision, USA) and then measured by 
flow cytometer (BD Biosciences, USA).  For each sample, 10,000 events were collected.  
6.4.13 Flow cytometry assay 
          The flow cytometry assay mainly characterized the change of immune cells within TME, 
as previously reported. In brief, mice were humanely sacrificed and the whole tumors were 
collected and incubated at 37 °C for 40-50 min, with the addition of collagenase A and DNAase. 
After three rounds of PBS washes, single cell suspensions were harvested in MACs buffer, then 
subjected to fluorescein-conjugated staining. For intracellular staining, penetration buffer (BD, 
Franklin Lakes, NJ) must be applied before adding antibodies. All stained cells were subject to 
flow cytometer.  
6.4.14 Immunofluorescence staining and Masson trichrome staining 
          Staining was performed on paraffin-embedded sections from tumor tissues. Briefly, all 
tissues for paraffin-embedding were resected, rinsed in PBS, and placed in 4 % PFA for over 48 
h at 4 °C. Immunofluorescence staining was performed by deparaffinization, antigen retrieval, 
permeabilization, and blocking in 1 % bovine serum albumin. All antibodies conjugated with 
fluorophores were added to tissue slides for at least 12 h at 4 °C. Then, nuclei were 
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counterstained with Prolong® Diamond Antifade Mountant with DAPI (ThermoFisher 
Scientific). Stained slides were imaged with Zeiss 880 Confocal microscopy (Germany). Five 
randomly microscopic fields were selected and quantified by Image J software. The Masson 
Trichrome assay was performed to detect collagen among tumor tissue. Tumor slides were 
stained using a Masson Trichrome Kit by the UNC Tissue Procurement Core. 
6.4.15 Quantitative real-time PCR (RT-PCR) assay 
          Total RNA was extracted from the whole tumor using RNeasy® Microarray Tissue Mini 
Kit (Qiagen, Hilden, Germany). We then reverse-transcribed cDNA with iScriptTM cDNA 
Synthesis Kit and amplify cDNA with iScriptTM Reverse Transcription Supermix for RT-PCR 
(Bio-Rad, Hercules, CA). RT-PCR reactions were run in 7500 Real-Time PCR System and 
subject to analysis with 7500 Software, compared to and normalized by GAPDH endogenous 
control. 
6.4.16 TUNEL assay 
          According to DeadEnd Fluorometric TUNEL System (Promega, Madison, WI) 
instructions, tumor tissue slides were stained and subject to fluorescence microscopy imaging. 
Fragmented DNA of apoptotic cells (FITC-positive) indicate TUNEL-positive nuclei. Slides 
were mounted, and nuclei were stained with Prolong® Diamond Antifade Mountant with DAPI 
(ThermoFisher Scientific), followed by imaging under Confocal microscopy. 
6.4.17 Safety of treatments 
          All mice under different treatments were humanely sacrificed at endpoint of tumor 
inhibition study, where whole blood and serum of hosts were harvested and subject to test by 
UNC histology facility. Creatinine, BUN, AST and ALT indicate renal and liver functions. RBC, 
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WBC, PLT, HGB and HCT indicate myelosuppression level. Major organs were collected, H&E 
stained and compared. Throughout the tumor inhibition study, mice body weights were 
monitored and recorded every other day starting from the treatment. 
6.4.18 Statistical analysis  
          One-way ANOVA and a two tailed Student's t-test were performed in Prism 5.0 Software. 
Data were compare with PBS control group and between groups. Data averages from each group 
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CHAPTER 7 
SUMMARY AND FUTURE PERSPECTIVES 
 
          Management of advanced melanoma is still a major challenge and gaining a better 
understanding of melanoma biology is essential to address the challenges associated with 
existing therapies. In clinical practice, the immune system in cancer patients has always been 
weakened by tumor invasion and chemotherapy, and the understanding of immunotherapy in 
recent years has become a promising strategy for cancer treatment and immune system 
reconstruction.45 To effectively diagnose and treat melanoma, and also provide preventive 
insights, we learn from successful animal models that present relative clinical symptoms. 
Adoptive T-cell therapy, therapeutic vaccines, and chimeric antigen receptor (CAR) T-cell 
therapy are some of the novel strategies currently being explored in clinical trials.  
          NPs can be potentially exploited as efficient drug delivery vehicles and may reduce side 
effects associated with some of the present therapeutics. Theoretically, the NP platforms can be 
exploited for combinatorial therapy by designing multi-modal particles. However, clinical 
translation of NP technologies needs further improvement. Although most investigations have 
focused on delivering therapy directly to melanocytes, a few of them have achieved better effects 
in an advanced melanoma models. Thus, more and more studies have explored the therapeutic 
potential of other target sites associated with melanoma.201 
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          Among those immunotherapies, cancer vaccines, which can be characterized by the use of 
subunit antigens, has been studied widely in cancer treatment over the years, and many clinical 
trials have been conducted based on these vaccination strategies. Although the identification and 
production of antigens has been accomplished, most cancer vaccine studies have failed to 
illustrate clinical benefit. Traditional vaccines are administered by intramuscular injection, where 
the local immune response is triggered in muscle cells and muscle-resident immune cells before 
the antigen-presenting cells like DCs infiltrate from circulation to capture antigens.202 However, 
the same strategy cannot be simply employed in the treatment of cancer due to the complex 
microenvironment of the tumor, especially in advanced tumor models, where DCs in the TME 
are largely tolerogenic with compromised antigen capturing and presenting abilities.  
          For those failed vaccine clinical studies, most of the therapy employed a naked 
administration of the vaccine, and the rest were compromised by vectors like DCs, viral vectors, 
and even naked nucleic acids, which can hardly induce immune response because the immune 
cell evolved as more likely to recognize a dense, highly repetitive epitope arrangement of the 
antigen. However, the nanoparticle-based vaccine with targeted delivery-loading antigen brought 
promise to cancer vaccine development.203 With further understanding of TME, immunotherapy 
has reshaped the landscape of traditional chemotherapy and made novel delivery target strategies 
possible.204 Our group has revealed that a key mechanism of drug resistance in advanced 
melanoma models is due to the barrier created by stroma cells, which are a main component of 
the tumor immunosuppressive microenvironment, and further proved that the suppressive TME 
could be reversed by silencing the inhibitory cytokines secreted by tumor and stroma cells.85 By 
co-formulating the immune-modulating agents with traditional chemotherapy drugs, a synergistic 
tumor inhibition effect was observed.87, 103 The work in this dissertation further indicated that co-
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delivering vaccines with microenvironment modulation would greatly enhance treatment of 
melanoma. 
          For better vaccine design, systemic DC-targeted RNA vaccines formulated with lipid 
carriers in Phase 1 trials have indicated the possibility of a universally applicable strategy that 
could formulate polypeptide-antigen-based vaccines in the form of RNA.205 Aluminum salts, 
which act in part by generating antigen depots (and in part by stimulating chemokines) at the 
injection site, have been used in human vaccines for almost 80 years. In recent years, novel 
adjuvants, especially PRR ligands, have raised much attention. Because PRR activation can 
stimulate the production of different cytokines/chemokines that could further increase the host’s 
ability to eliminate the pathogen. The encapsulation of pathogen-associated molecular patterns 
(PAMPs) to activate PRRs in vaccine formulations can often enhance and accelerate the 
induction of vaccine-specific immune response. PAMPs adjuvants can trigger the innate 
responses generating adaptive responses toward vaccine components.206, 207 
          Several studies have shown that co-delivery of immunomodulatory agents, such as PAMP 
ligands, can enhance the immune response by cancer vaccines. This strategy can be 
accomplished by nanoparticle-based cancer vaccines, which incorporate the ligands into 
nanoparticles by encapsulation and covalent conjugation. Several formulation strategies have 
been developed for ligand conjugation. Adjuvants were co-encapsulated and further 
modifications were made to enhance the deposition of LNs to initiate stimulation. Superior tumor 
inhibition was observed in subcutaneous models and metastasis models. Because a considerable 
number of DCs reside in LNs, LNs can be a good target for cancer vaccines. Direct LN-targeting 
protein NPs show rapid targeting and prolonged retention, providing a new solution for 
melanoma treatment.208 In light of the recent publication from Ribas group,209 vaccine strategy 
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developed in this dissertation would help CTL infiltrate into TME, thus potentially work 
synergistically with the reported high response rates (70% OR/32% CR) of DM to anti-PD-1 
therapy in clinics. 
          The study and clinical application of checkpoint inhibitors in cancer immunotherapy has 
shown excellent potential. In clinical settings, the antibody is given systemically and 
significantly increases the survival rate in advanced melanoma patients. Recent reports indicate 
that the side effects of autoimmune disease were observed due to the blockade of the normal 
function of T cells residing in normal tissue.210 Thus, our development of a local macromolecule 
delivery vesicle has been proposed as a solution. Moreover, co-stimulatory molecules such as 
PD-L2 are still being studies, as well as the glycosylation of PD-L1, may serve as new target in 
immune checkpoint therapy. 
          The desmoplasia of our established tumor model resulted from not only oncogenic BRAF 
mutation and PTEN silencing, but also tumor-specific signaling pathway network (e.g., 
Wnt/beta-catenin signaling could be upregulating collagen production independent of other 
aspects of the DM phenotype). On murine model of DM, the most effective treatment we 
employed so far is the combination of chemo-immuno therapy that synergistically induce 
immunogenic tumor cell death thus boosting immune-recognition and long-term memory 
immune-surveillance. To identify neoantigens released from ICD is a possible direction of 
pursuing in the design of second-wave targeted therapy, thus eradicating residual tumor cells. 
Compared to personalized designed vaccination, this approach offers general and broader 
application. Melanoma, especially DM are highly metastatic, thus the identification of circulating 
tumor cells is also crucial for early detection and prevention of tumor metastasis, as well as 
facilitating a deeper understanding of tumor dormancy.  In addition, tumor stroma within 
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immunosuppressive TME supported tumor cell growth as well as serving as the major source of 
collagen production. Our unpublished work indicates that FAP+ stroma cells neighboring tumor 
cells also harbor BRAF mutations in DM model, and that BRAF vaccination partially depletes 
these FAP+ cells, which improves CD8+ T cells’ functions within the TME. Thus, the function 
of these oncogenic hybrid cells in the role of tumorigenesis, metastasis and EMT transition is of 
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